




Cytokine responses to lipopolysaccharide 
in vivo and ex vivo 
 






























Cytokine responses to lipopolysaccharide 
in vivo and ex vivo 
 






ter verkrijging van 
de graad van Doctor aan de Universiteit Leiden, 
op gezag van de Rector Magnificus Dr. D.D. Breimer, 
hoogleraar in de faculteit de Wiskunde en 
Natuurwetenschappen en die der Geneeskunde, 
volgens besluit van het College voor Promoties 
te verdedigen op dinsdag 27 juni 2006 














Emile Frank Schippers 




Promotor:  Prof. Dr. J.T. van Dissel 
 
Referent:  Prof. Dr. T. van der Poll, Universiteit van Amsterdam 
 
Overige leden: Prof. Dr. P.C.M. van den Berg 
   Prof. Dr. W.A. Buurman, Universiteit van Maastricht 



































The study described in this thesis was supported, in part, by a grant (28-2875,23) of 






When you get the choice to sit it out or dance  
I hope you dance 
 


























Voor mijn ouders 























© 2006 E.F. Schippers, Leiden, The Netherlands 
All rights reserved. No part of this publication may be reproduced or transmitted in any 
form or by any means, electronic or mechanical, including photocopy, recording, or any 







Cover image: “Sepsis, veined into Oecology” by Eddie William Powell  
 
 
Printed by: Febodruk B.V. te Enschede 
 
 
Financial contribution to the publication of this thesis was kindly provided by MERCK 
SHARP & DOHME B.V., Bristol-Meyers Squibb B.V., Boehringer Ingelheim bv, Janssen-
Cilag B.V., GlaxoSmithKline, Abbott B.V., Roche Nederland BV, AstraZeneca BV, Pfizer 
 
bv, UCB Pharma B.V., Wyeth Pharmaceuticals bv, Schering-Plough B.V., Chiron 
Contents 
  
Chapter 1 General introduction and outline of the thesis 9
Chapter 2 No effect of preoperative selective gut decontamination on 
endotoxemia and cytokine activation during cardiopulmonary 
bypass: a randomized, placebo-controlled study 
Critical Care Medicine 2002; 30(1):38-43 31
Chapter 3 Letter to the Editor 
Critical Care Medicine 2003; 31(1):334-5 39
Chapter 4 TNF-α and IL-10 production upon whole blood stimulation with a 
wide range of LPS concentrations: estimating an individual's dose-
response characteristic described by the underlying receptor-ligand 
model 
Submitted 45
Chapter 5 TNF-α promoter, Nod2 and toll-like receptor-4 polymorphisms and 
the in vivo and ex vivo response to endotoxin 
Cytokine 2004; 26(1):16-24 63
Chapter 6 IL-10 and toll-like receptor-4 polymorphisms and in vivo and ex 
vivo response to endotoxin 
Cytokine 2005; 29(5):215-28 75
Chapter 7 Cytokine response to endotoxin in individuals heterozygous for the 
Delta32 mutation of chemokine receptor CCR5 
Cytokine 2003; 21(4):195-9 91
Chapter 8 Polymorphisms in the TNF-α and IL-10 promoter region, TLR-4  
of patients undergoing elective cardiac surgery 
Submitted 99
Chapter 9 Summary and general discussion 117
Chapter 10 Nederlandse samenvatting 127





















manifestations of disease may differ markedly between individuals. Some individuals may 
have an asymptomatic infection while others suffer life threatening consequences of the 
disease. This variability in clinical manifestation of infectious diseases has been attributed 
to differences in the ability of the causative microbial agent to cause disease (‘virulence’) 
and the premorbid health status of the patient (‘predisposition’). Between microbial 
species, and even within species, differences exist in the ability of the agent to cause 
disease. Also, the port of entrée of the agent and the site of infection are important. For 
example, invasion of a microbial agent into the central nervous system or abdominal cavity 
might cause more severe disease as compared to invasion of the same agent into the lung. 
On the other hand, the predisposition of the patient is determined by concomitant disease, 
such as cancer or cardiovascular disease, and factors such as religious and cultural forces 
that shape the approach toward therapy. Finally, inherited differences (‘genetic makeup’) 
in the individual’s ability to cope with an invading pathogen and mount an appropriate 
immune response play a role. This variability in response of the host applies to not only the 
clinical manifestations of infectious diseases, but also the response of an individual to 
treatment. It is important to appreciate that these multiple predisposing factors may 
influence both the incidence and the outcome in similar or conflicting ways. For example, 
a genetic make-up leading to an early and strong response to the invasion of a microbial 
agent, might decrease a person’s risk of infection but at the same time increase that 
person’s risk of an overly exuberant, and potentially harmful, inflammatory response. To 
help clarify an individual’s response to infection and classify its severity, the inflammatory 
reaction to infection has been captured in a definition of ‘sepsis’, characterised by fever or 
hypothermia, tachycardia, tachypnea, and leucocytosis or leucopenia. This sepsis 
syndrome may be accompanied by hypotension (‘septic shock’), hypotension refractory to 
fluid treatment (‘refractory septic shock’), and single or multiple organ system failure, 
ultimately leading to death (1). 
In the host response to infection, both cellular components and humoral components 
play a role. For instance, bacteria that breach the integrity of the mucosal lining of the 
respiratory or gastrointestinal tract are ingested (‘phagocytised’) by specialized host 
immune cells, the neutrophils and mononuclear phagocytes. In many instances, phagocytes 
are assisted in their task by another type of host cells, the lymphocytes, that may produce 
opsonising antibodies and thus help phagocytes recognize the invaders, or release 
substances, designated cytokines, that activate the phagocytes and enhance their 
phagocytic or antimicrobial activity. This complex process that constitutes the host 
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inflammatory response to invading pathogens (and is defined as “infection”) is 
orchestrated both by cell-to-cell contact as well as by cytokines secreted by the various 
host immune cells. Locally, the cytokines that may either stimulate (‘pro-inflammatory’) or 
dampen (‘anti-inflammatory’) the host inflammatory reaction in a complex system of 
checks and balances, help contain and eliminate the invading pathogens. Some 
inflammatory mediators act systemically, by inducing an acute phase response and fever, 
one of the pivotal signs of the sepsis syndrome. It is not until immunostimulatory 
components of pathogens like the endotoxin of Gram-negative bacteria or the invading 
bacteria reach the bloodstream and are disseminated through the circulation that a cascade 
of inflammatory reactions are triggered within the bloodstream and soon may affect the 
integrity of the whole body, e.g., through activation of neutrophils within the circulation, 
activation of the coagulation cascade, and complex fluid rearrangements. The perfusion of 
critical organs may become compromised through blood coagulation in small vessels and 
the formation of microthrombi, at the same time intravascular fluids leak away into the 
tissues. Eventually, multiple organ failure ensues. Clearly, in such a disproportional 
response, the system that checks and balances the host’ inflammatory reaction has become 
disrupted (2;3).  
Any rational intervention rests on an understanding of the host factors that direct the 
inflammatory response to microbial products and thus contribute to the progression of 
sepsis into septic shock, multiple organ failure and eventually death. Today, the severe 
stages of sepsis constitute an important cause of morbidity and mortality in individual 





In the last decade many of the mechanisms by which the host responds to the presence of 
microbial pathogens on its mucosal surfaces or in the tissues, have been elucidated, most 
up to their molecular level. In the cascade from recognition to response, first the host must 
recognize the presence of a potentially pathogenic invader. The discovery of a group of 
receptors called Toll-like receptors (TLRs) and accessory proteins involved in their 
functioning has renewed interest in specificity of pathogen recognition (6). Because these 
receptors are highly specific to microbial components such as endotoxin, alone or in 
concert and each elicit a particular activation response in the host cells, already the very 
first reaction to pathogens exerts some specificity (7;8). This recognition results in cellular 
and humoral responses, the latter often made up of the release of a mix of 
pro-inflammatory and anti-inflammatory cytokines. 
12
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However, it is not only the pathogen that dictates the type and intensity of the cytokine 
release. Also an individual host’s capacity to release such humoral factors must be taken 
into account. With the sequencing of the genome and recognition of the genetic variation 
within the human population, it became clear this variation is responsible for at least part 
of the inter-individual differences in cytokine release after challenge with microbial 
products (9). Soon it was recognized that such genetically determined variations in 
cytokine release could be relevant to explain the variability in susceptibility too, and 
outcome from, sepsis. In particular, interest focussed on genes that encode for proteins 
involved in the pathogenesis of sepsis including those involved in the initial recognition of 
bacterial products such as Toll-like receptors, and cytokines known to mediate the host 
inflammatory response, such as tumor necrosis factor (TNF)-α, interleukin(IL)-6 and 
IL-10. For many of these factors, polymorphic genes were discovered (10). A polymorphic 
gene is one in which a comparison of the DNA sequence of the gene in multiple 
individuals shows differences at a frequency of at least 1%. The sites within the genes that 
differ between individuals are called polymorphic sites and these may differ by insertions, 
deletions, or substitutions (e.g., ‘single nucleotide polymorphisms’ or SNPs) of one or 
more base pairs, or by the presence of a variable number of repeats of short, repetitive 
DNA sequences. Also, there may be one or more polymorphic sites within a single gene, 
and sites affected may pertain to coding regions of the gene or noncoding regions. The 
latter are important as well as they often affect regulation of gene expression. As of yet, 
only some of the variations observed have been linked to level and/or activity of the 
resulting protein, and therefore are known to affect cell function. Recent population 
association studies have indicated that polymorphisms in some of these genes indeed are 
associated with the severity of the response to infection. 
 
Lipopolysacharide-mediated inflammatory response 
 
The host response to bacterial invasion requires first the recognition of the presence of 
pathogens. The presence of a pathogen is detected by binding of pathogen-preserved 
molecules called ‘pathogen-associated molecular patterns’ or PAMPs on cell surface 
receptors known as ‘pattern recognition receptors’ or PRRs. Lipopolysaccharide (LPS; 
endotoxin), one of the major outer membrane components of the Gram-negative bacterial 
cell wall, is an important PAMP and thereby a powerful stimulator of the host 
inflammatory reaction. LPS elicits this response by binding to a cell surface receptor 
composed of at least three distinct proteins: CD14, Toll-like receptor-4 (TLR4), and MD-2 
(Figure 1) (11;12). 
13
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Figure 1: TLR4 signaling of LPS. LPS=lipopolysaccharide, LBP= lipopolysaccharide binding protein, TLR4=toll-like 
receptor-4, MD-2=myeloid differential protein, TIR-domain=Toll-Interleukin-1 resistance domain, MyD88=myeloid 
differentiation factor 88, TIRAP= TIR domain-containing adapter protein, IRAK-4=interleukin-1 receptor associated 
kinase-4, TRAF6=tumour necrosis factor-receptor associated factor 6, NF-κB=nuclear factor-κB, TRIF= TIR domain-
containing adapter inducing interferon-ß, TRAM=TRIF-related adapter molecule, IRF-3=interferon-regulating factor, 































At least two of these components, CD14 and TLR4, are polymorphic proteins and the 
various forms have been associated with altered functioning of the LPS receptor complex 
(13-18). 
TLR4 is part of a family of transmembrane proteins. The receptor is expressed on 
monocytes and macrophages and to a lesser extent on lymphocytes and other cell types. 
Recently, a polymorphism in the coding region of TLR4 has been characterised (13;14). 
The single nucleotide polymorphism (SNP) was identified in the fourth exon of the TLR4 
coding gene and results in replacement of a conserved aspartic acid at amino acid residue 
299 with glycine. The SNP is in linkage disequilibrium with a second SNP at amino acid 
399, which changes a threonine to an isoleucine. Both these amino acid replacements are 
located in the extracellular domain of the TLR4 receptor, and are thought to cause a 
functional defect in the receptors’ ability to bind LPS (13-15). Studies in mice demonstrate 
that TLR4 is required for the response to LPS and that replacement of a single amino acid 
can significantly reduce the responsiveness to LPS and enhance susceptibility to infection 
by Gram-negative bacteria (6). Ex vivo studies using primary human epithelial cells 
heterozygous for the variant TLR4 or studies using a transfected cell system in which the 
variant TLR4 is expressed also suggest that the TLR4 299-variant is associated with a 
decreased responsiveness to LPS (13). However, the search for clinical correlates of this 
putative reduced LPS-responsiveness has been less definite. A number of studies have 
shown that this TLR4 variant was associated with reduced responsiveness to LPS, as 
assayed by airway reactivity or the systemic cytokine response to inhaled LPS (13-15). 
Other studies suggested that this TLR4 variant was associated with proneness to develop 
Gram-negative bacterial infections and even septic shock (19-21). It therefore was 
surprising that there was a lack of association between the TLR4 variant and susceptibility 
to, or severity of, meningococcal disease, notwithstanding that some rare TLR4 mutations 
have been implicated in meningococcal susceptibility (22;23). In addition, ex vivo studies 
of whole blood or isolated blood leukocytes failed to show an altered response to LPS in 
cells sampled from individuals heterozygous for the TLR4 variant (24-26). 
Thus, it is still uncertain whether the in vivo response to LPS in humans having one 
copy of the TLR4 variant varies from that seen in individuals with two copies of wild-type 
TLR4. Clearly, additional studies in a large number of patients will be required to clarify 
whether the TLR4 variant indeed is associated with susceptibility to Gram-negative 
infection, and severity of the inflammatory host reaction, i.e., severity of sepsis. 
15
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CCR5 
 
Another receptor that might function as a PRR in bacterial infection is CCR5. This seven-
transmembrane spanning G protein-coupled receptor binds the CC chemokines 
macrophage inflammatory protein-1a (MIP-1a), MIP-1b, and RANTES. CCR5 is 
expressed on the cell surface of monocytes and CD45RO+ (memory) T-lymphocytes 
(27;28). Much of the interest in this molecule stems from its role as an HIV co-receptor, 
required for the infection of CD4-positive lymphocytes with macrophage-tropic HIV 
isolates. A genetic variant of this molecule exists due to a 32-nucleotide deletion (∆32) in 
the region encoding the second external loop; the deletion causes a frame shift and 
premature stop codon. By consequence, the encoded protein is not translated (29). 
Homozygosity for this deletion-induced null mutation was reported as a mechanism of 
resistance to HIV infection (29). Similarly, individuals heterozygous for the ∆32 mutation 
lack about halve of the surface associated CCR5 and when HIV-infected display a slower 
progression to AIDS and a longer disease-free survival compared with CCR5-wild-type 
HIV-infected individuals (30;31). The frequency of the mutated CCR5 allele is about 10% 
in Caucasians. Carriers of the ∆32 allele are healthy and, no phenotype could be attributed 
to a heterozygous or homozygous mutated CCR5 genotype (32).  
Studies in mice carrying a targeted disruption of this molecule presented evidence for a 
role of CCR5 in host defense against bacterial infection (33). For instance, after 
intraperitoneal challenge with lipopolysaccharide CCR5-deficient mice had a higher 
survival rate than mice carrying two CCR5 wild type genes. Also, the LD50 value of 
lipopolysaccharide was significantly lower in wild-type compared with the CCR5-deficient 
mice. Moreover, peritoneal macrophages of CCR5 knock-out animals differed from their 
wild-type littermates with regard to the cytokine production in response to LPS, by 
displaying reduced LPS-stimulated production of IL-1ß and IL-6. Of note, however, no 
difference in the release of TNF-α was found between knock-out and wild type mice. So 
far, it is uncertain whether heterozygosity for the ∆32 allele affects the cytokine response 




Another receptor reported to be involved in LPS responsiveness is Nod2, an intracellular 
protein that interacts with LPS through a C-terminal leucine-rich repeat (LRR) domain and 
is predominantly expressed within monocytes. The subsequent homodimerisation of Nod2 
molecules induces NF-kB translocation, and cytokine production. A mutation in Nod2 that 
apparently diminishes the ability of the protein to interact with LPS is associated with 
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Crohn’s disease (34). Studies thus far have focused on LPS responsiveness of recombinant 
Nod2. There is a lack of studies on LPS responsiveness of the natural Nod2 protein in 
humans. 
 
Tumor necrosis factor-α encoding gene and its promoter 
 
TNF-α is a pivotal member of the inflammatory cytokine cascade. It is responsible for the 
initial activation of the inflammatory response and if left unopposed plays an important 
role in the pathogenesis of septic shock, by mediating capillary leak, hypotension and 
coagulation events, resulting in acute respiratory distress syndrome (ARDS) and multiple 
organ system failure (35).  
As previously mentioned, a dysbalance between pro-inflammatory (mainly TNF-α) and 
anti-inflammatory cytokines (such as IL-10) may underlie clinical manifestation of severe 
sepsis. The mechanism by which such an exaggerated pro-inflammatory response develops 
is area of intense research. A genetically-determined inclination to produce very high or 
very low rather than intermediate amounts of TNF-α could be one of the contributing 
factors in this respect.  
TNF-α and genetic polymorphisms within the regulatory regions of the gene coding for 
TNF-α, are perhaps the most extensively studied of all cytokines and cytokine genes 
involved in sepsis (36-53). Upon stimulation by LPS human monocytes, the main 
producers of TNF-α, exhibit substantial inter-individual differences in TNF-α production 
(54). Studies have shown that inter-individual variation of TNF-α production capacity ex 
vivo may partly be explained by differences in genetic background (9;54). Because 
cytokine release is most likely transcriptionally regulated, polymorphisms in the regulatory 
region of the gene coding for TNF-α, the promoter region, is a significant target for this 
research. Several SNPs in the promoter region of the gene have been identified and were 
found to be associated with spontaneous and LPS-stimulated TNF-α production, assayed 
either ex vivo or in vivo (37;38;43;48;53;55). These SNPs include a G to A transition 308 
base pairs upstream from the transcriptional start site of the TNF-α gene. Ex vivo studies 
have demonstrated that the rare TNF-α-308 A allele is associated with increased gene 
transcription as compared with the wildtype TNF-α-308 G allele (41). Furthermore, the 
TNF-α-308 A allele has been associated with increased secretion of TNF-α from 
macrophages after LPS stimulation ex vivo (38).  
The promoter polymorphisms lie near putative DNA binding sites of transcription 
factors. For instance, by electrophoretic mobility shift assay it was demonstrated that 
nuclear proteins differ in their ability to bind to DNA fragments containing either an A or a 
G at the TNF-α-308 position (43). In a variety of infectious diseases, the TNF-α promoter 
17
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polymorphisms have been associated with clinical presentation and/or outcome of diseases. 
These include cerebral malaria, human immunodeficiency virus dementia in adults, 
meningococcal infections in children, and bacteraemia and septic shock, and community-
acquired pneumonia (36;37;45;46;46-48;48-50). For example, among patients with septic 
shock, the TNF-α-308 A allele was found more frequently in those who died compared 
with those who survived, and the risk of an adverse outcome was about 3.5-fold higher in 
patients with at least one copy of the TNF-α-308 A allele (48). Furthermore, the 
TNF-α-308 A allele was observed more frequently in patients with fatal meningococcal 
disease as compared with patients surviving the disease (56). However, the distribution of 
TNF-α-308 alleles did not differ between healthy controls and an ethnically similar cohort 
of adults with severe sepsis, or between survivors and nonsurvivors in the severe sepsis 
group (51). In this and several other studies, no association was found between plasma 
TNF-α concentration and the above described polymorphism. Also, no increased risk of 
septic shock or mortality was observed in a cohort of consecutively admitted postoperative 
surgical patients. Although most evidence supports an association between genotypes in 
the regulatory region of the gene coding for TNF-α, levels of TNF-α production and 
mortality in patients with sepsis, there are a significant number of studies that could not 
confirm such an association. Additional studies in large groups of well defined patients are 
needed to quantify the role of these genetic polymorphisms in TNF-α production and 
outcome from infectious disease. 
 
Interleukin-10 encoding gene and its promoter 
 
IL-10 is an important immunoregulatory cytokine. It is involved in the regulation of the 
host inflammatory response, through inhibition of TNF-α production and other cellular 
processes. In Gram-negative infection, the presence in the circulation of lipopolysaccharide 
signals the release of IL-10. The cytokine is produced primarily by monocytes and 
down-regulates besides TNF-α the expression of other cytokines such as IL-1α and -ß, 
IL-6, and IL-8. By its role in the balance of pro-inflammatory and anti-inflammatory 
cytokines, IL-10 may codetermine the course of various infectious diseases. Be the 
relationship causal or not, the stage of severity to which meningococcal meningitis 
progresses is associated with serum IL-10 concentrations, such that high serum IL-10 
levels are associated with poor or fatal outcome, whereas patients with mild disease and a 
good prognosis displayed much lower levels of IL-10 (57-59). Anti-inflammatory effects 
of IL-10 are evident in animal models of sepsis showing that neutralization of IL-10 results 
in an exaggerated pro-inflammatory response and death, while administration of IL-10 
confers protection (60). In some models such as bacterial peritonitis, however, IL-10 may 
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induce a state of immunosuppression and may inhibit bacterial clearance (61). In these 
circumstances, administration of IL-10 is associated with exacerbation of bacterial sepsis 
and increased mortality (61).  
Human monocytes exhibit substantial inter-individual differences in IL-10 production 
upon LPS stimulation ex vivo. A study suggested that differences in ex vivo IL-10 
production capacity may to a large extent be explained by the genetic makeup of the 
individuals being tested (62). Of note, inter-individual differences in production of IL-10 
could not be explained merely by corresponding changes in TNF-α production, thus 
implicating that the individual’s ability to produce IL-10 is not simply reflecting the 
individual’s ability to produce TNF-α (9). Because differences in IL-10 production are 
likely transcriptionally regulated, it has been suggested that differential transcription is the 
principle mechanism of inter-individual differences in IL-10 production. Indeed, IL-10 
production was shown to be proportionally related to mRNA production and not to the 
half-life of IL-10 (63).  
Located within the proximal 1.1 kb region upstream from the transcriptional start site 
which controls transcription of the IL-10 gene, four SNPs, at position -1330 (G or A), 
-1082 (G or A), -819 (C or T), -592 (C or A) have been identified (64-66). The -1082 G/A 
substitution occurs within a putative binding site of Ets, a transcription factor, whereas the 
-819 C/T lies within a putative positive regulatory region, and the -592 C/A polymorphism 
within a putative STAT 3 binding site and a negative regulatory region (67). Linkage 
disequilibrium between the alleles at the -1330 and -1082 sites on the one hand and -819 
and -592 sites on the other hand has been demonstrated such that -1330 A is always 
associated with -1082 G, -1330 G with -1082 A, -819 C with -592 C and -819 T with -592 
A. Therefore, only four haplotypes exist: AGCC, GACC, AGTA, and GATA. The 
influence of IL-10 promoter polymorphisms on IL-10 production was examined in several 
ex vivo stimulation studies and found associations between the production capacity of 
IL-10 ex vivo and haplotypes. For instance, the AGCC/AGCC genotype is associated with 
higher IL-10 production than the other haplotypes (68). Likewise, in a study in which only 
the IL-10-1082 site was examined, blood cells of individuals with the G allele released 
higher amounts of IL-10 compared with those of individuals with the A allele. In addition, 
the 5'-flanking regions from individuals homozygous for the three haplotypes AGCC, 
GACC, and GATA, were cloned into a luciferase vector and transiently transfected into 
cells. The AGCC construct demonstrated significantly increased transcriptional activity 
compared with the GATA construct, with the GACC construct demonstrated an 
intermediate transcriptional activity (67). In an ex vivo study in which the IL-10-592 site 
was examined, LPS-stimulated whole blood from healthy volunteers with the C allele 
produced higher amounts of IL-10 than individuals with the A allele at the -592 site. Taken 
19
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together, ex vivo evidence suggests that genetic variation in the promoter region of the 
IL-10 encoding gene influences the amount of IL-10 produced. 
Next, the association between the IL-10 haplotypes and susceptibility to infectious 
diseases and severity of disease was investigated, yielding conflicting results. For instance, 
in a cohort of adults with community-acquired pneumonia, the “high secretor” G allele at 
position -1082 was associated with severe disease when compared with the “low secretor” 
A allele (69). In a cohort of patients with culture proven pneumococcal disease, 54% of the 
patients developing septic shock had the high secretor G allele, as compared with 16% of 
those patients who did not develop septic shock. With respect to the IL-10-592 site, in a 
cohort of critically ill adults no increased risk of sepsis was apparent in those patients with 
the low secretor A allele at the -592 site, but the mortality was higher in those patients with 
the A allele as compared with those with the C allele, regardless of whether they met the 
criteria for sepsis (70). In a cohort of intensive care unit patients with a wide variety of 
medical, surgical, and traumatic conditions, there was no association between IL-10 
haplotypes and either serum IL-10 levels or mortality (71). Thus, clinical studies have been 
conflicting; on one hand, there appears to be an increased risk of more severe disease 
(development of septic shock) in those individuals who have the high secretor GG 
genotype at the -1082, yet there is a higher mortality in individuals with the low secretor 
genotype at the -592 site. The variable results in these studies may well be explained by the 
heterogeneity present among the groups studied.  
 
In vivo model for lipopolysaccharide-mediated cytokine response 
 
As illustrated in the previous paragraphs, clinical research into the role of genetic 
polymorphisms to susceptibility and outcome of lipopolysaccharide (LPS) mediated 
inflammatory disease, such as occurs in Gram-negative infection, is complex. Due to 
heterogeneity in underlying condition, type of infection, medication, etcetera, in the 
populations studied, inter-individual differences in release of cytokines may be caused by 
many factors besides genetic determinants. By consequence, background noise reduces the 
power of most studies to detect possible differences based on genetic background. Several 
approaches have been taken to circumvent this problem. First, small controlled studies 
were carried out in healthy subjects given low concentrations of LPS intravenously (72). 
However, the number of subjects and thereby ability to vary genetic background is limited 
and the injection of purified but chemically altered LPS directly into the bloodstream, 
without a local focus of inflammation represents an artificial model of severe sepsis. 
Another approach is to study cytokine release in reaction to naturally occurring 
endotoxemia in patients undergoing elective cardiac surgery (73-76). This approach 
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enabled us to study inter-individual differences in cytokine responses under controlled 
conditions of standardized surgery, and relate these to genotypes.  
Cardiopulmonary bypass surgery is a frequently performed surgical procedure, and 
during reperfusion upon aorta declamping a perioperative endotoxemia occurs in about 70 










bowel ischaemia  
 
Figure 2. Schematic representation (time-line) of the in vivo model. In patients undergoing cardiac surgery, extracorporal 
perfusion is applied. In the first phase of the procedure, the heart is perfused and stops beating, circulation and 
oxygenation is maintained by an extracorporal system(‘Heart-Lung machine’). During this phase the bowel is in a state of 
relative hypoperfusion. Following the completion of the surgery, the heart is restarted and pulsatile circulation is 
resumed, resulting in reperfusion of the bowel. Accumulated metabolites and translocated intestinal products come into 
the circulation, leading to endotoxemia and subsequent cytokine release. In severe cases this might lead to the 
postperfusion syndrome.  
 
 
Typically, during the phase of extracorporeal nonpulsatile circulation, the bowel undergoes 
relative hypo-perfusion, leading to splanchnic ischemia. Upon release of the aortic clamp 
and restart of pulsatile perfusion, gut reperfusion injury occurs frequently. The disturbance 
of the gut barrier function is marked by translocation of endotoxin from the gut into the 
systemic circulation, and leads to detectable levels of circulating endotoxin (74;75;77-81). 
The subsequent systemic inflammatory response varies from a relatively mild feverspike to 
a severe sepsis-like syndrome and potentially life threatening condition. The response is 
accompanied by complement activation, release of cytokines, leukocyte activation along 
with expression of adhesion molecules, and the production of substances such as 
oxygen-free radicals, arachidonic acid metabolites, platelet-activating factor (PAF), nitric 
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to increased cardiac output in the presence of reduced systemic vascular resistance (SVR) 
and high oxygen consumption, generally referred to as ‘hyperdynamic instability’ or 
postperfusion (or “post-pump”) syndrome (75;76;82-87). This condition requires prompt 
fluid replacement and treatment with vasoactive agents. Ultimately, the derangement of 
hemodynamic variables may be complicated by lactic acidosis, impaired organ perfusion, 
and pulmonary dysfunction, which cause an extended intensive care unit stay and even 
fatal outcome. 
Since the inflammatory response following cardiac surgery has similarities with sepsis, 
this condition of a natural occurring endotoxemia may serve as elegant model to study the 
host response in sepsis. Furthermore, the highly variable nature of the syndrome, both in its 
occurrence and in its severity, makes it clinically relevant to identify factors that help 
explain this variation, including possible genetic determinants. Currently, it is not known 
to what extend SNPs as those mentioned above contribute to the observed inter-individual 
variation in severity of the inflammatory response and development of the post-pump 
syndrome following cardiac surgery. Also, the standardized time course of the noxe 
enables study of the cytokine responses to the preceeding endotoxemia: in the model it is 
possible the sequentially measure the level of endotoxemia and the inflammatory response, 
making a quantitative mathematical approach to cytokine concentrations possible.  
 
Ex vivo model for lipopolysaccharide-mediated cytokine response 
 
The ex vivo cytokine production capacity of an individual is elegantly determined in the 
supernatant of whole blood after stimulation with LPS (54). This system provides a natural 
environment for cytokine producing cells, mainly being monocytes. The assay is generally 
accepted as gold standard of ex vivo assays to determine an individual’s ability to produce 
cytokines upon well defined stimuli. Day-to-day intra-individual variation and laboratory 
variation are small, i.e., both estimated at around 15% (54). The assay can distinguish 
‘high’ and ‘low’ producing individuals of TNF-α and IL-10 based on the cytokine 
concentration found in the supernatant upon stimulation with one single concentration of 
LPS. In one study the aforementioned approach was able to detect differences in ex vivo 
cytokine production in relatives of patients with poor or fatal outcome of meningococcal 
disease as compared to relatives of patients with more favorable outcome (9). These 
observations led to the hypothesis that inter-individual variation in cytokine production can 
be explained to a large extend by genetic background. Most studies assessed the 
association between gene(- promoter) polymorphisms and (whole blood) stimulation 
phenotype (i.e. individuals categorized as 'high' as compared to 'low' producers) by 
measuring the cytokine release after stimulation of whole blood with only one single – and 
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between studies varying – concentration of LPS (38;41;43;51;55;63;64;67;88-105). Not 
surprisingly, the conclusions of these studies have been conflicting.  
Categorizing individuals as 'high' as compared to 'low' producers based on the cytokine 
production upon stimulation by a single LPS concentration is not adequate. Firstly, the 
LPS concentrations applied always exceeded by far the concentrations of naturally 
occurring endotoxemia in patients with infectious diseases, hampering the translation of 
the ex vivo phenotype to the in vivo situation (106). Secondly, the cytokine concentrations 
found after stimulation with one single high concentration of LPS will at best reflect 
maximal production capacity, but will not necessarily provide insight in the cytokine 
response characteristics at lower LPS concentrations. Furthermore, aspects of the 
dose-response characteristics, for instance the LPS concentration at which 50% of the 
maximal cytokine concentration is reached and the maximal cytokine production capacity 
of the dose-response curve are not taken into account. Since the discovery of the TLR4, 
these aspects are of interest since this mode of LPS signaling is likely to follow the basic 
concepts of the receptor-ligand model used in other fields of research. Due to the elective 
nature of the surgical procedures included in our study, patients could be sampled before 
the operation and their ex vivo LPS-responsiveness assayed. Based on the dose response 
model know as the Cmax model we calculated the dose response characteristics of 
individuals by using supernatant cytokine concentrations after stimulation with a wide 
range of LPS concentrations (107). We hypothesized that the intra-individual day-to-day 
variation in the dose-response parameters is small as compared to the variation found in the 
intra-individual day-to-day variation found in a single point measurement and have better 
discriminative properties in labeling an individuals phenotype. If these premises were met, 
it would be suitable to use these parameters as patient characteristics in future research. 
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OUTLINE OF THE THESIS 
   
Part I  
  
In Chapter 1 a general introduction to the subject is given. In a prospective, randomized, 
placebo-controlled study described in Chapter 2, we examined whether preoperative 
selective gut decontamination aimed to eliminate the aerobic Gram-negative bowel flora 
would preclude perioperative endotoxemia, cytokine activation, and postoperative 
complications in elective cardiac surgery. In Chapter 3 we discuss some of the details 
concerning the effect of preoperative selective gut decontamination on aerobic Gram-
negative bacilli and fecal endotoxin concentrations. In Chapter 8 we investigated the role 
of perioperative endotoxemia, and cytokine activation, and of polymorphic forms of TLR4 
and SNPs in the promoter region of IL-10, on the postoperative response leading to 
hemodynamic stability, morbidity, complications and outcome in elective cardiac surgery. 
  
Part II  
  
In Chapter 4, based on the dose response model know as Cmax model, we calculated 
lipopolysaccharide-elicited cytokine dose-response characteristics of individuals by 
determining TNF-α and IL-10 concentrations in the supernatant after stimulation of blood 
cells with a wide range of LPS concentrations. We quantified the influence of the 
laboratory and intra-individual day-to-day variation on these parameters. We evaluated 
which ex vivo parameter describing the lipopolysaccharide-stimulated cytokine release is 
most suitable for use as patient characteristic in future studies correlating ex vivo cytokine 
production to genetic factors, and determined how much of the inter-individual variation 
could be attributed to these genetic factors. 
  
Part III  
  
In Chapter  5 we determined to what extent the lipopolysaccharide-induced TNF-α 
production capacity in vivo and ex vivo is determined by polymorphisms in Toll-like 
receptor-4 (TLR4), the TNF-α promoter region and Nod2. In Chapter 6 we determined to 
what extent lipopolysaccharide-induced IL-10 production capacity in vivo and ex vivo is 
determined by polymorphisms in TLR4 and the IL-10 promoter region. In Chapter 7, 
finally, we evaluated to what extend a naturally occurring mutation of the CCR5 gene (a 
32-basepair  deletion, ∆32) is associated with a differential in vivo and ex vivo cytokine 
production. 
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No effect of preoperative selective gut decontamination on
endotoxemia and cytokine activation during cardiopulmonary
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Cardiopulmonary bypass pre-disposes the intestines to in-adequate perfusion, hypoxicinjury, and increases in gut
permeability (1, 2). During cardiopulmo-
nary bypass, endotoxin that originates
from the gut has been shown to rise in
the circulation and may contribute to the
cytokine and complement activation al-
ready caused by the exposure of blood to
artificial surfaces of the oxygenator. The
resulting proinflammatory reaction can
cause fever and high oxygen consump-
tion in the direct postoperative period,
the so-called postperfusion (or “post-
pump”) syndrome (3–5). Because this in-
flammatory reaction has been associated
with increased morbidity after cardiac
surgery, clinicians have sought strategies
to attenuate this response.
The reaction to infection can be man-
ifested by a systemic inflammatory re-
sponse syndrome progressing to septic
shock and multiple organ dysfunction
syndrome (6). This chain of events is trig-
gered by bacterial components such as
endotoxin, peptidoglycan, lipoteichoic
acid, lipoprotein, and exotoxins, and exe-
cuted through many mediators (7–9). In
Gram-negative infection, the presence of
endotoxemia plays a pivotal role in the
morbidity and mortality associated with
bacteremia caused by aerobic Gram-
negative microorganisms (7, 10, 11). Ev-
idence as to the central role of endotoxin
in cytokine activation and the proinflam-
matory reaction in Gram-negative infec-
tion has stimulated interest in the trans-
location of aerobic Gram-negative
bacteria and endotoxin during cardiopul-
monary bypass. It has been hypothesized
that reducing the number of aerobic
Gram-negative microorganisms in the
bowel at the time of cardiac surgery
would diminish the gut ischemia-associ-
ated translocation of Gram-negative bac-
teria. Thus, presumably, circulating en-
dotoxin during cardiopulmonary bypass
would diminish as well (12, 13). This hy-
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Background: Cardiopulmonary bypass predisposes the
splanchnic region to inadequate perfusion and increases in gut
permeability. Related to these changes, circulating endotoxin has
been shown to rise during cardiac surgery, and may contribute to
cytokine activation, high oxygen consumption, and fever (“post-
perfusion syndrome”). To a large extent, free endotoxin in the gut
is a product of the proliferation of aerobic Gram-negative bacteria
and may be reduced by nonabsorbable antibiotics.
Objective. To evaluate the effect of preoperative selective gut
decontamination (SGD) on the incidence of endotoxemia and
cytokine activation in patients undergoing open heart surgery.
Design: Prospective, randomized, placebo-controlled double-
blind trial.
Setting: Tertiary-care university teaching hospital.
Intervention: Preoperative administration for 5 to 7 days of oral
nonabsorbable antibiotics (polymyxin B and neomycin) vs. pla-
cebo. The efficacy of SGD was assessed by culture of rectal
swabs.
Patients: Forty-four patients (median age 65 yrs, 29 males)
were included in a pilot study to establish the sampling points of
perioperative measurements. Seventy-eight consecutive patients
(median age 65 yrs, 55 males) were enrolled for the prospective
study; of these, 51 were randomly allocated to take SGD (n  24)
or placebo (n  27); 27 were included in a control group (no
medication).
Measurements and Results: SGD but not placebo effectively
reduced the number of rectal swabs that grew aerobic Gram-
negative bacteria (27% vs. 93%, respectively; p < .001). SGD did
not affect the occurrence of perioperative endotoxemia, nor did it
reduce the tumor necrosis factor-, interleukin-10, or interleu-
kin-6 concentrations (p > .20), as determined before surgery,
upon aorta declamping, 30 mins into reperfusion, or 2 hrs after
surgery. Also, SGD did not alter the incidence of postoperative
fever or clinical outcome measures such as duration of artificial
ventilation and intensive care unit and hospital stay.
Conclusion: SGD effectively reduces the aerobic Gram-nega-
tive bowel flora in cardiac surgery patients but fails to affect the
incidence of perioperative endotoxemia and cytokine activation
during cardiopulmonary bypass and the occurrence of a postper-
fusion syndrome. (Crit Care Med 2002; 30:38–43)
KEY WORDS: selective gut decontamination; cardiac surgery;
cardiopulmonary bypass; endotoxemia; cytokine; systemic in-
flammatory response syndrome
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pothesis followed the observation in mice
that free endotoxin in the intestinal tract
mainly is a product of the proliferation of
aerobic Gram-negative bacteria (14), and
may be amenable to treatment with anti-
biotics (15, 16). In rats, selective gut de-
contamination aimed at eradicating the
aerobic Gram-negative microorganisms
was effective in preventing bacterial
translocation and reduced gut-derived
endotoxemia and mortality after severe
thermal injury (17). In man, a reduction
in the aerobic Gram-negative bowel flora
can be readily achieved by selective gut
decontamination with nonabsorbable an-
tibiotics (12, 18, 19), and thus may rep-
resent a relatively low-cost strategy to
prevent postoperative complications in
patients undergoing elective heart sur-
gery. The aim of the present prospective,
randomized, placebo-controlled study
was to investigate in patients undergoing
elective cardiac surgery with cardiopul-
monary bypass, the effect of preoperative
selective gut decontamination on periop-
erative endotoxemia, cytokine activation,
and postoperative complications.
METHODS
The study was performed at the Leiden
University Medical Center, a 800-bed second-
ary and tertiary referral hospital. Patients 18
yrs and older, undergoing cardiac surgery and
consecutively referred to the Department of
Cardiothoracic Surgery were enrolled follow-
ing institutional approval by the local medical
ethics committee (protocol P168/96). Each pa-
tient gave a written, informed consent.
Anesthesia protocol was standardized and
consisted of premedication with lorazepam
(0.05 mg/kg) per os and induction with a bolus
sufentanil (1–2 g/kg) and a bolus midazolam
(0.1 mg/kg). Curarization was achieved with a
pancuronium injection (0.1 mg/kg) at induc-
tion. Anesthesia was maintained with contin-
uous infusion of sufentanil (1–3 g/kg/hr) and
midazolam (0.1 mg/kg/hr). The patient was
ventilated with an air-oxygen mixture to ob-
tain a PaCO2 of 4.7–5.3 kPa. Heparin sulfate
was administered before start of cardiopulmo-
nary bypass at a dose of 3 mg/kg and subse-
quently at doses adapted to maintain the acti-
vated clotting time above 400 secs. At the end
of cardiopulmonary bypass, the heparin action
was antagonized by protamine sulfate. Bypass
priming included gelatin, mannitol, sodium
bicarbonate, and heparin. After venous and
arterial cannulation, cardiopulmonary bypass
was commenced using a membrane oxygen-
ator (Baxter, Uden, The Netherlands). Flow
rates at about 2.4 L/min/m2 with nonpulsatile
flow were set to maintain a mean arterial
pressure of 50–70 mm Hg, and a PaO2 between
9 and 11 kPa, and a PaCO2 of 4.7–5.3 kPa. Next,
antegrade cardioplegia with cold crystalloids
was administered for myocardial preservation.
During bypass, the core temperature was
maintained at 28°C. A pulmonary artery cath-
eter and three-way central venous catheter
were inserted after induction of anesthesia.
Standard antimicrobial surgical prophylaxis
consisted of flucloxacillin.
Intervention. At the outpatient clinic, pa-
tients were randomly allocated to selective gut
decontamination or placebo, and took this
medication home. Randomization was per-
formed by the hospital pharmacist using a
computer-generated code for randomized al-
location to medication or placebo; patients
and investigators were blinded until comple-
tion of the study. On Thursday morning in the
week before surgery, patients were notified by
phone of the exact day of operation. Patients to
be operated on Tuesday, Wednesday, or Thurs-
day were instructed to take their medication
for 5, 6, or 7 days, respectively; last medication
was taken at the night before surgery. Patients
received four times daily two tablets each con-
taining neomycin 125 mg and polymyxin B
500,000 E or placebo. Leftover tablets were
taken in and counted at admission. The tablets
for selective gut decontamination were pre-
pared by the hospital pharmacist and have
been in use for many years in the hematology
and bone marrow transplant unit of our hos-
pital (18, 19). Patients to be operated on Mon-
day or Friday were instructed not to take their
medication, as logistic reasons concerning
part of the perioperative blood sampling and
microbiological culture precluded the inclu-
sion of these patients; tablets were taken in
and counted at admission.
Before the prospective selective decontam-
ination study was started, a pilot study (in-
cluding 44 consecutive patients) was done to
determine the time-points for blood sampling.
Microbiological Surveillance. In all pa-
tients who took medication, microbiological
surveillance was performed by culture of rec-
tal swabs taken the evening before surgery and
screening for aerobic Gram-negative microor-
ganisms. Rectal swabs were used to swab Mc-
Conkey 3 and sheep red blood cell-plates, and
subsequently added in brain-heart infusion
broth and cultured overnight at 37°C. Aerobic
Gram-negatives were identified macroscopi-
cally and on the basis of growth characteristics
and biochemically by API. The culture of aer-
obic Gram-negative microorganisms on the
solid plates as well as in the fluid medium is
categorized as “many bacteria present”; a pos-
itive culture in the brain-heart infusion broth
only as “few bacteria present” (18, 19). In two
patients, no rectal swabs were available; these
patients were later found to be allocated in the
selective gut decontamination group.
Endotoxin and Cytokine Sampling and As-
say. Blood for endotoxin determination was
collected in pyrogen-free tubes (Kabi-Vitrum,
Amsterdam, The Netherlands) and platelet-
rich plasma was prepared by centrifugation.
Endotoxin was determined in platelet-rich
plasma by a quantitative photometric assay
with end-point measurement as described
(11); the assay’s lower detection limit for en-
dotoxin is about 3.0 pg/mL; concentrations
5 pg/mL were considered to indicate endo-
toxemia (11, 20). Blood for determination of
cytokines was collected in pyrogen-free ethyl-
enediaminetetraacetic acid tubes (Chromoge-
nics, Amsterdam, The Netherlands) and im-
mersed in ice. Plasma was prepared by
centrifugation at 3000 g for 5–10 mins at 4°C
and stored at 70°C. Tumor necrosis factor
(TNF)-, interleukin (IL)-10, and IL-6 concen-
trations were determined with a standard en-
zyme-linked immunoassay technique (Central
Laboratories for Bloodtransfusion, Amster-
dam, The Netherlands; Medgenix Diagnostics,
Floury, Belgium) (11); the lower detection
limit was 0.5 pg/mL for TNF-, and 5.0 pg/mL
for IL-10 and IL-6. For the IL-6 determina-
tions, samples were available from 22 of 24
patients receiving selective gut decontamina-
tion, and from 23 of 27 patients receiving
placebo. All samples were determined in a
blinded fashion; results were not available un-
til completion of the study.
Analysis of Data. Analysis of variance, non-
parametric testing, and logistic regression
analysis were used to assess an association
between medication (selective gut decontam-
ination or placebo) and endotoxin, cytokines,
clinical parameters (postoperative fever, and
duration of artificial ventilation, cardiotho-
racic intensive care unit [ICU] and hospital
stay) and outcome of hospitalization. Data for
endotoxin and cytokine levels were used after
log-transformation (11). When indicated, en-
dotoxemia and cytokines were entered as cat-
egorical variable, using cutoff concentrations
of 5 pg/mL for endotoxin and TNF-, 100
pg/mL for IL-6, and 25 pg/mL for IL- 10. These
cutoff values are somewhat arbitrarily but
based on previous assessment in clinical stud-
ies (11, 20). Multiple organ dysfunction syn-
drome (MODS) was considered when a patient
had three or more organ system failures dur-
ing a 24-hr period in the postoperative phase.
Statistical significance was tested two-
tailed, with the  set to 0.05.
RESULTS
Pilot Study. In 44 consecutive patients
(median age 67 yrs, 29 male), a total of
247 measurements of endotoxin concen-
tration were taken after anesthetic induc-
tion, on aorta declamping, at the end of
and 30 mins after stopping the cardiopul-
monary bypass (i.e., extracorporal perfu-
sion), on surgical closure, and at the ICU
about 2 hrs after surgery. In 64 of these
samples (26%). the endotoxin concentra-
tion was 5 pg/mL.
None of the 44 patients had endotox-
emia directly after anesthetic induction.
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Twenty-four patients (55%) did not have
a raised endotoxin concentration at any
point during the operation; four patients
in this group, however, had endotoxemia
at admission to the ICU. Twenty patients
(45%) had 52 episodes of endotoxemia
during and after cardiopulmonary bypass.
In 16 of these patients, at least two sep-
arate consecutive samples were positive,
whereas 8 patients still had endotoxemia
at admission to the ICU. On the basis of
the pilot study, it was decided to measure
the endotoxin concentrations in the pro-
spective study after anesthetic induction,
on aorta declamping, 30 mins into body
reperfusion (i.e., 30 mins after stopping
the extracorporal perfusion), and at the
ICU about 2 hrs after surgery.
Allocation of Patients and Compara-
bility of Groups. Seventy-eight patients
were randomized to receive placebo or
selective gut decontamination. Of these,
24 patients received selective gut decon-
tamination and 27 patients took placebo.
The other patients (n  27) were oper-
ated upon on days outside the study pro-
tocol and were allocated in the noninter-
vention, control group. Patients receiving
selective gut decontamination did not dif-
fer from those taking placebo or the non-
intervention control group with respect
to age, gender, smoking history, diabetes
mellitus, and other co-morbidities like
emphysema (p  .20), surgical procedure
(coronary artery bypass graft and/or valve
replacement) and ASA score (Table 1).
Aerobic Gram-Negative Gut Flora. In
patients receiving placebo, aerobic Gram-
negative bacteria were cultured from the
rectal swab in 25 out of 27 patients
(93%); in 3 of these, the microorganisms
were cultured only from the broth. In
patients given selective gut decontamina-
tion, the number of patients carrying aer-
obic Gram-negative bacteria was signifi-
cantly (p  .001) decreased: in only 6 of
22 patients (27%) were such microorgan-
isms isolated; in 2 of these patients the
bacteria were present only in the broth
(Table 2).
Perioperative Endotoxemia. In all but
one patient (selective gut decontamina-
tion), endotoxin levels were 5 pg/mL
directly after anesthetic induction. On
aorta declamping and 30 mins into reper-
fusion, endotoxemia was common in
both patients receiving selective gut de-
contamination and those given placebo:
between 31% and 61% of the patients had
5 pg/mL endotoxin in the blood. Nei-
ther the percentage of patients with en-
dotoxemia nor the actual plasma concen-
tration of endotoxin differed significantly
(p  .20) between patients receiving se-
lective gut decontamination or placebo
(Table 3; Fig. 1). Similarly, on arrival at
the ICU 2 hrs after surgery, the number
of patients with a significant endotoxin
level was similar (p  .20) in the groups.
Of note, the subgroup of patients receiv-
ing selective gut decontamination and
showing no growth of aerobic Gram-
negative microorganisms in the rectal
swab had similar rates of endotoxemia as
those in this group with such bacteria
still present. Also, in the nonintervention
control group, 37% to 65% of the pa-
tients had 5 pg/mL endotoxin in the
blood on aorta declamping and during
body reperfusion (data not shown),
whereas the actual plasma concentration
of endotoxin did differ significantly (p 
.20) from those in patients receiving se-
lective gut decontamination or placebo
(Fig. 1).
Perioperative Cytokine Activation.
Plasma concentrations of the cytokines
rose significantly at the end of cardiopul-
monary bypass and reached maximum
values at 30 mins after start of reperfu-
sion (TNF-, IL-10) or at admission to
the ICU (IL-6). Overall cytokine concen-
trations were highly similar (p  .20) in
patients receiving selective gut decon-
tamination and those given placebo (Ta-
ble 3; Fig. 1). Also, if the TNF-, IL-10,
and IL-6 measurements were dichoto-
mized at various different values, cyto-
kine activation was similar (p  .20) in
patients receiving selective gut decon-
tamination and those given placebo, and,
in addition, did not differ from those in
the control group (Fig. 1). In the ICU, 2
hrs after surgery, TNF- and IL-10 al-









(n  27) p Value
Age, yrs 64 (58–69) 65 (57–71) 65 (55–72) .20
Gender, male (%) 16 (67) 17 (63) 22 (81) .20
Weight, kg 75 (67–87) 79 (70–87) 80 (71–93) .20
Active smoker, n (%) 4 (17) 4 (19) 7 (26) .20
Type of operation .20
CABG 20 22 21
Valve replacement 1 2 2
CABG  valve replacement 1 1 1
Other 2 2 3
ASA score 3, % 80 76 90 .20
Perioperative data
Operation time, mins 255 (176–308) 264 (197–280) 222 (188–261) .20
Perfusion time, mins 120 (83–152) 111 (91–149) 104 (70–131) .20
Aorta clamp time, mins 58 (45–87) 69 (38–89) 66 (42–83) .20
Flow bypass, min-max, L/min 3.7–4.5 3.8–4.6 3.8–4.6 .20
Lowest temperature, °C 28.1 (27–31) 30.2 (28–32) 30.2 (28–32) .18
Postoperative data
Hospital stay, days 11 (9–15) 10 (9–13) 9 (8–12) .13
Fatalities, n (%) 1 (4) 1 (4) 2 (7) .20
CABG, coronary artery bypass graft.
aMedian values and interquartile range are between parentheses.
Table 2. Efficacy of selective gut decontamination in intervention group





Aerobic Gram-negative bacteria .001
BHI broth and plates 4 22
BHI broth only 2 3
Absent 16 2
BHI, brain-heart infusion.
aCulture of rectal swab, categorized as explained under the Methods section; bin two patients, no
rectal swabs were available.
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ready were decreasing in all groups,
whereas IL-6 increased further, as com-
pared with the levels upon aorta declamp-
ing. In the patients who did not have
endotoxemia, plasma TNF-, and IL-6
rose significantly during surgery, albeit
less than in patients with endotoxemia (p
 .015); IL-10 levels were not different
between patients with or without endo-
toxemia.
In four patients receiving selective gut
decontamination and seven patients re-
ceiving placebo, but none in the control
group, glucocorticosteroids were admin-
istered during the operation. Glucocorti-
costeroids raised the IL-10 concentra-
tions significantly (p  .01) and led to a
somewhat decreased IL-6 concentration
at admission to the ICU (118 pg/mL,
range 40–760; 350 pg/mL, range 40–
23,000, respectively; p  0.02), but the
administration did not affect either
TNF- (p  .80) or endotoxin concentra-
tions (p  .50).
Clinical Evaluation. No differences
between the groups were observed re-
garding the length of stay in the ICU, the
duration of artificial ventilation, and
postoperative complications like reopera-
tion (mostly for bleeding complications),
multiple organ failure, or fatal outcome.
Patients who received selective gut de-
contamination had a temperature peak
above 38.5°C on the first postoperative
day more often than the placebo or con-
trols (Table 4). However, the percentage
of patients with a temperature rise above
38.5°C that sustained at least 6 hrs did
not differ significantly between the
groups, and at 1 day after the operation,
the temperature of the patients in the
various groups was identical (Table 4).
Furthermore, 1 day after the operation,
the systolic and diastolic blood pressure,
pulse rate, blood leukocyte count, and
serum creatinine concentrations did not
differ between the groups (p  .15; data
for blood leukocyte count included in Ta-
ble 2).
DISCUSSION
The association between morbidity in
cardiac surgery patients and periopera-
tive plasma endotoxin and cytokine acti-
vation is important in terms of the reduc-
tion in morbidity that would follow a
description of the underlying pathophys-
iological mechanism and validation of a
successful (pre- or perioperative) inter-
vention strategy aimed at this mecha-
nism. The present prospective, random-
ized, placebo-controlled study in patients
undergoing cardiac surgery with cardio-
pulmonary bypass demonstrates that 1
wk of preoperative selective gut decon-
tamination with nonabsorbable antibiot-
ics has no effect on the occurrence of
perioperative endotoxemia, cytokine acti-
vation, and the postperfusion systemic
inflammatory response syndrome. Thus,
given the effective reduction of aerobic
Gram-negative microorganisms by the
decontamination measure, our findings
lend no support to the presumptive cen-
tral role that the live, replicating micro-
organisms in the gut are thought to be
the predominant source of circulating
endotoxin during cardiopulmonary by-
pass and in the pathophysiology of the
postperfusion syndrome (13, 21).
Our results show that selective gut
decontamination with polymyxin B and
neomycin given for 5–7 days is very ef-
fective in the reduction of aerobic Gram-
negative flora from the gut: in most pa-
tients a complete eradication of these
microorganisms was achieved, as was






Decontamination (n  24) Placebo (n  27)
Endotoxemia (5 pg/mL) .20
Anesthetic induction 1/23 (4 ) 0/25 (0 )
Release of aortic clamp 14/23 (61) 15/26 (58)
30-min reperfusion 11/23 (48) 12/26 (38)
At admission to ICU 11/23 (48) 8/26 (31)
TNF- (5 pg/mL) .20
Anesthetic induction 1/24 (4 ) 0/27 (0 )
Release of aortic clamp 6/24 (25) 6/27 (22)
30-min reperfusion 13/24 (54) 13/27 (48)
At admission to ICU 10/24 (42) 12/27 (44)
IL-6 (100 pg/mL) .20
Release of aortic clamp 5/22 (23) 2/23 (9 )
At admission to ICU 18/22 (82) 15/23 (65)
IL-10 (25 pg/mL) .20
Anesthetic induction 1/24 (4 ) 0/27 (0 )
Release of aortic clamp 13/24 (54) 11/27 (41)
30-min reperfusion 12/24 (50) 11/27 (41)
At admission to ICU 6/24 (25) 8/27 (30)
ICU, intensive care unit; TNF, tumor necrosis factor; IL, interleukin.
Figure 1. Plasma endotoxin concentrations in
patients undergoing open heart surgery, and at
the cardiothoracic intensive care unit (ICU). Pa-
tients were randomized to receive placebo or
selective gut decontamination (decont). The box
plots display the median, the 25th and 75th per-
centiles, and smallest and largest endotoxin val-
ues that are not outliers. Endotoxin was deter-
mined in platelet-rich plasma by a quantitative
photometric assay with end-point measurement;
the detection limit for endotoxin is about 3.0
pg/mL. Tumor necrosis factor (TNF)- and inter-
leukin (IL)-10 were measured by enzyme-linked
immunosorbent assay; the detection limit is 0.5
pg/mL and 5.0 pg/mL, respectively.
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previously shown in hematologic and
bone marrow transplant patients during
the extended episodes of granulocytope-
nia (18, 19). Studies in these patients had
also demonstrated that, on average, selec-
tive gut decontamination needs to last for
at least 5 days to be effective in the com-
plete eradication of aerobic Gram-nega-
tive bowel flora (18). The present report
extends these findings to patients under-
going elective cardiac surgery. The
choice of polymyxin B in this regimen
seems especially appropriate as this bac-
tericidal antibiotic is well known for its
endotoxin-binding properties (22).
Our findings add to previous studies
showing that, during cardiopulmonary
bypass, cytokine activation occurs in the
absence of endotoxemia, and confirm
that perioperative endotoxemia in itself is
a weak predictor of clinical outcome in
cardiac surgery patients. Another rich
source of cytokines during cardiopulmo-
nary bypass is the pulmonary circulation,
and may lead to myocardial stunning
(23). Some of our patients received a dose
of glucocorticosteroids during surgery,
and, in accordance with reported data,
the plasma IL-10 concentrations were
markedly increased in these patients (24).
However, the administration did not af-
fect the endotoxin and TNF- levels, as
previously shown for methylpred-
nisolone, administration of which did not
prevent or attenuate endotoxemia during
cardiopulmonary bypass (25).
The present findings are in contrast to
the efficacy of selective gut decontamina-
tion to lower endotoxin and cytokine con-
centrations in cardiac patients, as previ-
ously reported by Martinez-Pellús et al.
(13, 21). In their open, randomized study,
selective gut decontamination was ad-
ministered for 3 days before operation,
and succeeded in just over half of their
patients in the elimination of fecal aero-
bic Gram-negative bacteria.
Nevertheless, plasma endotoxin,
TNF-, and IL-6 concentrations were sig-
nificantly reduced in treated patients
compared with controls, and in the sub-
group of treated patients with no growth
of aerobic Gram-negative microorgan-
isms, endotoxin was undetectable in all
samples. We are uncertain of how to ex-
plain the differences between their find-
ings and ours in the effectiveness of se-
lective gut decontamination to prevent or
at least reduce perioperative endotoxemia
and cytokine activation. The detection
limit of our endotoxin assay, i.e., about 3
pg/mL, appears to be lower than theirs,
and the fact that they considered all en-
dotoxin values 5 pg/mL as 0 pg/mL for
the statistical analysis may be relevant to
explain some of the differences in re-
ported endotoxin levels. Their assay may
fail to adequately detect circulating endo-
toxin from anaerobic Gram-negative mi-
croorganisms such as the gut commensal
Bacteroides spp., to which patients un-
dergoing cardiac surgery are likely ex-
posed (26) and may be responsible for up
to 10% of the free endotoxin in the intes-
tinal tract (15). On average, selective gut
decontamination aimed at eradicating
the live, aerobic Gram-negative coliforms
results in a reduction of the endotoxin
concentration of fecal supernatant to
10% of the untreated controls (15, 27),
leaving an endotoxin pool of about 0.1–
1.0 mg/g of feces (16, 27). The endotoxin
measurements in subsequent samples in
our patients were highly consistent, and
the percentage of patients in whom we
measured significant endotoxin concen-
trations (i.e., approximately 50%) is not
different from that observed in studies by
others (4, 21, 28–30). As neither the per-
centage of patients with a significant en-
dotoxemia nor the actual circulating en-
dotoxin concentrations during cardiac
surgery were affected by preoperative se-
lective gut decontamination, the present
findings suggest that, at least in man, the
size of the free endotoxin pool is not the
key limiting factor in the pathophysiolog-
ical mechanism that controls circulating
endotoxin during cardiac surgery.
Our study was placebo-controlled and
double-blinded, and performed in only
one center, in contrast to the study by
Martinez-Pellús et al (21, 31). Signifi-
cantly, their finding that overall outcome
was not very different between treated
patients and controls—although precise
clinical outcomes were not considered—
is in accordance with our study that failed
to demonstrate a positive effect of preop-
erative selective gut decontamination on
the occurrence of postoperative fever and
clinical outcome. In our study, patients
screened because of elective cardiac sur-
gery were eligible for inclusion. Although
the population was heterogenous in
terms of age, co-morbidity, etc., the mix-
ture of patients in our study seems to
represent that seen in many university
and large community hospitals (4, 21,
28–30). Because we did not evaluate the
use of selective gut decontamination in
hospitalized patients, our findings do not
exclude the possibility that preoperative
selective gut decontamination may be of
relevance in such a highly selected pa-
S elective gut decon-tamination effec-tively reduces the
aerobic Gram-negative
bowel flora in cardiac sur-
gery patients but fails to af-




the occurrence of a postper-
fusion syndrome.









ICU stay, days 3 (2–6) 2 (2–4) .20
Artificial ventilator, days 1.0 (1–4) 1.0 (1–3) .20
Temperature, 38.5 °C (%) 23 (96) 15 (56) .03
Temperature, 38.5 °C for 6 hrs (%) 17 (71) 11 (41) .16
Temperature, at 24 hrs, °C 37.7 (37.4–37.8) 37.5 (37.2–37.7) .20
Leukocytes at 24 hrs 9.9 (8.2–12.3) 8.3 (7.4–8.7) .20
Reoperation (%) 4 (17) 5 (19) .20
Multiple organ failure (%) 1 (4) 0 (—) .20
ICU, intensive care unit.
aMedian values and interquartile range are between parentheses.
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tient group. However, consistent with
our findings, selective decontamination
of the digestive tract in patients undergo-
ing elective orthotopic liver transplanta-
tion failed to abolish perioperative endo-
toxemia or the development of organ
system failure and did not enhance sur-
vival (32). Interestingly, the preoperative
loading of patients with glutamine, aimed
to protect the gut mucosal barrier during
insufficient perfusion, did not prevent en-
dotoxemia during and shortly after car-
diac surgery (33).
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We read with interest the comment by Dr. Oudemans-van Straaten and colleagues (1) on 
our trial investigating the effect of preoperative selective gut decontamination (SGD) on 
endotoxemia and cytokine activation during cardiopulmonary bypass (2). Their main point 
of criticism concerns the choice of neomycin over tobramycin in our SGD regimen. 
Furthermore, they claim that there is a lack of correlation between fecal aerobic Gram-
negative bacilli and endotoxin concentration. Dr. Oudemans-van Straaten and colleagues 
(1) suggest that the use of neomycin instead of tobramycin is responsible for the absence of 
an effect of our SGD regimen on endotoxemia. We would like to counter their critical 
notes.
The SGD regimen used in our randomized controlled trail was highly effective in 
eradicating aerobic Gram-negative bacilli (AGNB) from the bowel; 73% of the patients 
taking the trial medication had no AGNB at all, whereas others had strongly reduced 
numbers in the culture of a rectal swab (2), confirming previous studies on the 
effectiveness of this regimen in hematology and bone marrow transplant patients (3;4). 
This finding implicates that the regimen has a very potent antimicrobial activity and 
thereby reputes the theoretical objection made by Dr. Oudemans-van Straaten and 
colleagues (1) that neomycin is “inactivated” by feces (1). Moreover, their proposition is 
based on rather artificial experiments that showed inactivation of several antibiotics by 
fecal material in vitro. These findings remain of undetermined significance since they have 
never been shown to correlate with the ability of the selected antibiotics to reduce AGNB 
or endotoxin in feces (5). Furthermore, the neomycin dose used in our study (250 mg every 
6 hrs, i.e., 1000 mg/day) is very high. Even in the theoretical situation that <99% of the 
total amount of neomycin would be “inactivated” by feces, the remaining free 
concentration would still be well above the “minimal inhibitory concentration” of most 
target microorganisms (e.g., fecal amount is approximately 200 g/day, total concentration 
of neomycin is about 5000 µg/g feces, 1% of this equals about 50 µg free neomycin/g 
feces). Their remark that neomycin, as opposed to tobramycin, fails to show “anti-
endotoxin” properties is not substantiated by the literature they refer to: In the study by 
Rogers et al. (6), neomycin was combined with streptomycin and amfotericin B and not 
with polymyxin as we did, making direct comparison impossible. The suggestion of Dr. 
Oudemans-van Straaten and colleagues(1) that tobramycin has strong “anti-endotoxin” 
properties is not substantiated by the study of Sjolin et al. (7), which showed no such 
property of tobramycin when added to cefuroxime-treated Escherichia coli cultures. The 
effect of aminoglycosiden in lowering endotoxin concentrations, although they might have 
a slightly different antibacterial spectrum, is most likely due to their mode of action being 
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rapid killing and inhibition of endotoxin synthesis and not an “anti-endotoxin” effect as 
such (8). Altogether we do not find it feasible to attribute “anti-endotoxin” properties to 
antibiotics as a separate entity apart from their primary mode of action being antimicrobial 
activity. Polymyxin is not an exception to this rule; the mode of action of this unique 
bactericidal polypeptide is binding to the bacterial outer membrane components, mainly 
being lipopolysaccharides and phospholipids. Not surprisingly, this compound is able to 
neutralize much of the toxic actions of endotoxin, that is, mainly ex vivo (9;10).
We do not believe that endotoxin and AGNB levels do not correlate. Several studies 
have shown this correlation (6;11;12).
We have no doubt that the SGD regime used in our study, like other studies showing 
correlation between reduction in AGNB and endotoxin concentrations, lowered fecal 
endotoxin concentrations. Therefore, our conclusion remains that reducing AGNB in the 
gut from patients undergoing elective cardiac surgery does not reduce the perioperative 
endotoxemia and subsequent inflammatory response. These findings suggest that, at least 
in humans, the total size of the free endotoxin pool is not the key limiting factor in the 
pathophysiological mechanism that controls circulating endotoxin during cardiac surgery 
(2). For instance, the lower endotoxin content due to Gram-negatives other than the AGNB 
could well account for a concentration of endotoxin that already saturates the underlying 
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TNF-α and IL-10 production upon whole blood stimulation with a 
wide range of LPS concentrations: estimating an individual's dose-










































Individuals are commonly described as 'low' or 'high' producers of cytokines based on ex 
vivo stimulation of their cells with various stimuli, most often lipopolysaccharide. This 
dichotomous characteristic is subsequently used as reference in clinical and genetic studies. 
Since this approach is not based on a physiological model and studies using this approach 
yielded conflicting results, we investigated whether it was possible to better describe an 
individuals cytokine production profile using a receptor-ligand interaction model that is 
fully characterized by two parameters, i.e., EC50, the estimated LPS concentration at which 
half of the cytokine concentration is reached and the Emax, the estimated maximal 
concentration of cytokine released. Repeated measurements over several weeks disclosed 
that these two parameters were highly constant for individuals, yet differed between 
individuals. In contrast with this, only the TNF-α concentration measured after stimulation 
with the lowest LPS concentration (0.1 ng/mL) was different between the subjects, 
whereas IL-10 concentrations were only different between the subjects after stimulation 
with the lower LPS concentrations (i.e. 0.1 through 100 ng/mL). Our findings suggest that 
relevant information on cytokine release is lost, when the commonly applied approach is 
taken, i.e. testing the TNF-α and or IL-10 release after stimulation with a single, and often 
high, LPS concentration. 
Studies aimed at correlating in vitro with in vivo phenotypes and genetic 
polymorphisms should for this purpose use large dose-response ranges of whole blood 
stimulation with LPS to be able to closely estimate these dose-response characteristics. 
Such dose-response characteristics are more likely to be good estimates of an individual’s 
in vitro cytokine production profile and therefore more suitable as a reference used in 
studies that investigate the genetic factors that make up for the large inter-individual 





Ex vivo cytokine production capacity of an individual is elegantly determined in the 
supernatant of whole blood after stimulation with lipopolysaccharide (LPS). The system 
provides a natural environment for cytokine producing cells, mainly being monocytes. 
Based on a rather small day-to-day intra-individual variation and laboratory variation, both 
estimated at around 15%, in combination with a rather large inter-individual variation, the 
system is able to distinguish ‘high’ and ‘low’ producing individuals of TNF-α and IL-10 
based on the cytokine concentration found in the supernatant upon stimulation with one 
single concentration of LPS (1). In one study the aforementioned approach was able to 
detect differences in ex vivo cytokine production in relatives of patients with poor or fatal 
outcome of meningococcal disease as compared to relatives of patients with more 
favorable outcome (2). These observations led to the conclusion that the inter-individual 
variation found in these cytokine concentrations is to be explained to a large extend by 
genetic background (2;3). Many studies set out to search for genetic factors explaining this 
variation. Better understanding of the pathways involved in LPS sensing and intracellular 
signaling were essential in the search for these genes. Studies mainly focused on finding 
associations between specific gene(-promoter) polymorphisms and (whole blood) 
stimulation phenotype (i.e. individuals categorized as 'high' as compared to 'low' 
producers) based on a cytokine measurement after stimulation with one single – but 
between studies varying – concentrations of LPS (2-30). The conclusions of these studies 
have been conflicting. Part of the explanation for this might be differences in the handling 
of samples, differences in the various assays, cellular sources (whole blood, isolated cells), 
the LPS composition, incubation times, and, likely most importantly the differences in the 
LPS concentrations used to stimulate the cells. Categorizing individuals as 'high' as 
compared to 'low' producers based on cytokine production upon a single LPS concentration 
might not be adequate. First, the LPS concentrations used in these studies almost always 
exceeded the concentrations found in patients with infectious disease, hampering the 
translation of the in vitro phenotype to the in vivo situation. Secondly, the cytokine 
concentrations found after stimulation with a single high concentration of LPS will reflect 
the maximal production capacity, but might not necessarily provide insight in the cytokine 
response at lower LPS concentrations. Furthermore, aspects of the dose-response 
characteristics, for instance the LPS concentration at which 50% of the maximal cytokine 
concentration is reached and the maximal cytokine production capacity of the dose-
response curve are not taken into account. Since the discovery of the toll-like receptor 4, 
the main extra cellular receptor for LPS, these aspects are of increased interest since this 
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mode of LPS signaling is likely to follow the basic concepts of the receptor-ligand model 
used in other fields of research (31). Based on the dose response model know as the Cmax 
model we calculated the dose response characteristics of individuals by using supernatant 
cytokine concentrations after stimulation with a wide range of LPS concentrations. In order 
to be able to quantify the influence of the laboratory and the intra-individual day-to-day 
variation on these parameters we performed each measurement separately in duplicates and 
repeated the assay several times over several weeks. We hypothesize that the intra-
individual day-to-day variation in the dose-response parameters is small as compared to the 
variation found in the intra-individual day-to-day variation found in a single point 
measurement and have better discriminative properties in labeling an individuals 
phenotype. If these premises were met, it would be suitable to use these parameters as 
patient characteristics in future research. 
 
Materials and Methods 
 
Subjects and blood sample collection. 
We studied two healthy male subjects. Neither of the subjects used any prescription drugs, 
nor where they active smokers. No dietary restrictions were applied on the day of blood 
collection nor on the days prior. In the 3 weeks before and during the sampling the subjects 
did not experience any signs or symptoms of infection such as fever. Blood samples were 
drawn at 9:00 am using a Vacutainer® blood collecting system in four endotoxin-free 
collection tubes (Endo Tube ET, 4 mL, containing 120 IU sodium heparin, Chromogenix, 
Amsterdam, Netherlands), through puncture of a large antecubial vene. From each tube a 
separate whole blood stimulation assay, i.e. two whole blood stimulations for each 
cytokine, was performed without delay as described below. The whole procedure was 
repeated 7-9 times over a 3-week period. 
 
Whole blood stimulation assay and LPS preparation. 
Briefly, whole-blood samples were mixed 1:1 with RPMI 1640 (Gibco, Germany) and LPS 
(Escherichia coli O111, Sigma) diluted in RPMI 1640 was added to final concentrations of 
0.1, 1, 10, 100, 1000 and 10,000 ng/mL and a total volume of 1 ml using 24-well microtiter 
plates. On each day fresh LPS dilutions were prepared from one single batch of LPS (5 
mg/ml, stored at -80 0C). The stimulations were performed by incubation of the 1:1 diluted 
blood without LPS addition as a negative control. Cells were subsequently stimulated for 4 
and 24 hours at 37 0C under 5% CO2 for determination of TNF-α and IL-10, respectively. 
Supernatants (4 times 200 µl for each LPS concentration) were collected after 
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centrifugation of the microtiter plates at 600 x g at 4 0C and stored at -70 0C in 250 µl 
aliquots for final measurement of the cytokines. 
 
TNF-α and IL-10 measurement. 
Cytokine concentrations in the supernatants derived from the repeated stimulation assays 
were analysed on a single day using one ELISA batch. Tumor necrosis factor (TNF)-α and 
Interleukin-10 concentrations were determined with a standard ELISA technique (PeliKine 
CompactTM, Central Laboratory of the Netherlands Red Cross Blood transfusion Service, 
Amsterdam, The Netherlands); the lower detection limit was 4.0 pg/mL. Each cytokine 
concentration was measured in duplicate. In case of laboratory failure, supernatants were 
retested using a new, previously unfrozen aliquot. In such case all supernatants derived 
from the two whole blood stimulations from that single vena puncture were retested.  
 
Calculation of ex vivo TNF-α, IL-10 and LPS dose-response. 
Dose-response characteristics for the mean of the whole blood stimulation for each 
cytokine (i.e. TNF-α or IL-10) were calculated for each subject using the ligand-receptor 
response model as previously described (31). The basis for this model is the principal that 
the interaction between a ligand (i.e., LPS) and its receptor is the first step leading to the 
response. The effect is correlated with the number of receptors occupied and is maximal 
when all receptors are occupied. The ligand concentration at which 50% of the maximal 
response is reached (EC50) is a parameter of the affinity of the ligand for its receptor. 
Taking together, the assumptions lead to the Emax model, mathematically described as the 
Hill equation.  
In the first approach we used a single step Emax equation as a model.  
 
EN = EN,max  x C/(EC50 + C)        (model 1) 
 
Where EN is the observed cytokine concentration at a given LPS concentration C, EC50 
is the estimated LPS concentration at which 50% of the maximal cytokine concentration is 
reached, and EN,max is the estimated maximal cytokine concentration.  
In a second approach, for instance if we assumed that the release of cytokine might be 
described better as a two-stage process; first, stimulation leads to the release of preformed 
cytokines, stored intracellular in granules; secondary, stimulation activates gene 
transcription and de novo production of cytokines. Furthermore, the measured amount of 
cytokine released upon stimulation with LPS is most likely a sum of cytokine released by 
stimulation of different pathways. Together, this would result in a two-step release, with 
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different time coefficients and possibly different regulatory set points, depending on the 
intensity of the stimulus. To fit for such a model, the second analysis was based on two 
Emax equations revealing four dose-response characteristics for the LPS-induced cytokine 
production (i.e. TNF-α or IL-10) in each subject.  
 
EN = EN,max-1  x C/(EC50-1 + C) +  EN,max-2  x C/(EC50-2 + C)  (model 2) 
 
Where EN is the observed cytokine concentration at a given LPS concentration C, EC50-1 
and EC50-2 are the estimated LPS concentration at which 50% of the maximal cytokine 
concentration at the first stage and the second stage was reached, respectively, and EN,max-1 
and EN,max-2 is the estimated maximal cytokine concentration at the first stage and the 
second stage, respectively. 
The characteristics were calculated by non-linear regression using SPSS 12.0.1. 
 
Statistical Analysis. 
The spread in the TNF-α and IL-10 ELISA measurements was estimated by calculating the 
mean of the paired differences of each duplicate measurement divided by the mean of these 
measurements. This coefficient was calculated for each LPS concentration. 
For the whole blood assay the coefficient of variation (the standard deviation (SD) 
divided by the mean) was determined for each LPS concentration. For this calculation the 
mean of the duplicate measurements were used. The coefficients of variation were 
calculated pair wise in repeated experiments (yielding the mean of individual coefficients 
of variation). Because the coefficient of variation is less subject to scaling effects as 
compared to the SD, values of the coefficient of variation for different experimental 
conditions were pooled to assess overall variation. Comparison of means was performed 
by ANOVA or its non-parametric alternative (Mann-Whitney U test) where appropriate. 
Furthermore, we performed an analysis of variance to estimate day-to-day and inter-
individual variance, adjusted for LPS concentrations and the individual tested. 
Calculations of the correlation coefficient between duplicate measurements were assessed 




Within ELISA variation. 
For each of the LPS concentrations thirty-six duplicate ELISA measurements for TNF-α 
and thirty for IL-10 were available. The spread of the TNF-α and IL-10 ELISA 
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measurement was estimated as described in the methods. Briefly, the paired differences of 
each duplicate measurement were divided by their mean. For each LPS concentration the 
mean of these coefficients (eighteen for TNF-α and fifteen for IL-10) was calculated, 
revealing the mean spread relative to the mean for both TNF-α and IL-10 at each of the 
LPS concentrations. For TNF-α this mean spread relative to mean, after stimulation with 
0.1, 1, 10, 100, 1000 and 10,000 ng/mL LPS, was 10.9, 11.9, 13.2, 11.9, 14.5 and 15.1%, 
respectively. Since these percentages were not statistically different, the data were pooled 
revealing an overall spread relative to the mean of 12.9%. For IL-10 the spread relative to 
the mean after stimulation with 0.1, 1, 10, 100, 1000 and 10,000 ng/mL LPS was 37.5, 
11.2, 17.0, 17.5, 19.1 and 13.6%, respectively. The percentage after stimulation with 0.1 
ng/mL was high as compared to the other percentages, likely due to low concentrations of 
IL-10 (i.e. close to the level of detection) leading to a relatively high impact of even small 
differences in the test result (i.e. scaling effect). For this reason in the calculation of the 
overall spread relative to the mean, the data after stimulation with 0.1 ng/ml LPS were 
disregarded, leading to an overall spread relative to the mean of 15.7%. 
 
TNF-α and IL-10 within whole blood stimulation variation. 
The variation in the whole blood stimulation assay was investigated by performing the 
assay in duplicate; for each assay a single tube, drawn from one subject through a single 
vena puncture, was used as described in the methods. The cytokine measurements were 
performed on a single day, using a single ELISA batch. In each supernatant the cytokine 
measurement was performed in duplicate and the mean of the two ELISA measurements 
was used for this analyses. 
The TNF-α concentration found with the first whole blood stimulation correlated with 
the second with r = 0.812, 0.676, 0.664, 0.773, 0.827 and 0.767 after stimulation with 0.1, 
1, 10, 100, 1000 and 10,000 ng/mL LPS, respectively. Correlation between the two TNF-α 
measurements after stimulation with all LPS concentrations combined was very high (r = 
0.961). The same procedure was done for the IL-10 assay. The IL-10 concentration found 
with the first whole blood stimulation correlated with the second with r = 0.959, 0.946, 
0.693, 0.782, 0.776, 0.979 after stimulation with 0.1, 1, 10, 100, 1000 and 10,000 ng/mL 
LPS, respectively. Correlation between the two IL-10 measurements after stimulation with 
all LPS concentrations combined was very high (r = 0.979). A plot of the differences 
against the means, to estimate the repeatability of the assay, is given in Fig. 1 for TNF-α 
and Fig. 2 for IL-10. 
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Figure 1. Ex vivo production of TNF-α in 18 whole blood samples in two subjects stimulated in duplicate with 0.1, 1, 10, 
100, 1000 and 10.000 ng/mL lipopolysaccharide. Each dot represents the difference between both measurements (first 
minus second) dependent on the mean of both measurements.
 
For TNF-α the mean of the paired differences using all data was 17.2 pg/mL (95% 
confidence interval around the mean difference -2346 to 1367 pg/mL). The coefficient of 
variation (the standard deviation (SD) divided by the mean) was 8.4, 15.6, 10.1, 10.7, 3.2 
and 11.1% after stimulation with 0.1, 1, 10, 100, 1000 and 10,000 ng/mL LPS, 
respectively. Taking together this leads to an overall mean coefficient of variation of 9.9%. 
For IL-10 the mean of the paired differences using all data was 136.7 pg/mL (95% 
confidence interval around the mean difference -392 to 1610 pg/mL). The coefficient of 
variation (the standard deviation (SD) divided by the mean) was 30.5, 9.1, 3.0, 3.0, 3.7 and 
2.0% after stimulation with 0.1, 1, 10, 100, 1000 and 10,000 ng/mL LPS, respectively. 
Taking these percentages taking together, ignoring the data from the stimulation with 0.1 
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Figure 2. Ex vivo production of IL-10 in 15 whole blood samples in two subjects stimulated in duplicate with 0.1, 1, 10, 
100, 1000 and 10.000 ng/mL lipopolysaccharide. Each dot represents the difference between both measurements (first 
minus second) dependent on the mean of both measurements.
 
Day-to-day variation in whole blood stimulation. 
As described in the methods the whole blood stimulation was performed in two subjects 
over a period of three weeks. To investigate the day-to-day variation in the assay the mean 
cytokine concentration from two whole blood stimulations performed on the same day 
were used for each subject separately. The data are shown in Table 1. The coefficients of 
variation for TNF-α measurements were around 20% at each of the LPS concentrations in 
both subjects. For IL-10 the coefficients of variation were higher, i.e. around 35%. 
Coefficients for the IL-10 measurements were especially high in the extremes of the LPS 
concentrations used (Table 1). 
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Table 1. Intra-individual variation over 3 weeks in ex vivo production of TNF-α and IL-10 upon whole blood 
stimulation (performed in duplicate) with LPS in various concentrations 





















1 0.1 9 916 318 34.7  7 6.5 5.6 84.8 
 1 9 2861 631 22.1  7 229 72 31.4 
 10 9 4507 752 16.7  7 568 183 32.2 
 100 9 4948 1096 22.2  7 822 332 40.4 
 1000 9 5898 1513 25.7  7 1737 1180 67.9 
 10,000 9 9293 2049 22.0  7 3895 1245 32.0 
2 0.1 9 1286 256 19.9  8 45.5 19.5 42.9 
 1 9 3282 422 12.9  8 502 116 23.1 
 10 9 4106 544 13.2  8 921 206 22.4 
 100 9 4598 776 16.9  8 1203 266 22.1 
 1000 9 5524 1054 19.1  8 2652 1701 64.1 
 10,000 9 8387 2617 31.2  8 5106 3555 69.6 
Observations are means of two whole blood stimulation performed on a single day. CV, coefficient of variation 
expressing relative spread of ex vivo cytokine production over 3 weeks. LPS, lipopolysaccharide. 
 
Multivariate analysis of variance. 
Next, we examined in a multivariate model the variance in the TNF-α and IL-10 
concentrations released within and between experiments. In this analysis TNF-α and IL-10 
concentrations were analyzed after logtransformation. For TNF-α, there was a LPS dose-
dependent (p < 0.0001) increase in the cytokine concentration measured. After adjusting 
for the LPS concentration, there was no significant difference in the concentration of 
TNF-α measured within separate runs (i.e. duplicate whole blood stimulations) performed 
on a single day; between days, the concentration of TNF-α measured differed significantly 
(p = 0.005), but this accounted for only about 4% of the total variance observed. Adjusting 
for the between day variance and LPS concentrations, the concentration of TNF-α 
measured did not differ between the two subjects. For IL-10, similarly to TNF-α, there was 
a LPS dose-dependent (p < 0.0001) increase in the cytokine concentration measured. After 
adjusting for the LPS concentration, there was no significant difference in the 
concentration of IL-10 measured within separate runs (i.e. duplicate whole blood 
stimulations) performed on single day; between days, the concentration of IL-10 measured 
differed somewhat, i.e., on average for about 2% of the total variance observed, but this 
inter-day difference did not reach a level of significance (p = 0.066). However, after 
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adjusting for the between day variance and LPS concentrations, the concentration of 
IL-10 measured did differ significantly between the subjects (p < 0.001), accounting for 
about 27% of the total between subjects variance observed.   
 
Variation in dose-response characteristic using Hill-equation. 
As described in the methods the results from the whole blood stimulation measurements 
using the wide range of LPS concentrations was used to calculate the dose-response 
characteristics using the receptor-ligand model, i.e. the Emax model using the Hill equation. 
For these calculations the means of the two whole blood stimulation assays performed on 
the same day were used (Table 1). The results are shown in Table 2. 
Table 2. Intra-individual variation over 3 weeks of dose response characteristics calculated from TNF-α and IL-10 
production upon whole blood stimulation (performed in duplicate) with LPS in various concentrations 






















TNF-α           
1 EC50 9 2.498 1.508 60.4  9 2.180 3.482 159.7 0.063 
 Emax 9 6636 1416 21.3  9 6016 1614 26.8 0.489 
2 EC50–1 9 0.605 0.163 26.9  9 0.279 0.0924 33.1 <0.001 
 Emax–1 9 4721 858.5 18.2  9 4297 615.3 14.3 0.340 
 EC50–2 9 9.7x109 2.5x109 257.7  9 4285 2420 56.5 0.605 
 Emax–2 9 3.2x109 8.4x109 260.9  9 5808 3236 55.7 0.136 
IL-10           
1 EC50 7 1986 1135 57.2  8 721.5 839.6 116.4 0.029 
 Emax 7 4630 1517 32.8  8 5418 4414 81.5 0.867 
2 EC50–1 7 2.017 0.805 39.9  8 1.090 0.439 40.3 0.014 
 Emax–1 7 627.6 218.5 34.8  8 969.0 176.4 18.2 0.006 
 EC50–2 7 13629 20537 150.7  8 6204 11503 185.4 0.152 
 Emax–2 7 6557 3036 46.3  8 6126 4830 78.8 0.779 
Observations are means of two whole blood stimulation performed on a single day. CV, coefficient of variation 
expressing relative spread of ex vivo cytokine production over 3 weeks. LPS, lipopolysaccharide. EC50, LPS 
concentration at which 50% of the maximal cytokine concentration is reached. Emax, maximal cytokine concentration. 
*Mann-Whitney U test. 
 
For the TNF-α measurements nine measurements were available. As compared to model 
1, model 2 revealed a good estimate of the EC50-1 as well as Emax-1. The coefficient of 
variation for TNF-α EC50-1 was 26.9 and 33.1 for subject 1 and 2, respectively. For the 
TNF-α Emax-1, these values were 18.2 and 14.3 for subject 1 and 2, respectively.  
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For IL-10, seven measurements were available for the first subject and eight were 
available for subject two. As for TNF-α model 2 performed best in a way that a rather 
precise estimation of EC50-1 as well as Emax-1 could be made. The coefficient of variation 
for EC50-1 was 39.9 and 40.3 for subject 1 and 2, respectively. For the Emax-1, these values 
were 34.8 and 18.2, respectively (Table 2). 
Finally for each of the subjects a best estimation of the dose response characteristics 
was calculated, using the same measurements as described above, for each of the 
cytokines. The results of this analysis are shown in Table 3. 
 
Table 3. Dose response characteristics of TNF-α and IL-10 calculated from repeated whole blood stimulation 
assays with LPS in various concentrations in two subjects  




 No. of 





TNF-α      
1 EC50 9 1.903  9 0.8816 
 Emax 9 6565  9 5855 
2 EC50–1 9 0.6033  9 0.2613 
 Emax–1 9 4780  9 4280 
 EC50–2 9 4981  9 3284 
 Emax–2 9 6761  9 5452 
IL-10      
1 EC50 7 1279  8 829 
 Emax 7 4350  8 5421 
2 EC50–1 7 2.212  8 1.014 
 Emax–1 7 692.1  8 981.2 
 EC50–2 7 2961  8 1952 
 Emax–2 7 4152  8 4932 
Observations are means of two whole blood stimulation performed on a single day. CV, coefficient of variation 
expressing relative spread of ex vivo cytokine production over 3 weeks. LPS, lipopolysaccharide. EC50, LPS 
concentration at which 50% of the maximal cytokine concentration is reached. Emax, maximal cytokine 
concentration. 
 
Using these characteristics, the cytokine concentrations were calculated using model 1 
and model 2 for each of the LPS concentrations used. The results for both subjects are 











































































Figure 3. Ex vivo production of TNF-α in subject 1 (A) and subject 2 (B), IL-10 in subject 1 (C) and subject 2 (D). 
Whole blood stimulation was performed nine times over a 3 week period in duplicate. Each data point represents the 
mean of the two whole blood stimulations performed on the same day and the standard deviation (SD). Lines represent 
the fitted concentrations predicted by model 1 (---) and model 2 (…), respectively. 
 
Comparison of TNF-α and IL-10 measurements between the subjects. 
First, at each of the LPS concentrations the cytokine concentrations were compared 
between the two subjects. For TNF-α there was a significant difference in the 
concentrations found after stimulation with 0.1 ng/mL (p = 0.019, Mann-Whitney U test). 
After stimulation with the other LPS concentration no statistically difference differences 
between the two subjects were found (ANOVA and Mann-Whitney U test). Secondly, the 
dose response characteristics were compared between the two subjects. The results are 
shown in Table 2. Both with model 1 and model 2 the EC50-1 values were higher in subject 
1 as compared to subject 2, however the difference was only statistically different using 
model 2 (p < 0.001, Mann-Whitney U test, Table 2). For IL-10 the concentrations were 
different between the two subjects after stimulation with 0.1, 1, 10 and 100 ng/mL LPS (p 
< 0.001, <0.001, 0.004 and 0.021, Mann-Whitney U test, respectively, data not shown). 
The EC50-1 values derived from model 1 and model 2 were statistically different between 
the two subjects (p = 0.029 and 0.014, respectively, Mann-Whitney U test). Furthermore, 
the Emax-1 derived from model 2 was statistically different between the two subjects (p = 
0.006, Mann-Whitney U test, Table 2). 
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Discussion 
 
The main finding of the present study is that the dose-response characteristics of TNF-α 
and IL-10 release by human peripheral blood cells, upon stimulation with a wide range of 
LPS concentrations, can be described adequately by a receptor-ligand interaction model 
that is fully characterized by two parameters, i.e., EC50, the estimated LPS concentration at 
which half of the cytokine concentration is reached and the Emax, the estimated maximal 
concentration of cytokine released. Repeated measurements made over several weeks 
disclosed that these two parameters were highly constant for individuals, yet differed 
between individuals. These differences in dose-response characteristics would have been 
discarded however, if only one or two LPS concentrations had been used to test the 
cytokine response of these individuals. For instance, only the TNF-α concentration 
measured after stimulation with the lowest LPS concentration (0.1 ng/mL) was different 
between the subjects, whereas IL-10 concentrations were only different between the 
subjects after stimulation with the lower LPS concentrations (i.e. 0.1 through 100 ng/mL). 
These findings suggest that relevant information on cytokine release is lost, when the 
commonly applied approach is taken, i.e. testing the TNF-α and or IL-10 release after 
stimulation with a single, and often high, LPS concentration. Such an approach yields one 
value that doesn't represent a physiological model of release and often shows variation 
over time. By contrast, we estimated two parameters that fully characterize an underlying 
model and are intrinsic parameters that are insensitive to day-to-day variation. 
Two examples may illustrate the relevance of our approach. First, the TNF-α-308 AA or 
GA genotypes are generally being termed as the high TNF-α producing genotypes and the 
TNF-α-308 GG as the low producing genotype. A study using reporter gene constructs 
demonstrated convincingly that the -308A allele is a much stronger transcriptional 
activator as compared to the more frequently occurring -308G allele (13). However, studies 
using ex vivo stimulation assays using various stimuli, cells and incubation times revealed 
conflicting results (8;14;17;18;20;23;25-29;32). In one study a difference between the two 
TNF-308 genotypes was detected at the lowest LPS concentration (1 ng/mL), whereas at 
the high concentration (100 ng/mL), no difference was detected (8). Although comparison 
of the studies is hampered by differences in the assays used, studies using low LPS 
concentrations or other rather poor stimuli are more likely to detect (non-significant) 
differences between the two TNF-308 genotypes (17;18;26). Although we did not 
determine genetic factors in our study, we detected significant differences between the two 
subjects at the lowest LPS concentration used, and more importantly the dose-response 
parameters based on the whole range of LPS concentrations remained significantly 
different between the subjects. 
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Secondly, The IL-10-1082 GG and GA genotypes are generally termed as high IL-10 
producing and the IL-10-1082 AA as the low producing genotype. In a previous study in 
cardio-thoracic surgery patients, we were only able to confirm this finding in carriers of the 
GATA allele after stimulation with low LPS concentrations (10 and 100 ng/mL), whereas 
no differences were detected at the highest LPS concentrations (1000 ng/mL) (30). More 
interestingly the EC50 value, estimated from the measurements of IL-10 after stimulation 
with the whole range of LPS concentrations, was significantly higher in carriers of the 
GATA haplotype, indicating lower LPS sensitivity. Furthermore, carriers of the AGCC 
allele were only distinguishable from the other individuals based on the estimated EC50, 
whereas IL-10 concentrations produced upon stimulation with a range of LPS 
concentrations (10, 100 and 1000 ng/mL LPS) were not different. Similarly to this 
example, we expect that discrepancies found in studies results could well be explained by 
differences in the LPS stimulus used in the ex vivo assay. Either the concentration or the 
composition of the LPS used could be different in the way that the cytokine concentrations 
measured are at different levels of the dose-response curve. Our approach could to some 
extend normalize these differences. By calculating the dose-response characteristic based 
on a wide range of LPS concentrations the intrinsic dose-response characteristics could be 
calculated, making comparison between studies possible. 
The whole blood stimulation we used is similar to the assays used by others. In a 
previous study similar variation coefficients were found in repeated whole blood 
stimulation measurements over a smaller LPS range as used in our study. Similar to our 
results this study showed slightly higher variation in IL-10 production as compared to 
TNF-α. Due to the small range of LPS concentrations used in this study (ranging from 10-
1000 ng/mL) calculation of dose-response characteristics was not possible. 
So far, no other studies used the approach of estimating dose-response characteristics 
for an individual based on cytokine production upon a wide range of LPS concentrations in 
a whole blood stimulation system. In previous studies, based on the observed cytokine 
production ex vivo, individuals were designated as 'high' or 'low' producers. Also, 
individuals with specific polymorphisms of their cytokine genes, were given the same 
labels, after the presumed relationship between that genotype and the corresponding in 
vitro cytokine production profile. 
In summary, we conclude that labeling subjects as ‘high’ or ‘low’ cytokine producers 
based on the in vitro production of cytokines after stimulation with one single, 
supraphysiological LPS concentration, might proof to be to rough a measure to describe a 
subjects cytokine production profile. Based on our result we expect that characterization of 
an individual's cytokine production profile by means of dose-response characteristics, 
calculated from in vitro cytokine production upon a wide range of LPS concentrations, is a 
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more suitable approach. Studies aimed at correlating in vitro with in vivo phenotypes and 
genetic polymorphisms should for this purpose use large dose-response ranges of whole 
blood stimulation with LPS to be able to closely estimate these dose-response 
characteristics. These dose-response characteristics are more likely to be good estimates of 
an individual’s in vitro cytokine production profile and therefore more suitable as a 
reference used in studies that investigate the genetic factors that make up for the large 
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Abstract
Humans exhibit substantial inter-individual differences in TNF-a production upon endotoxin stimulation. To determine to what
extent the lipopolysaccharide-induced TNF-a production capacity in vivo and ex vivo is determined by polymorphisms in toll-like
receptor-4 (TLR4), the TNF-a promoter region and Nod2, we screened for two TLR4 polymorphisms, a Nod2 polymorphism and
the TNF-a promoter polymorphisms. We measured the perioperative endotoxemia and TNF-a production and the TNF-a
production capacity of each patient in a whole-blood stimulation assay using blood drawn before anesthesia, using various LPS
concentrations, in patients undergoing elective cardiac surgery. This operation represents a major surgical trauma associated with
ischemiaereperfusion injury and triggers an endotoxemia and profound inflammatory response. In vivo TNF-a production was
positively correlated with the level of endotoxemia after aortic declamping; thus TNF-a levels were higher in patients having
endotoxemia compared to patients without endotoxemia. This correlation was observed in patients with any of the genotypes
studied, and did not differ between the various genotypes. In vivo TNF-a levels correlated best with those ex vivo after stimulation
with 1000 ng/mL LPS, and the estimated maximal TNF-a release capacity. Subjects with the wild-type TLR4 gene had similar levels
of TNF-a upon LPS stimulation ex vivo as compared with patients carrying Asp299Gly and/or the Thr399Ile TLR4 polymorphism.
Our results indicate that polymorphisms in the TLR4 receptor, Nod2 and TNF-a promoter region are not strongly associated with
in vivo and ex vivo TNF-a production capacity upon endotoxin stimulation. This suggests that in this model of natural LPS release,
the variation between individuals in TNF-a release can only modestly be determined by genetic background (TNF-a promoter,
Nod2 and TLR4) of the individual.
 2004 Elsevier Ltd. All rights reserved.
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1. Introduction
Sepsis-induced organ failure (and death) appears to
be due to the activation of a mediator cascade initiated
by microbial components. TNF-a is a central cytokine
in this inflammatory cascade and is believed to play an
important role in the pathogenesis of septic shock [1]. In
Gram-negative infection, the presence of lipopolysac-
charide (LPS) in the circulation plays a pivotal role in
the release of TNF-a. Human monocytes, the main
producers of TNF-a, exhibit substantial inter-individual
differences in TNF-a production. Genetic studies have
shown that inter-individual variation of TNF-a pro-
duction capacity ex vivo may partly be explained by
differences in genetic background [2]. These genetic
differences are likely to be located in genes involved in
the innate immune system. For instance, the single
nucleotide polymorphism (SNP) in the TNF-a promoter
at position 308 has been correlated with ex vivo
TNF-a production capacity in one study [3]. So far,
) Corresponding author. Tel.: C31-71-526-2613; fax: C31-71-526-
6758.
E-mail address: e.f.schippers@lumc.nl (E.F. Schippers).
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other known SNPs in the TNF-a promoter have not
been evaluated in this way.
Toll-like receptor-4 (TLR4) is part of a large family
of transmembrane proteins and is believed to be crucial
in mediating LPS effects. TLR4 is expressed on
monocytes and macrophages, and to a lesser extent on
lymphocytes and other cell types [4,5]. The common,
co-segregating missense mutations (Asp299Gly and
Thr399Ile) affecting the extracellular domain of the
TLR4 receptor are associated with a blunted response to
inhaled LPS in humans [6]. The recently described
association between the Asp299Gly polymorphism in
TLR4 and Gram-negative septic shock suggests a func-
tional defect in TLR4 leading to increased susceptibility
to Gram-negative bacteremia [7]. Another receptor that
recently has been reported to be involved in LPS
responsiveness is Nod2. Nod2 is an intracellular protein
that interacts with LPS by a C-terminal leucine-rich
repeat (LRR) domain [8]. Subsequent homodimerisa-
tion of Nod2 molecules induces NF-kB translocation
[8,9]. A Nod2 mutation that diminishes the LPS
responsiveness of the protein is associated with Crohn’s
disease [10]. Studies thus far have been focused on the
LPS responsiveness of recombinant Nod2 and are
lacking on the LPS responsiveness of the natural Nod2
protein, which is predominantly expressed by mono-
cytes.
Cardiopulmonary bypass surgery leads to perioper-
ative endotoxemia in most patients, and this procedure
may serve as a model to study the association of genetic
polymorphism and endotoxin-mediated TNF-a produc-
tion. The aims of the current study were to assess the
intersubject variation in TNF-a production upon whole-
blood stimulation with LPS and to determine the
correlation between production rates and various SNPs
in the TNF-a promoter region and the TLR4 coding
region. We also studied the intersubject variation in in
vivo TNF-a production following cardiopulmonary
bypass surgery in the same way.
2. Results
2.1. Patients
We studied 159 consecutive patients undergoing
elective cardiac surgery with cardiopulmonary bypass
(Table 1). There was a predominance of male patients
(66%), 35 patients were active smokers (22%) whereas
20 patients (12%) had diabetes mellitus. Surgical
procedures were extensive; 20 patients (12%) underwent
CABG combined with valve replacement, 49 patients
(30%) underwent valve replacement only, whereas 89
patients (54%) underwent CABG only. Eight patients
underwent other surgical procedures, mainly aortic
surgery.
2.2. TNF-a promoter mutation analysis
Typing for the TNF-a single nucleotide polymor-
phisms was successful in most patients; in a minority of
the samples no definite typing could be established
(Table 2).
2.3. TLR4 mutation analysis
The TLR4 Asp299Gly and Thr399Ile substitutions
were successfully determined in all patients. The
Asp299Gly mutation was found in 17 patients
(10.7%); 16 patients were heterozygous and one was
homozygous. Except for that in one patient the TLR4
Asp299Gly mutation was accompanied by the TLR4
Thr399Ile mutation. Two patients were identified with
isolated TLR4 Thr399Ile mutations (Table 2). The
patient homozygous for the Asp299Gly mutation was
also homozygous for the Thr399Ile mutation.
2.4. Nod2 mutation analysis
Determination of the Nod2 insertion mutation was
successful in 143 patients. The insertion was found in
Table 1
Characteristics of 159 patients undergoing elective cardiac surgery with
cardiopulmonary bypassa
Preoperative data
Age (years) 65 (56e72)
Weight (kg) 78 (68e88)
Male, n (%) 106 (67)
Active smoker, n (%) 31 (20)
Diabetes (types I and II), n (%) 19 (12)






CABG only, n (%) 87 (55)
Valve replacement only, n (%) 47 (30)
CABG and valve replacement, n (%) 19 (12)
Other, n (%) 6 (4)
Perioperative data
Operation time (min) 240 (183e285)
Perfusion time (min) 116 (85e141)
Aorta clamp time (min) 71 (49e90)
Lowest temperature ((C) 29 (28e31)
Postoperative data
Days on ventilator 1 (1e2)
ICU stay (days) 3 (2e5)
MOF, n (%) 6 (3.8)
Hospital stay (days) 11 (9e15)
Fatalities, n (%) 14 (9)
CABG: coronary artery bypass graft, ICU: intensive care unit, MOF:
multiple organ dysfunction.
a Median values and interquartile range in parentheses.
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10 patients (7%, see Table 2). All patients carrying the
Nod2 insertion were heterozygous.
2.5. Ex vivo measurements
Blood samples for ex vivo LPS stimulation were
available from 127 patients. In general, we found a dose-
dependent TNF-a production upon stimulation of
whole blood with increasing concentrations of LPS.
Mean TNF-a levels upon stimulation with 0, 10, 100
and 1000 ng/mL LPS were 5.1 (SD 5.9), 9766 (SD 4782),
13,462 (SD 6688) and 18,070 (SD 7721) pg/mL, re-
spectively (Table 3). For each patient we estimated the
doseeresponse characteristics (i.e. EC50 and Emax), as
described in Section 4. No differences were found in the
TNF-a levels between the patient groups carrying the
different TNF-a promoter polymorphisms at positions
238, 308, and 376 at any of the LPS concentrations
used, or between their EC50 and Emax (all pO0:2, Table
3). The 308AA homozygous patient could not be
included in this analysis since no data from this patient
were available. Neither the TNF-a production at any of
the LPS concentrations, nor the Emax or EC50 was
different in patients carrying TLR4 mutations versus the
wild-type group (all pO0:085, Table 3).
2.6. Endotoxin measurements
Perioperative blood samples for endotoxin measure-
ments were available for most patients. Endotoxin levels
were R5 pg/mL directly before anesthetic induction in
four out of 152 patients (2.6%). On aorta declamping
(time-point 2), 30 min into reperfusion (time-point 3)
and on arrival at the ICU (approximately 2 h after
surgery, time-point 4) 74 out of 142 patients (52.1%), 71
out of 143 patients (49.7%) and 54 out of 151 patients
(35.8%) had endotoxin levels R5 pg/mL, respectively
(Table 4). In 85 out of 143 patients (59.4%) the
endotoxin level at either time-point 2 and/or 3 was
R5 pg/mL. Median endotoxin levels increased to 5.0
and 4.9 pg/mL at aorta declamping and 30 min into
reperfusion, respectively, and decreased afterwards to
4.2 pg/mL on arrival at the ICU.
Table 2
TNF-a promoter polymorphism, TLR4 and Nod2 genotype/haplotype
in 159 patients undergoing elective cardiac surgery with cardiopulmo-
nary bypass
TNF-a promoter genotype, n (%)
238 GG 123 (95)
GA 6 (5)
308 GG 99 (67)
GA 48 (32)
AA 1 (1)
376 GG 133 (96)
GA 5 (4)





Nod2 genotype, n (%)
3020insC presentb 10 (7)
3020insC absent 133 (93)
a One out of 16 patients homozygous, all others heterozygous.
b All patients carrying the Nod2 insertion were heterozygous.
Table 3
TNF-a production ex vivo on whole-blood stimulation with LPSa according to phenotype/genotypeb
10 ng/mL 100 ng/mL 1000 ng/mL TNFmax EC50[LPS]
All patients (n ¼ 127) 9766G 4782 13,462G 6688 18,070G 7721 16,891G 7359 15.4G 33.4
TNF-a promoter genotype (n)
238 GG (100) 9537G 4962 13,293G 6951 17,832G 8131 16,735G 7759 17.3G 37.4
GA (5) 6151G 3355 8140G 3757 12,307G 6775 11,059G 5750 10.7G 4.70
308 GG (81) 9928G 4537 13,609G 6514 18,142G 7385 16,902G 7140 12.1G 17.9
GA (41) 9561G 5436 13,296G 7226 18,085G 8695 17,032G 8067 22.6G 52.8
376 GG (108) 9567G 4911 13,235G 6809 17,764G 7917 16,581G 7472 15.9G 35.3
GA (3) 11,076G 4421 15,533G 3400 16,982G 3690 16,777G 3421 6.10G 3.78
TLR4 haplotype (n)
299C/399C (111) 9754G 4934 13,238G 6724 17,700G 7776 16,414G 7320 12.6G 18.6
299/399C (1) 10,830G e 12,723Ge 28,575Ge 30,168G e 90.8G e
299/399c (13) 9306G 3440 14,183G 5822 19,321G 6155 18,733G 5852 34.9G 87.0
299C/399 (2) 12,868G 6247 21,572G 10,573 25,274G 12,483 24,747G 12,205 9.63G 0.20
Nod2 genotype
3020insC presentd (7) 10,133G 4946 12,335G 4936 16,755G 6393 15,226G 5618 7.3G 4.2
3020insC absent (107) 9629G 4898 13,379G 6880 18,032G 7888 16,880G 7538 16.8G 36.1
a Levels of TNF-a without LPS stimulation were below 50 ng/mL in all cases.
b Values are expressed as meanG SD. Incomplete data due to incomplete sampling.
c One out of 13 patients homozygous, all others heterozygous.
d All patients carrying the Nod2 insertion were heterozygous.
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2.7. TNF-a measurements
Plasma TNF-a concentrations before anesthetic in-
duction, on aorta declamping, 30 min into reperfusion and
on arrival at the ICU were 1.5 (IQR: 0.0e2.6), 2.6 (IQR:
0.6e5.0), 5.3 (IQR: 3.3e9.5) and 4.3 (IQR: 2.3e7.5) pg/
mL, respectively. TNF-a levels at 30 min into reperfusion
were higher in patients having endotoxemia (defined as
having an endotoxin levelO5 pg/mL at aorta declamping
and/or 30 min into reperfusion) compared toTNF-a levels
in patients without endotoxemia (p ¼ 0:027). At other
time-points the median TNF-a levels were higher in
patients having endotoxemia; however, this was not
statistically significant. TNF-a production at the different
time-points was similar in all TNF-a promoter genotypes
and TLR4 haplotype subgroups (all p > 0:2, Table 5). The
308AA homozygous patient could not be included in
this analysis since no data from this patient were available.
We found no differences in TNF-a levels in patients
carrying the Asp299Gly or the Thr399Ile TLR4 poly-
morphisms as compared to wild-type patients.
2.8. Correlations between endotoxemia
and TNF-a levels
A significant positive correlation between endotoxin
level and TNF-a concentration was found at 30 min into
reperfusion (r ¼ 0:210; p ¼ 0:040). On aortic declamp-
ing and ICU arrival no significant correlation was found
(p > 0:4). Furthermore, no significant differences were
found in the correlation between endotoxin level and
TNF-a concentrations between the TNF-a promoter
genotypes and TLR4 haplotypes.
2.9. Correlations between ex vivo TNF-a production
and in vivo TNF-a concentrations
A significant positive correlation between TNF-a
concentration at 30 min into reperfusion with ex vivo
TNF-a production using 1000 ng/mL LPS and TNFmax
was found (r ¼ 0:241; p ¼ 0:032 and r ¼ 0:237;
p ¼ 0:035). At other LPS concentrations a positive
correlation was also observed; however, this did not
reach level of statistical significance (r ¼ 0:172; p ¼ 0:128
and r ¼ 0:106; p ¼ 0:349, at 10 and 100 ng/mL, re-
spectively). No other significant correlations were found
between ex vivo and in vivo measured TNF-a levels.
3. Discussion
The main findings of the present study are that the
TNF-a levels measured in vivo after cardiac surgery
with cardiopulmonary bypass correlate significantly
with the intensity of endotoxemia during the reperfusion
phase upon aortic declamping, and with the maximal
TNF-a release ex vivo upon stimulation with lipopoly-
saccharide in whole blood drawn before anesthesia.
Although the aforementioned correlation is statistically
significant, the extent of its scope seems to be rather
limited due to the relatively low correlation coefficient.
None of the inter-individual variation in endotoxin-
stimulated TNF-a responses, however, could be ex-
plained by the known TLR4 and TNF-a promoter
polymorphisms, including the 308 G/A substitution.
The model we choose, i.e. measuring naturally
occurring endotoxemia and subsequent pro-inflamma-
tory cytokine release in vivo in patients undergoing
cardiac surgery, enables us to study inter-individual
differences in these responses and relate these to
genotypes. We found significant endotoxemia in over
half of the patients undergoing cardiac surgery with
cardiopulmonary bypass which is in accordance with
previous studies [11,12]. The endotoxemia probably
derives from the gut and reperfusing bowel after a phase
of ischemia during cardiopulmonary bypass and occurs
when the systemic circulation is restored. We found the
highest plasma concentration of endotoxin immediately
after aortic declamping. Most patients already had
lower levels of circulating endotoxin 2e3 h later, upon
arrival at the ICU. As endotoxin triggers the production
of TNF-a within minutes to 1 h, we sampled the patients
30 min after peak endotoxemia (time-point 3) and 2e3 h
later (time-point 4). Indeed, 30 min into reperfusion,
shortly after the beginning of endotoxemia, we observed
a significant positive correlation between circulating
endotoxin levels and TNF-a production, indicating the
importance of the role of endotoxin in the perioperative
release of TNF-a. However, although we found a
significant correlation, its magnitude is limited, suggest-
ing that many other factors apart from endotoxin play
a role in the total TNF-a production in these patients.
The in vivo TNF-a release was significantly corre-
lated with the maximal TNF-a release ex vivo upon
stimulation with lipopolysaccharide. Thus, the ex vivo
LPS-stimulation assay is a predictor for the in vivo
release of TNF-a during endotoxemia after cardiac
surgery. Since we used different concentrations of LPS
we were able to calculate descriptive parameters of the
doseeresponse relation for each patient. Also, to
estimate spread relative to the mean, the coefficients of
variation (standard deviation [SD] divided by the mean)
were calculated for all LPS concentrations. The values
were 48.9%, 49.7% and 42.7% for 10, 100 and 1000




Anesthetic induction 4/152 (2.6)
Release of aortic clamp 74/142 (52.1)
30 min reperfusion 71/143 (49.7)
On ICU admission 54/151 (35.8)
a Endotoxemia R5 pg/mL.
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variation found in other populations and exceeds the
variation that can be explained by the laboratory varia-
tion only, which is estimated at 7.5e12.3% [13]. This
indicates that the variations we found between subjects
are to be explained by factors other than laboratory
variation only. Since we find it feasible to assume that
the LPS concentration needed for the release of 50% of
the maximally evoked TNF-a, the TNF-EC50, is
a marker of LPS sensitivity we evaluated to what extent
this parameter could predict the in vivo response to
endotoxin. Theoretically, important inter-individual
differences in the doseeresponse characteristics of
TNF-a production by LPS can be overlooked by
using measurements derived from one single (supra-
physiological) LPS concentration. We found a signifi-
cant correlation between the TNF-a production ex vivo
using the highest LPS concentration (i.e. 1000 ng/mL)
and in vivo TNF-a levels, but no significant correlation
between TNF-EC50 and in vivo measured TNF-a levels.
This indicates that the maximal TNF-a production
capacity measured ex vivo is at present the best
predictor of in vivo TNF-a levels upon cardiac surgery.
To our knowledge no other study investigated the
correlation between endotoxin-mediated TNF-a produc-
tion ex vivo and in vivo.
Since several studies indicated the role of genetics in
innate immunity we investigated the influence of various
known polymorphism in the TNF-a promoter, the
TLR4 and Nod2 genes. We found no correlation
between the level of perioperative TNF-a production
and TNF-a promoter SNPs, TLR4 polymorphisms and
the presence of the Nod2 insertion. Also, we found no
Table 5
Perioperative TNF-a production according to phenotype/genotypea
Anesthetic induction Aorta declamping 30 min into reperfusion On arrival at the ICU
All patients 1.5 (0.0e2.6) 2.6 (0.6e5.0) 5.3 (3.3e9.5) 4.3 (2.3e7.5)
n ¼ 112 n ¼ 106 n ¼ 108 n ¼ 110
Endotoxemiab
Negative 1.5 (0.2e2.7) 2.5 (0.6e4.1) 4.5 (2.5e6.8) 4.0 (2.4e5.5)
n ¼ 38 n ¼ 38 n ¼ 37 n ¼ 37
Positive 1.3 (0.1e2.5) 2.7 (0.6e6.2) 5.6 (3.6e12.0) 4.6 (2.2e8.2)
n ¼ 70 n ¼ 68 n ¼ 70 n ¼ 70
TNF-a promoter genotype
238 GG 1.7 (0.2e2.6) 2.5 (0.3e5.1) 5.3 (3.3e10.9) 4.3 (2.4e7.6)
n ¼ 83 n ¼ 78 n ¼ 79 n ¼ 81
GA 0.3 (0.0e1.8) 2.1 (1.3e6.5) 4.6 (1.4e6.6) 2.0 (1.1e4.6)
n ¼ 6 n ¼ 6 n ¼ 6 n ¼ 6
308 GG 1.5 (0.2e2.7) 2.0 (0.4e5.9) 5.2 (3.1e9.3) 4.2 (2.1e7.0)
n ¼ 72 n ¼ 68 n ¼ 69 n ¼ 70
GA 1.6 (0.2e2.7) 3.0 (1.2e5.1) 6.3 (4.6e12.8) 5.9 (3.3e10.1)
n ¼ 33 n ¼ 31 n ¼ 32 n ¼ 33
376 GG 1.6 (0.2e2.6) 2.3 (0.4e4.5) 5.4 (2.8e9.8) 4.2 (2.3e7.5)
n ¼ 88 n ¼ 82 n ¼ 84 n ¼ 87
GA 1.1 (0.0e2.8) 0.0 (0.0e2.1) 4.9 (4.1e5.1) 6.7 (5.6e7.3)
n ¼ 5 n ¼ 5 n ¼ 5 n ¼ 5
TLR4 haplotype
299C/399C 1.4 (0.0e2.6) 2.6 (0.7e4.5) 5.2 (3.4e10.0) 4.3 (2.4e7.8)
n ¼ 100 n ¼ 95 n ¼ 96 n ¼ 98
299/399C 2.8 (e) 8.3 (e) 8.1 (e) 7.5 (e)
n ¼ 1 n ¼ 1 n ¼ 1 n ¼ 1
299/399c 1.7 (0.4e3.2) 4.4 (0.5e7.7) 6.4 (3.0e7.8) 4.3 (0.9e7.3)
n ¼ 9 n ¼ 8 n ¼ 9 n ¼ 9
299C/399 1.9 (0.6e3.3) 0.0 (0.0e0.0) 3.2 (0.6e5.8) 1.4 (0.3e2.4)
n ¼ 2 n ¼ 2 n ¼ 2 n ¼ 2
Nod2 genotype
3020insC presentd 1.0 (0.2e2.6) 2.6 (0.7e3.3) 4.0 (2.3e16.1) 2.4 (1.0e8.9)
n ¼ 7 n ¼ 7 n ¼ 7 n ¼ 7
3020insC absent 1.5 (0.0e2.6) 2.7 (0.5e6.0) 5.4 (3.4e10.0) 4.4 (2.5e7.6)
n ¼ 94 n ¼ 89 n ¼ 91 n ¼ 92
a Median values and interquartile range in parentheses. Lower detection limit for TNF-a and endotoxin was 0.1 and 3.0 pg/mL, respectively.
b Positive defined as having an endotoxin levelR5 pg/mL at aorta declamping and/or 30 min into reperfusion, negative defined as an endototoxin
level !5 pg/mL at both time-points.
c One out of 13 patients homozygous, all others heterozygous.
d All patients carrying the Nod2 insertion were heterozygous.
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correlation between ex vivo TNF-a production capacity
and TNF-a promoter SNPs, TLR4 polymorphisms and
the presence the Nod2 insertion. The frequencies of the
various genotypes were similar to those found in other
populations (Table 2) [3,10,14e16]. Although a type II
error could be responsible for overlooking the differ-
ences in TNF-a production capacity between the
various polymorphisms studied, our data suggest that
their role, if present, is rather limited, and cannot be
attributed to the large inter-individual differences found
in TNF-a production capacity. Therefore, we conclude
that the various polymorphisms studied play no
clinically significant role in the cardiac surgery associ-
ated pro-inflammatory reaction in response to endotox-
emia. The demographic characteristics of the cardiac
surgery patients were similar to the patients of other
groups described in the literature [17,18], making direct
extrapolation of our findings possible.
Many studies have dealt with the question to what
extent genetic variants affect regulation of the innate
immune response. The results have been conflicting; to
a large extent this can probably be explained by various
models that have been used. Several studies evaluated
the role of TNF-a promoter SNPs in susceptibility and
severity of infections and septic shock [16,19e22].
Although some of the studies found increased suscept-
ibility and/or severe outcome of sepsis or septic shock in
carriers of a common TNF-a promoter polymorphism
(i.e. 308 G/A) [16,19e22], in none of the studies was
the in vivo TNF-a response positively correlated with
this increased risk. These findings suggest that this
polymorphism does not exert its effect on sepsis
susceptibility and/or outcome by differences in gene
expression and/or TNF-a production. One study inves-
tigated the response to endotoxin in a more controlled
fashion. Recently, Fijen et al. found no differences in
TNF-a levels between the TNF-(308) genotypes in an
experimental human endotoxemia model in healthy
subjects [23]. These findings confirm our observation.
Only few studies investigated the association of SNPs
within the TNF-a promoter and the capacity of TNF-a
production upon LPS stimulation ex vivo. Results from
studies using reporter constructs for TNF-a gene
expression have been conflicting [24e27]. Also, data
from several studies using ex vivo stimulation assays
indicated an effect at some LPS concentrations at some
of the incubating times, while no effect was found at
other LPS concentrations and different incubating times
[3,15,28].
Three studies investigated the role of TLR4 poly-
morphisms in susceptibility and outcome of Gram-
negative infections in patients carrying either the
Asp299Gly and/or the Thr399Ile mutations [7,29,30].
Only two studies indicated higher susceptibility [7,29],
none of the studies found higher mortality. So far, only
one study investigated the role of the common TLR4
polymorphisms in in vitro LPS stimulation of isolated
monocytes [31]. This study used LPS derived from
various microorganisms at a large range of concen-
trations. No differences were found between heterozy-
gote carriers of the co-segregating Asp299Gly/Thr399Ile
polymorphisms compared to the wild-type subjects.
Although in this study isolated monocytes were used,
our results are consistent with its results.
In a study conducted by Ogura et al. it was
demonstrated that human embryonic kidney cells trans-
fected with the Nod2 gene including the 3020insC
mutation showed much less NF-kB activity in response
to LPS, indicating the importance of the intact Nod2
protein in response to LPS [10]. A recent study,
however, suggests that Nod2 is a general sensor of both
Gram-negative and -positive peptidoglycan (PGN) and
not so much LPS itself [32]. The unpurified LPS used by
Ogura et al. might have been contaminated by PGN,
leading to a misinterpretation of their observation. In
our study no effect was found from the presence of this
mutation on in vivo and ex vivo TNF-a production
capacity upon endotoxin, confirming the conclusion by
Girardin that endotoxin is not the ligand for Nod2.
In summary, based on our results and the largely
conflicting findings in the literature, we propose that it is
unlikely that the TNF-a promoter polymorphisms, the
presence of the common TLR4 polymorphisms or the
Nod2 insertion play an important role in LPS-mediated
TNF-a production capacity in vivo and ex vivo. Thus, it
remains unclear which and to what extent the additional
genetic and environmental factors (e.g. sCD14, MD-2,
LBP, lipoproteins) determine the large inter-individual
variation found in in vivo and ex vivo responses to LPS.
4. Materials and methods
4.1. Patients
The study was performed at the Leiden University
Medical Center, an 800-bed secondary and tertiary
referral hospital. To be eligible for enrolment, the
patients had to be 18 years or older and scheduled for
elective cardiac surgery with cardiopulmonary bypass
between July 1, 1998 and December 30, 1999. We
obtained institutional approval from the local medical
ethics committee (protocol #P168/96). Each patient gave
a written, informed consent. The patients studied were
159 consecutive patients undergoing elective cardiac
surgery with cardiopulmonary bypass. Of these, 122 had
been included in a previously published study on the
effect of selective gut decontamination (SGD) on
endotoxemia and cytokine activation [33]. Of these 122
patients 24 received preoperative SGD consisting of
polymyxin B and neomycin. In the previously men-
tioned study perioperative endotoxemia and subsequent
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cytokine activation were found not to be influenced by
the SGD regimen. Also, the results were not different
when these patients were excluded from the analysis.
Patients were followed-up throughout their stay in the
hospital. Demographic characteristics were systemati-
cally collected for all patients entering the study.
4.2. Study design
On the day of surgery blood samples for ex vivo
whole-blood LPS stimulation, using pyrogen-free tubes
(Kabi-Vitrum, Amsterdam, The Netherlands), and
DNA extraction were drawn before anesthesia. Blood
samples for the determination of in vivo endotoxin and
cytokine levels were collected from each patient before
anesthetic induction, on aorta declamping, 30 min into
body reperfusion (i.e. 30 min after stopping the extra
corporal perfusion), and at the ICU admission (approx-
imately 2 h after surgery). In a previous pilot study, we
found that endotoxemia occurs most likely at these
time-points [33].
4.3. Whole-blood LPS stimulation
Cytokine production was determined in whole-blood
samples ex vivo as previously described [34]. Briefly,
whole-blood samples were mixed 1:1 with RPMI 1640
(Gibco, Germany) and lipopolysaccharide (Escherichia
coli 0111:B4, Difco, Detroit, MI) was added to the final
concentrations of 10, 100 and 1000 ng/mL and cells were
stimulated for 4 h at 37 (C under 5% CO2 atmosphere.
Tumor necrosis factor-a (TNF-a) concentrations were
measured in the supernatant as described later.
4.4. Endotoxin measurements
Blood for endotoxin determination was collected in
pyrogen-free tubes (Kabi-Vitrum, Amsterdam, The
Netherlands) and platelet-rich plasma was prepared by
centrifugation. Endotoxin was determined by a quanti-
tative photometric assay with end-point measurement as
described elsewhere [35]. The assay’s lower detection
limit for endotoxin was about 3.0 pg/mL [35].
4.5. TNF-a measurements
Blood for determination of TNF-a was collected in
pyrogen-free ethylenediaminetetraacetic acid (EDTA)
tubes (Chromogenics, Amsterdam, The Netherlands)
and immersed in ice. Plasma was prepared by centrifu-
gation at 3000g for 5e10 min at 4 (C and stored at
70 (C. TNF-a concentrations in the supernatants of
the ex vivo whole-blood assay and the samples from the
in vivo TNF-a production were analyzed at completion
of the study. Tumor necrosis factor (TNF)-a concen-
trations were determined with a standard ELISA
technique (Central Laboratories for Bloodtransfusion,
Amsterdam, The Netherlands; Medgenix diagnostics,
Floury, Belgium); the lower detection limit for TNF-a
was 0.1 pg/mL [35].
4.6. DNA isolation
DNA was isolated from citrate blood from each
patient, red blood cells were lysed with three volumes of
lysis buffer (1.55 M NH4Cl, 0.1 M KHCO3, 0.01 M
EDTA, pH 7.4); the remaining cells were incubated for
17 h at 37 (C with SDS and proteinase K. The DNA
was extracted using phenol and chloroform as described
by Maniatis et al. [36].
4.7. TNF-a promoter mutation analysis
Typing for the TNF-a single nucleotide polymor-
phisms 238, 308 and 376 was performed by PCR
amplification. Forward and reverse primers used are
given in Table 6. Primers were purchased from
Biosource International (Foster City, CA). PCR ampli-
fications were performed using the Thermolyne Ampli-
tron II Thermal Cycler (Barnstead/Thermolyne,
Dubuque, IA). The PCR conditions were as follows:
10 min at 95 (C followed by 35 cycles of 60 s at 95 (C,
60 s at 58 (C, 60 s at 72 (C for 238 and 376, and for
308 the conditions were 60 s at 94 (C, 60 s at 60 (C,
and 60 s at 72 (C. The PCR-amplified products were
electrophoresed on a 10% polyacrylamide gel to detect
the size differences of the fragments between the
polymorphisms, following digestion with a specific re-
striction enzyme (Table 6).
4.8. TLR4 mutation analysis
The TLR4 Asp299Gly mutation was determined by
allele-specific PCR amplification of the involved region
using sense primer 5#-CTT AGA CTA CTA CCT CGA
TGA-3# (wild-type) or 5#-CTT AGA CTA CTA CCT
CGA TGG-3# (mutant) in combination with the anti-
sense primer 5#-TAA GCC TTT TGA GAG ATT
TGA-3#. PCR was performed on w300 ng DNA by 12
cycles of 10 s denaturing at 95 (C and 60 s at 65 (C,
followed by 20 cycles of 10 s at 95 (C, 50 s at 60 (C, and
30 s elongation at 72 (C. Beta-actin primers (sense 5#-
TCT GGC ACC ACA CCT TCT ACA A-3# and anti-
sense 5#-GTG GTG GTG AAG CTG TAG CCG-3#,
amplified product is 334 bp) were included as positive
control. Generation of the amplified products was
evaluated with 1.2% agarose gel electrophoresis and
ethidium bromide staining. Detection of the mutant
896G allele was verified by sequence analysis. The TLR4
Thr399Ile mutation was determined by PCR amplifica-
tion of the involved region with sense primer 5#-GCT
GTT TTC AAA GTG ATT TTG GGA GAA-3# to
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create a Hinf I cleavage site when the mutant allele is
amplified. After PCR amplification in combination with
anti-sense primer 5#-CAC TCA TTT GTT TCA AAT
TGG AAT G-3# the amplicon was incubated with HinfI
as recommended by the supplier and cleavage of the
product was evaluated by 2% agarose gel electrophore-
sis and ethidium bromide staining.
4.9. Nod2 mutation analysis
The Nod2 3020insC mutation that renders truncation
of the Nod2 at position 1007 was determined using the
allele-specific multiplex PCR assay described by Ogura
et al. [8].
4.10. Calculation of ex vivo LPS/TNF-a
doseeresponse
For each patient two characteristics of the LPS-
induced TNF-a release were calculated by non-linear
regression with the doseeresponse model according to
the Hill equation (Eq. (1)).
EN ¼ EN;max!C=ðEC50CCÞ ð1Þ
where EN is the observed TNF-a production at a given
LPS concentration C, EC50 is the estimated LPS con-
centration at which 50% of the maximal TNF-a re-
sponse is reached, and EN,max is the estimated maximal
TNF-a production. In a previous pilot study we found
that measuring the TNF-a production at the LPS
concentration we used (i.e. 10, 100 and 1000 ng/mL)
was sufficient to calculate the doseeresponse character-
istics EC50 and EN,max (E.S., unpublished observation,
report in preparation).
4.11. Statistical analysis
For statistical analysis blood samples with TNF-a
and endotoxin levels below the limit of detection were
entered as half of the value of the lower detection limit
(0.05 and 1.5 pg/mL, respectively). To determine
whether polymorphisms in the TLR4 gene, the presence
of the Nod2 insertion and the TNF-a promoter were
associated with levels of in vivo TNF-a production,
repeated measurement models (SPSS 11.0, mixed) were
used to determine whether the patterns of TNF-a pro-
duction over time were different between polymor-
phisms. For this analysis log-transformed TNF-a levels
were used. The ex vivo TNF-a production character-
istics between the various genotypes were compared
using a ManneWhitney U test. Correlations were
assessed non-parametrically using Spearman correlation
test. Statistical significance was tested two-tailed, with
the a set to 0.05.
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Abstract
To determine to what extent lipopolysaccharide-induced IL-10 production capacity is determined by polymorphisms in toll-like
receptor-4 (TLR4) and the IL-10 promoter region, we measured in vivo IL-10 and TNF-a production in patients undergoing elective
cardiopulmonary bypass surgery, a major surgical trauma associated with ischemia-reperfusion injury that triggers an endotoxemia
and profound inflammatory response in most patients. Ex vivo the IL-10 and TNF-a production was measured in a whole blood
stimulation assay, using 3 LPS concentrations. Positive correlations were found between TNF-a and IL-10 production ex vivo, upon
stimulation with each of the LPS concentrations. Also, the estimated TNF-a and IL-10 EC50, and TNF-amax and IL-10max were
positively correlated (rZ 0.203; pZ 0.023 and rZ 0.287; pZ 0.001, respectively), indicating that these parameters describing LPS
sensitivity and maximal production capacity, respectively, can be estimated by measuring either TNF-a or IL-10. Interleukin-10
concentrations in patients experiencing endotoxemia in vivo negatively correlated with the IL-10 levels produced upon stimulation
with 1000 ng/mL LPS as well as the estimated IL-10max ex vivo. In vivo, a positive correlation between the TNF-a concentration at
time-point 2 and the IL-10 concentration at time-point 3 was found, consistent with an important contribution of the magnitude of
TNF-a release upon the subsequent IL-10 production. Carriers of the IL-10 promoter 1330G, 1082A, 819T, 592A (GATA)
haplotype had lower IL-10 production ex vivo upon stimulation with 10 and 100 ng/mL LPS and higher EC50 values (the estimated
LPS concentration at which 50% of the maximal IL-10 response is reached) as compared to carriers of the other haplotypes
combined, indicating decreased LPS sensitivity ex vivo. These individuals did not differ from the others in interleukin-10 production
capacity upon stimulation with a high LPS concentration (i.e., 1000 ng/mL) and the estimated IL-10max values, were similar,
indicating unimpaired maximal IL-10 production capacity ex vivo. Carriers of the IL-10 promoter AGCC haplotype had lower EC50
values as compared to carriers of the other haplotypes combined, indicating increased LPS sensitivity ex vivo. In accordance with
this finding, carriers of the AGCC haplotype had higher circulating IL-10 levels in vivo. The common TLR4 polymorphisms
(Asp299Gly and Thr399Ile) were associated with slightly higher IL-10 production capacity ex vivo and in vivo, however, this was
not statistically significant. Our results indicate that polymorphisms in the proximal IL-10 promoter region are associated with in
q Supported by a grant (#28-2875,23) of ZorgOnderzoek Nederland, formerly the Dutch Foundation for Preventive Medicine PraeventieFonds.
The study protocol was approved by the Medical Ethics Committee of the Leiden University Medical Center (protocol #P168/96). All subjects gave
permission for blood sampling after written information was provided.
* Corresponding author. Tel.: C31 71 526 2613; fax: C31 71 526 6758.
E-mail address: e.f.schippers@lumc.nl (E.F. Schippers).
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vivo and ex vivo LPS sensitivity. The contribution to the inter-individual variation, however, is limited since the variation between
individuals in LPS sensitivity and IL-10 production capacity can only partly be attributed to these IL-10 promoter polymorphisms.
 2005 Elsevier Ltd. All rights reserved.
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1. Introduction
Interleukin-10 (IL-10) is an important immunoregu-
latory cytokine. It is involved in the regulation of
inflammatory responses through direct influence over
tumor necrosis factor (TNF)-a production. Also, IL-10
plays an important role in the course of infectious
diseases, for instance, the severity to which meningo-
coccal meningitis progresses is associated with serum
IL-10 concentrations, such that a high serum IL-10 level
was observed in patients with a poor or fatal outcome,
whereas patients with mild disease and a good prognosis
had lower serum IL-10 levels [1e3]. In Gram-negative
infection, the presence of lipopolysaccharide (LPS) in
the circulation plays a pivotal role in the release of IL-
10. Human monocytes, the main producers of IL-10,
exhibit substantial inter-individual differences in IL-10
production upon LPS stimulation ex vivo [4]. A study
investigating the inter-individual variation of IL-10
production following LPS stimulation of whole blood
cultures ex vivo suggested that the differences in IL-10
production capacity can to a large extent be explained
by differences in genetic background [5]. The inter-
individual differences in produced IL-10 could not
simply be explained by corresponding differences in
TNF-a production, implicating that the differences in
the individual’s ability to produce IL-10 are not simply
reflecting differences in the individual’s ability to
produce TNF-a [5]. It has been suggested that differen-
tial transcription is the principle mechanism of the inter-
individual differences in IL-10 production [6]. Indeed,
the IL-10 production is proportionally related to mRNA
production and not to the half-life of IL-10 [7]. Given
the fact that the differences in IL-10 production are most
likely transcriptionally regulated, the IL-10 promoter
region has been an important target for investigation [6].
In the IL-10 promoter, 11 single nucleotide polymor-
phisms (SNPs) have been described. Studies of SNPs in
the proximal 1.1 kb have yielded the existence of
a relative small number of haplotypes [8e10]. The
dimorphic polymorphisms (G or A at position 1330, G
or A at position 1082, C or T at position 819, C or A
at position 592) are in preferential allelic association,
namely AGCC, GACC and GATA haplotypes. It has
been shown that the differences in the production
capacity of IL-10 ex vivo are associated with IL-10
haplotypes [6]. Furthermore, the SNP in the IL-10
promoter at position 2849 was associated with differ-
ences in IL-10 production ex vivo upon stimulation with
1000 ng/mL LPS and transcriptional activity [11e13].
So far, other known SNPs in the IL-10 promoter have
not been evaluated in this way.
Toll-like receptor-4 (TLR4) is part of a large family
of transmembrane proteins and is believed to be crucial
in mediating LPS effects. TLR4 is expressed on
monocytes and macrophages, and to a lesser extent on
lymphocytes and other cell types [14,15]. The recently
described association between the Asp299Gly poly-
morphism in TLR4 and Gram-negative septic shock
suggests a functional defect in TLR4 leading to in-
creased susceptibility to Gram-negative bacteremia [16].
Cardiopulmonary bypass surgery leads to perioper-
ative endotoxemia in most patients, and this procedure
may serve as a model to study the association of genetic
polymorphism and endotoxin mediated IL-10 production
in vivo. The most immunoreactive reactive component of
endotoxin is lipid A, being a structural element of LPS.
The aims of the current study were to assess the inter-
individual variation in IL-10 production upon whole
blood stimulation with LPS, to determine the correla-
tion between production rates and various SNPs in the
IL-10 promoter region as well as the TLR4 coding
region, and to determine how much of the inter-
individual variation could be attributed to these genetic
factors. We also studied the inter-individual variation in
the in vivo IL-10 production following cardiopulmonary
bypass surgery in the same way.
2. Results
2.1. Patients
We studied 159 consecutive patients undergoing
elective cardio-thoracic surgery with cardiopulmonary
bypass. The patient characteristics have been described
previously [17]. Briefly, there was a predominance of
male patients (66%), the median age for males and
females was 65 and 67, respectively ( pZ 0.091). Active
smoking occurred in 35 patients (22%) whereas 20
patients (12%) had diabetes mellitus. Surgical proce-
dures were extensive; 20 patients (12%) underwent
coronary artery bypass surgery (CABG) combined with
valve replacement, 49 patients (30%) underwent valve
replacement only, whereas 89 patients (54%) underwent
CABG only. Eight patients underwent other surgical
procedures, mainly aortic surgery.
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2.2. IL-10 promoter genotyping
Typing for the IL-10 single nucleotide polymor-
phisms was successful in most patients; in a minority of
the samples no definite typing could be established
(Table 1). As previously described the 4 defined
proximal dimorphic polymorphisms (A or G at position
1330, G or A at position 1082, C or T at position
819, C or A at position 592) resulted in three allelic
associations, namely AGCC, GACC, and GATA
haplotypes, resulting in six subsequent biallelic haplo-
types (Table 1). The haplotype frequencies were similar
to the frequencies described previously [9].
2.3. TLR4 genotyping
The TLR4 Asp299Gly and Thr399Ile substitutions
were successfully determined in all the patients. The
Asp299Gly substitution was found in 17 patients
(10.7%), 16 patients were heterozygous and 1 patient
was homozygous. Except for 1 patient the TLR4
Asp299Gly substitution was accompanied by the TLR4
Thr399Ile substitution. Two patients were identified with
an isolated TLR4 Thr399Ile substitution (Table 1). The
patient homozygous for the Asp299Gly substitution was
also homozygous for the Thr399Ile substitution.
2.4. Ex vivo IL-10 measurements
Blood samples for ex vivo LPS stimulation were
available from 125 patients. In general, we found a dose
dependent IL-10 production upon stimulation of whole
blood with increasing concentrations of LPS. Median
IL-10 levels upon stimulation with 0 ng/mL LPS were
below or at the lower level of detection in the majority of
patients [median 3.0 pg/mL (IQR: 3.0e3.0)], and no
differences were found between the various groups (data
not shown). Median IL-10 levels upon stimulation with
10, 100 and 1000 ng/mL LPS were 801 (IQR:
506e1221), 1482 (IQR: 996e1974) and 3493 (IQR:
2534e4673) pg/mL, respectively (Table 2). For each
patient we estimated the doseeresponse characteristics
EC50 and Emax (i.e., EC50 is the estimated LPS
concentration at which 50% of the maximal IL-10
response is reached, and Emax is the estimated maximal
IL-10 production), as described in the methods.
We first investigated whether any association was
present between the IL-10 promoter polymorphisms and
the levels of IL-10 production upon stimulation with the
different LPS concentrations, and the estimated dosee
response characteristics (i.e. EC50 and Emax) ex vivo. As
shown in Table 2, the level of IL-10 produced following
ex vivo LPS stimulation was not statistically different in
the six biallelic genotypes of the proximal IL-10
promoter and the distal SNPs. However, carriers of
the GATA haplotype (homozygous and heterozygous
carriers combined), as compared to carriers of the other
haplotypes combined, had lower IL-10 levels after
stimulation with 10 and 100 ng/mL LPS [619 (IQR:
431e1011) versus 826 (IQR: 575e1142), pZ 0.041 and
1253 pg/mL (IQR: 808e1707) versus 1651 (IQR:
1194e2042), pZ 0.006, respectively, Fig. 1). Further-
more, these patients had significantly higher EC50 values
[159 (IQR: 97e293) versus 122 ng/mL (IQR: 67e190),
pZ 0.027, Fig. 2], indicating decreased LPS sensitivity.
More interestingly, the IL-10 concentration after stim-
ulation with the highest LPS concentration (i.e. 1000 ng/
mL), and the estimated Emax were not different in
the two groups [3357 (IQR: 2111e4517) versus 3529
(IQR: 2634e4738), pZ 0.377 and 3966 pg/mL (IQR:
2174e5345) versus 3737 (IQR: 2844e5585), pZ 0.767,
respectively]. However, homozygous carriers of the
GATA haplotype, as compared to all other patients
combined, had higher EC50 and Emax values [230 (IQR:
141e502) versus 134 ng/mL (IQR: 78e196), pZ 0.013
and 5122 pg/mL (IQR: 3758e7555) versus 3605 (IQR:
2533e5242), pZ 0.035, respectively]. On the other
hand, patients carrying the AGCC haplotype (homozy-
gous and heterozygous carriers combined), as compared
to carriers of the other haplotypes combined, had
slightly lower EC50 values [125 (IQR: 66e204) versus
159 ng/mL (IQR: 106e230), pZ 0.041], indicating higher
LPS sensitivity (Fig. 2).
Patients carrying the Asp299Gly polymorphism as
compared to carriers of wild-type alleles, had somewhat
higher IL-10 concentrations upon stimulation with 100
and 1000 ng/mL LPS [1799 (IQR: 1237e2058) versus
Table 1
IL-10 promoter haplotype/genotype in 159 patients undergoing
elective cardiac surgery with cardiopulmonary bypass
IL-10 promoter genotype, n (%)







IL-10 promoter genotype, n (%)
3575 AT 70 (51)
TT 50 (37)
AA 16 (12)
2849 GG 72 (55)
AG 56 (42)
AA 4 (3)
2763 CC 61 (46)
AC 61 (46)
AA 11 (8)





a One out of 16 patients homozygous, all others heterozygous.
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1458 pg/mL (IQR: 957e1956), pZ 0.174 and 4171
(IQR: 3351e4856) versus 3457 pg/mL (IQR: 2425e
4685), pZ 0.083, respectively]. The same trend was
observed when comparing carriers of the Thr399Ile
polymorphism with carriers of wild-type alleles [1783
(IQR: 1245e2006) versus 1451 pg/mL (IQR: 944e1969),
pZ 0.177 and 4130 (IQR: 3357e4567) versus 3426
pg/mL (IQR: 2418e4690), pZ 0.111, respectively]. In
Table 2
IL-10 production ex vivo on whole blood stimulation with LPS according to IL-10 and TLR4 genotype/haplotypea
10 ng/mL 100 ng/mL 1000 ng/mL IL-10max EC50[LPS]
All patients (nZ 125) 801 (506e1121) 1482 (996e1974) 3493 (2534e4673) 3817 (2712e5445) 139 (82.6e226)
IL-10 promoter genotype (n)
1330/1082/819/592
AGCC/AGCC (28) 819 (518e1195) 1476 (921e2042) 3341 (2411e4259) 3526 (2454e4823) 145 (60.4e195)
AGCC/GACC (30) 922 (630e1129) 1666 (1309e2161) 3722 (2856e5353) 3985 (3100e6056) 105 (75.8e161)
AGCC/GATA (24) 646 (409e1081) 1129 (787e1734) 2765 (1898e4216) 3352 (1986e4694) 134 (67.0e268)
GACC/GACC (12) 800 (698e1001) 1799 (1189e2025) 3680 (2826e4540) 3959 (3124e5225) 144 (71.8e192)
GATA/GATA (12) 741 (478e963) 1446 (1043e1520) 4088 (3185e5906) 5122 (3758e7555) 230 (141e502)
GACC/GATA (17) 508 (393e982) 1108 (691e1869) 3493 (1694e4985) 3965 (2064e6092) 145 (109e254)
IL-10 promoter genotype (n)
3575 AT (55) 826 (516e1188) 1492 (968e2036) 3386 (2531e4840) 3542 (2348e5793) 117 (75.2e223)
TT (40) 757 (490e1009) 1378 (989e1878) 4075 (2819e5012) 4792 (3176e6403) 167 (132e300)
AA (13) 813 (482e1179) 1680 (760e2089) 3228 (1951e3852) 3470 (2406e4431) 67 (23.9e145)
2849 GG (60) 665 (489e1027) 1482 (979e1992) 3868 (2704e5498) 4627 (3135e6685) 165 (103e262)
AG (42) 832 (445e1221) 1360 (760e1866) 3044 (1812e3826) 3330 (1960e4425) 113 (42.1e235)
AA (3) 869 (813e1135) 1814 (1783e1887) 4130 (3528e4259) 4693 (3587e4849) 144 (59.8e147)
2763 CC (48) 678 (478e1009) 1412 (973e1992) 3798 (2363e5025) 4213 (2700e6403) 150 (95.9e224)
AC (49) 855 (510e1164) 1430 (1005e1834) 3444 (2553e4243) 3966 (2798e4727) 139 (79.8e267)
AA (9) 813 (370e1269) 1680 (664e1950) 3341 (1562e4735) 3470 (1767e5393) 144 (89.3e221)
TLR4 haplotype (n)
299C/399C (109) 801 (490e1148) 1450 (930e1940) 3395 (2411e4673) 3587 (2373e5345) 133 (76.8e226)
299/399C (1) 1080 (e) 2251 (e) 7381 (e) 9582 (e) 301 (e)
299/399b (13) 716 (526e950) 1783 (1228e1979) 4130 (3345e4511) 4693 (3627e5813) 144 (109e241)
299C/399 (2) 852 (664e1040) 1887 (1633e2140) 4476 (3722e5229) 5130 (4230e6031) 152 (143e160)
a IL-10 concentrations are in pg/mL. Values are expressed as median values and interquartile range between parentheses. Data on 0 ng/mL LPS not
shown, the majority of IL-10 levels were below or at lower detection limit, and now differences were found between the various groups.









































































































Fig. 1. IL-10 production upon whole blood stimulation with 10, 100 and 1000 ng/mL LPS respectively, and the estimated IL-10max. Left panel
represents carriers of the GATA haplotype (lighter box plots) as compared with all others. Middle panel represents carriers of the AGCC haplotype
(lighter box plots) as compared with all others. Right panel represents carriers of the GACC haplotype (lighter box plots) as compared with all
others. The box plots display the median, the 25th and 75th percentiles, and the smallest and largest IL-10 concentrations that are not outliers. IL-10
was measured by enzyme-linked immunosorbent assay; the detection limit was 4 pg/mL. )pZ 0.041, ))pZ 0.006.
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accordance with these findings, the estimated IL-10 Emax
was higher in the carriers of either the Asp299Gly or the
Thr399Ile polymorphism as compared to wild-type
allele carriers [4771 (IQR: 3682e6506) versus 3604
pg/mL (IQR: 2399e5404), pZ 0.064 and 4693 (IQR:
3738e6031) versus 3596 pg/mL (IQR: 2386e5425),
pZ 0.085, respectively]. Although none of the described
differences reached the level of statistical significance,
the consistency in the observations suggest an increased
in vitro IL-10 production capacity at high concentra-
tions of LPS in patients carrying either the Asp229Gly
or the Thr399Ile polymorphism. No differences in EC50
value were found between the various groups (all
pO 0.38).
2.5. In vivo endotoxin measurements
Perioperative blood samples for endotoxin measure-
ments were available from most patients and have been
described in detail previously [17]. Briefly, endotoxin
levels were R 5 pg/mL directly before anesthetic in-
duction in 4 out of 152 patients (2.6%). On aorta
declamping (time-point 2), 30 min into reperfusion
(time-point 3) and on arrival at the ICU (approximately
2 h after surgery, time-point 4) 74 out of 142 patients
(52.1%), 71 out of 143 patients (49.7%) and 54 out of
151 patients (35.8%) had endotoxin levels R 5 pg/mL,
respectively. In 85 out of 143 patients (59.4%) the
endotoxin level at either time-point 2 and/or 3 was
R 5 pg/mL. Median endotoxin levels increased from
below the level of detection to 5.0 and 4.9 pg/mL at
aorta declamping and 30 min into reperfusion, respec-
tively, and decreased afterwards to 4.2 pg/mL on arrival
at the ICU.
2.6. In vivo IL-10 measurements
Plasma IL-10 concentrations before anesthetic in-
duction were below or at the lower level of detection in
the majority of patients [median 2.0 pg/mL (IQR:
2.0e4.0)]. On aorta declamping, 30 min into reperfusion
and on arrival at the ICU were 32 (IQR: 10e88), 37
(IQR: 11e87) and 8.0 (IQR: 4.0e26) pg/mL, respec-
tively (Table 3). No differences in IL-10 levels at any of
the time-points were found between the six biallelic
genotypes of the proximal IL-10 promoter and the distal
SNPs, or the TLR4 haplotypes and genotypes (all
pO 0.17). However, carriers of the AGCC haplotype
(homozygous and heterozygous carriers combined), as
compared to carriers of the other haplotypes combined,
had slightly higher IL-10 levels at time-points 2 and 3
[35.0 (IQR: 11.0e88.5) versus 19.5 pg/mL (IQR:
6.5e49.0), pZ 0.053 and 43.0 (IQR: 13.0e112) versus
24.0 pg/mL (IQR: 10.0e62.3), pZ 0.038, respectively].
Furthermore, when combining measurements from
consecutive time-points (i.e. time-point 2 and 3 or 2, 3
and 4 combined, respectively) the differences were more
clear [43.0 (IQR: 12.0e106) versus 23.5 pg/mL (IQR:
10.0e55.3), pZ 0.005 and 24.0 (IQR: 7.0e72.0) versus
16.0 pg/mL (IQR: 5.0e39.3), pZ 0.016, respectively].
Also, homozygous carriers of the GATA haplotype, as
compared to all other patients combined, had lower IL-
10 at time-points 2 and 3 [17.0 (IQR: 4.3e28.3) versus
35.0 pg/mL (IQR: 11.0e89.0), pZ 0.026 and 20.0
(IQR: 10.0e33.0) versus 39.0 pg/mL (IQR: 11.0e105),
pZ 0.065, respectively]. Furthermore, when combining
measurements from consecutive time-points (i.e. time-
point 2 and 3 or 2, 3 and 4 combined, respectively) the
differences were more clear [18.0 (IQR: 5.5e32.0) versus
37.5 pg/mL (IQR: 11.0e106), pZ 0.04 and 13.5



























































Fig. 2. Estimated EC50 values, calculated as described in the methods. Left panel represents carriers of the GATA haplotype (right box plot) as
compared with all others. Middle panel represents carriers of the AGCC haplotype (right box plot) as compared with all others. Right panel
represents carriers of the GACC haplotype (right box plot) as compared with all others. The box plots display the median, the 25th and 75th
percentiles, and the smallest and largest EC50 values that are not outliers. )p Z 0.027.
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pZ 0.010, respectively]. To determine whether the
patterns of IL-10 production over time were different
between carriers the proximal IL-10 promoter haplo-
types or their six subsequent biallelic genotypes, we used
a repeated measurements model as described in the
methods. For this analysis log-transformed IL-10 levels
were used as dependent variable. Since the time-point
proved to be the most significant variable in this model
Table 3
Perioperative IL-10 production according to IL-10 and TLR4 genotype/haplotypea
Anesthetic induction Aorta declamping 30 min into reperfusion On arrival at the ICU
All patients 2.0 (2.0e4.0) 32 (10e88) 37 (11e87) 8.0 (4.0e26)
nZ 150 nZ 137 nZ 138 nZ 148
Endotoxemiab
Negative 2.0 (2.0e4.0) 19 (8.0e68) 33 (11e92) 5.5 (4.0e25)
nZ 56 nZ 55 nZ 54 nZ 56
Positive 2.0 (2.0e4.0) 34 (11e103) 41 (12e89) 7.0 (2.0e24)
nZ 82 nZ 80 nZ 82 nZ 81
IL-10 promoter genotype
1330, 1082, 819, 592/1330, 1082, 819, 592
AGCC/AGCC 2.0 (2.0e4.0) 48 (14e207) 44 (16e203) 9.0 (2.0e30)
nZ 31 nZ 29 nZ 28 nZ 31
AGCC/GACC 2.0 (2.0e4.0) 32 (8.3e80) 37 (11e88) 6.0 (2.0e29)
nZ 40 nZ 36 nZ 37 nZ 39
AGCC/GATA 2.0 (2.0e4.0) 53 (13e87) 45 (16e83) 9.0 (4.0e22)
nZ 29 nZ 24 nZ 25 nZ 28
GACC/GACC 2.0 (2.0e2.5) 14 (6.0e46) 11 (6.0e63) 5.0 (2.0e17)
nZ 14 nZ 15 nZ 15 nZ 15
GATA/GATA 2.0 (2.0e4.0) 17 (4.3e28) 20 (10e33) 5.0 (4.0e22)
nZ 15 nZ 14 nZ 15 nZ 15
GACC/GATA 2.0 (2.0e3.0) 35 (17e168) 36 (20e177) 6.5 (2.5e25)
nZ 17 nZ 15 nZ 14 nZ 16
IL-10 promoter genotype
3575 TA 2.0 (2.0e4.0) 43 (10e102) 50 (11e159) 7.0 (2.8e30)
nZ 67 nZ 60 nZ 59 nZ 66
TT 2.0 (2.0e4.0) 25 (8.0e50) 24 (10e60) 9.0 (4.0e25)
nZ 46 nZ 43 nZ 43 nZ 45
AA 2.0 (2.0e3.5) 23 (9.8e209) 28 (11e190) 6.0 (2.0e26)
nZ 16 nZ 14 nZ 15 nZ 16
2849 GG 2.0 (2.0e4.0) 32 (8.0e76) 34 (11e81) 9.0 (4.0e26)
nZ 68 nZ 62 nZ 61 nZ 67
AG 2.0 (2.0e4.0) 49 (11e128) 41 (11e140) 7.0 (2.0e31)
nZ 54 nZ 49 nZ 50 nZ 53
AA 3.0 (2.0e5.5) 11 (4.0e73) 12 (8.0e55) 7.0 (2.8e20)
nZ 4 nZ 3 nZ 3 nZ 4
2763 CC 2.0 (2.0e4.0) 28 (8.0e57) 33 (11e63) 9.0 (4.0e26)
nZ 57 nZ 51 nZ 51 nZ 56
AC 2.0 (2.0e4.0) 49 (11e135) 42 (11e194) 8.0 (2.0e28)
nZ 59 nZ 54 nZ 54 nZ 58
AA 2.0 (2.0e4.0) 39 (9.0e212) 36 (11e249) 5.0 (4.0e30)
nZ 11 nZ 10 nZ 10 nZ 11
TLR4 haplotype
299C/399C 2.0 (2.0e4.0) 32 (10e90) 33 (11e109) 8.0 (2.0e27)
nZ 132 nZ 122 nZ 122 nZ 130
299/399C 2.0 (e) 80 (e) 42 (e) 8.0 (e)
nZ 1 nZ 1 nZ 1 nZ 1
299/399c 4.0 (2.0e4.0) 43 (10e50) 43 (21e67) 9.0 (5.0e17)
nZ 15 nZ 12 nZ 13 nZ 15
299C/399 2.0 (2.0e2.0) 9.0 (2.0e16) 21 (5.0e37) 7.5 (6.0e9.0)
nZ 2 nZ 2 nZ 2 nZ 2
a IL-10 concentrations are in pg/mL. Median values and interquartile range between parentheses. Lower detection limit for IL-10 and endotoxin
were 4.0 and 3.0 pg/mL, respectively.
b Positive defined as having an endotoxin level of R 5 pg/mL at aorta declamping and/or 30 min into reperfusion, negative defined as an endotoxin
level of !5 pg/mL at both the time-points.
c One patient out of 15, 12, 13 and 15 homozygous, respectively, all others heterozygous.
8282
Chapter 6
we used this variable as a fixed-factor, leaving baseline
measurements (time-point 1) out of the analysis. To
investigate the influence of other relevant variables (i.e.
TNF-a and endotoxin concentrations) they were in-
troduced in the model. We did not find statistically
significant differences in the pattern of IL-10 production
over time between any of the proximal IL-10 promoter
haplotypes and the distal SNPs.
The median IL-10 levels were lower at all post-
operative time-points in carriers of the 299 and 399 wild-
types alleles as compared to carriers of the Asp299Gly
or the Thr399Ile polymorphisms respectively, however,
this was not statistically significant (all pO 0.37). The
patterns of IL-10 production over time were not
different between carriers of the substitutions as
compared to the wild-types.
2.7. Correlations between endotoxin
and IL-10 levels
A positive correlation between endotoxin and IL-10
levels was observed when analysing all paired samples
(nZ 572, rZ 0.433; pZ!0.001). After excluding
either all paired samples at time-point 1 or all paired
samples with endotoxin and/or IL-10 level below the
level of detection (i.e., endotoxin and IL-10 level below
3.0 and 4.0 pg/mL, respectively) or both, the correlation
decreased but remained statistically significant (nZ 424,
rZ 0.115; pZ 0.018, nZ 395, rZ 0.333; pZ!0.001
and nZ 350, rZ 0.132; pZ 0.013, respectively). Fur-
thermore, median IL-10 levels, at all post-operative
time-points were higher in patients having endotoxemia
(defined as having an endotoxin level of O5 pg/mL at
aorta declamping and/or 30 min into reperfusion) as
compared to patients without endotoxemia, however,
this difference did not reach the level of statistical
significance (all pO 0.14, Table 3).
2.8. Correlations between ex vivo IL-10 production
and in vivo IL-10 concentrations
Since in vivo IL-10 concentrations were found to
correlate with the level of endotoxemia after aorta
declamping, suggesting a causative role for endotoxin in
the IL-10 production, it seems plausible to investigate
whether a correlation could be found between the in
vitro IL-10 production upon LPS stimulation and the in
vivo IL-10 concentrations during endotoxemia. A
significant negative correlation between IL-10 concen-
tration at aorta declamping and 30 min into reperfusion
with ex vivo IL-10 production using 1000 ng/mL LPS
was found (rZ0.303; pZ 0.001 and rZ0.210;
pZ 0.030, respectively). Also, a significant negative
correlation was found between IL-10 concentration at
aorta declamping with ex vivo IL-10 production using
100 ng/mL LPS (rZ0.216; pZ 0.024).
Furthermore, we found a negative correlation be-
tween IL-10 concentration at aorta declamping and
30 min into reperfusion with the estimated IL-10max
(rZ0.305; pZ 0.001 and rZ0.225; pZ 0.018,
respectively). After dividing the patients into two groups
according to the presence or the absence of endotoxemia
(endotoxemia positive patients, defined as patients
having an endotoxin levelO 5 pg/mL at aorta declamp-
ing and/or 30 min into reperfusion or endotoxemia
negative patients defined as patients having an endo-
toxin level! 5 pg/mL at both the time-points) the
correlations were only significant in the endotoxemia
positive patients. In the patients having endotoxemia,
a negative correlation between IL-10 concentration
at aorta declamping and 30 min into reperfusion with
ex vivo IL-10 production upon stimulation with
1000 ng/mL LPS was found (rZ0.389; pZ 0.001
and rZ0.282; pZ 0.023, respectively). In accordance
with this finding the same negative correlation was
observed between IL-10 concentration at aorta declamp-
ing with ex vivo IL-10 production upon stimulation with
100 ng/mL LPS (rZ0.280; pZ 0.023). Moreover,
a significant negative correlation between IL-10 concen-
tration at aorta declamping and 30 min into reperfusion
with the estimated IL-10max was found (rZ0.377;
pZ 0.002 and rZ0.279; pZ 0.022, respectively).
2.9. Correlations between IL-10 and TNF-a
production ex vivo and in vivo
Data on ex vivo TNF-a production and in vivo
TNF-a concentrations have been published previously
[17]. Herein, we investigated whether any correlations
existed between the ex vivo IL-10 and TNF-a production
and in vivo concentration were present (Table 4).
We observed positive correlations between TNF-a and
IL-10 production ex vivo upon stimulation with all the
LPS concentrations tested (Table 4, r ranging from 0.305
to 0.563, all p! 0.007). Furthermore, the estimated
TNF-a EC50 and IL-10 EC50, as well as the TNF-amax
and IL-10max were positively correlated (rZ 0.203;
pZ 0.023 and rZ 0.287; pZ 0.001, respectively). The
observed positive correlation between TNF-a and IL-10
EC50 values, being markers of LPS determined by ex vivo
TNF-a and IL-10 production, respectively, indicates that
LPS sensitivity influences ex vivo TNF-a and IL-10
production in the same direction.
In vivo no significant correlations were observed
between TNF-a and IL-10 concentrations at any of the
time-points (Table 4). We find this remarkable since one
might expect a positive correlation, especially at the
time-points at which endotoxemia occurs most signifi-
cantly. We hypothesized that the correlation might be
absent due to the fact that TNF-a is released early upon
endotoxemia, whereas IL-10 is released later and peaks
when TNF-a levels already decrease. This hypothesis
83 83













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































was substantiated by the observation of a positive
correlation between TNF-a concentration at time-point
3 and IL-10 production at time-point 4 (i.e. on average
2 h later, rZ 0.258; pZ 0.007), indicating some contri-
bution of the TNF-a release magnitude on the sub-
sequent IL-10 production.
3. Discussion
The main findings of the present study are that the
circulating IL-10 concentrations following cardiopul-
monary bypass in patients undergoing cardio-thoracic
surgery correlate positively with the intensity of
endotoxemia during the reperfusion phase upon aortic
declamping. Patients carrying the AGCC allele had
slightly higher post-operative IL-10 levels as compared
to carriers of all other haplotypes combined. Homozy-
gous carriers of the GATA allele had lower post-
operative IL-10 levels as compared to all other patients.
Furthermore, AGCC allele carriers had lower IL-10
EC50 values (i.e. higher LPS sensitivity ex vivo) as com-
pared to patients carrying the other alleles, whereas
carriers of the GATA allele showed the opposite (i.e.
higher EC50 values; lower LPS sensitivity). For both the
AGCC and the GATA allele carriers, the maximal
induced IL-10 production upon ex vivo LPS stimulation
was similar as compared to the other groups. The in vivo
IL-10 release during reperfusion (i.e. at aorta declamp-
ing and 30 min into reperfusion) in patients experiencing
endotoxemia was significantly correlated with the IL-10
production ex vivo upon stimulation with 1000 ng/mL
and the estimated maximal IL-10 production capacity
(the IL-10max), no correlation was found between the
IL-10 EC50 ex vivo with in vivo IL-10 levels.
The model we choose, i.e. measuring naturally
occurring endotoxemia and subsequent cytokine release
in vivo in patients undergoing cardio-thoracic surgery,
enables us to study the inter-individual differences in
these responses and relate these to genetic factors. In
a previous publication we described the TNF-a response
in the same way. We found significant endotoxemia in
over half of the patients undergoing cardiac surgery with
cardiopulmonary bypass which is in accordance with
previous studies [18,19]. At the peak of endotoxemia,
upon aortic declamping and 30 min into reperfusion, we
observed a significant positive correlation between
circulating endotoxin levels and IL-10 production,
indicating a role of endotoxin in the perioperative
release of IL-10. However, although we found a signif-
icant correlation, it’s magnitude is limited, suggesting
that many other factors apart from endotoxin play
a role in the variation of IL-10 production in these
patients.
Since we used 3 different concentrations of LPS in
our ex vivo whole blood assay we were able to calculate
descriptive parameters of the doseeresponse relation for
each patient. Also, to estimate spread relative to the
mean, the coefficients of variation (standard deviation
[SD] divided by the mean) were calculated for all LPS
concentrations. The values were 50.4%, 46.4% and
94.8% for 10, 100 and 1000 ng/mL LPS, respectively.
This variation is similar to the variation found in other
populations and exceeds the variation that can be
explained by the laboratory variation only, which is
estimated at 9.9e12.3% [4]. This indicates that the
variations we found between subjects are to be explained
by other factors than laboratory variation only. Since
we find it feasible to assume that the LPS concentration
needed for the release of 50% of the maximally evoked
IL-10, the EC50, is a marker of LPS sensitivity we
evaluated to what extent this parameter could presage
the in vivo response to endotoxin. Theoretically,
important inter-individual differences in the doseeres-
ponse characteristics of IL-10 production upon LPS
stimulation can be overlooked by measuring IL-10
production upon stimulation with only one single
(supra-physiological) LPS concentration.
We found that the level of ex vivo IL-10 production
upon stimulation with 1000 ng LPS/mL was significantly
correlated with the in vivo production upon significant
endotoxemia. Thus, the ex vivo LPS stimulation assay is
a predictor of the in vivo release of IL-10 during
endotoxemia after cardiac surgery. Remarkably, how-
ever, the correlation is inverse; high ex vivo IL-10
production capacity is associated with low in vivo
circulating IL-10 levels. The explanation of this finding
is puzzling. To our knowledge no other study investi-
gated the correlation between endotoxin mediated IL-10
production ex vivo and in vivo. With respect to the
validity of the comparison of the ex vivo and in vivo
IL-10 production, and the conclusions drawn, several
factors should be taken into account. In our analysis we
correlated IL-10 concentrations in vivo with in vitro
production capacity. In these analyses the time factor is
rather artificially ignored to a certain extent. In vivo the
time between exposure to the stimulus (endotoxin) and
measurement of the cytokine was several hours at the
maximum. In vitro, however, we measured the IL-10
concentration at 24 h after adding LPS. In a previous
study it was demonstrated that after 18 h of ex vivo
stimulation the IL-10 mRNA levels reached the highest
level making measurement of IL-10 after 24 h as
indicator of maximal IL-10 production capacity logical
[7]. Day-to-day intra-individual variation of IL-10
concentrations after 24 h of stimulation was low (about
10%). Giving the wide range of IL-10 production levels
between individuals this measurement seems a good
basis to demonstrate genetically defined variation [6]. We
measured the ex vivo IL-10 production in a blood sample
drawn several hours before the in vivo production
capacity was measured, probably making the variation
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due to day-to-day variation even smaller. Although in all
patients a standardized anesthesia protocol was fol-
lowed, differences in the use of certain medical devices
and medications might have influenced our results. Also,
not all patients experienced the same amount of
endotoxin stimulus in vivo. Although most patients
had significant endotoxemia at the later time-points,
some did not. To be able to study the relationship
between endotoxin and IL-10 release we specifically
studied their relation in patients with significant endo-
toxemia. We found even stronger correlations in the
patients experiencing endotoxemia, indicating the rele-
vance of endotoxin as stimulus in the in vivo IL-10
production. Furthermore, for the in vitro stimulation
assay we used crude Escherichia coli LPS rather than
purified lipid A, the ligand for TLR4. Recent studies
indicate that these preparations can be contaminated
with relevant traces of other bacterial products, i.e.
lipoproteins, rather than lipid A, that signal through
other receptors deriving from the TLR family, especially
TLR2 [20,21]. This might have complicated our con-
clusions on the role of the TLR4 genotype. However, our
in vivo model reflects a physiological exposure to
naturally occurring endotoxemia. Also, in Gram-nega-
tive bacterial infection it is likely that the innate immune
system is confronted with a mixture of endotoxins. One
study reported post-operative down-regulation of TLR2
and TLR4 receptors on PBMC’s after abdominal
surgery [22]. No data exist on TLR receptor down-
regulation in cardio-thoracic surgery with extracorporal
bypass.
Since several studies indicated a role of genetics in
cytokine release we investigated the influence of the
various known polymorphism in the IL-10 promoter.
The frequencies of the various genotypes were similar
to those found in other populations (Table 1)
[9,10,13,23e28]. We found that the carriers of the
GATA haplotype had lower LPS sensitivity and IL-10
production ex vivo, furthermore, homozygous GATA
carriers also had lower IL-10 production in vivo. On the
other hand, carriers of the AGCC haplotype had higher
sensitivity to LPS. In a study of twins by Reuss et al. the
AGCC haplotype was associated with higher (around
20%) transcriptional activity in a reporter gene assay
using luciferase as reporter [23]. The study emphasizes
the importance of the SNP at position 1082 in the
transcriptional activity of the proximal promoter. It is
suggested that an A at position 1082 confers optimal
binding affinity for the transcriptional factor PU.1 that
inhibits gene expression, resulting in an increased
transcriptional activity when a G is present at position
1082. However, in the study by Reuss et al. levels of
produced IL-10 upon whole blood stimulation using
100 ng/mL LPS were not different between the various
haplotypes [23]. An explanation for this finding could be
that the LPS concentration used in their assay was too
high to pick up the differences we found at the lower
LPS concentrations. As mentioned before, we found no
differences in IL-10 levels using the highest LPS
concentration (1000 ng/mL). The phenotype of in-
creased LPS sensitivity we found ex vivo in AGCC
haplotype carriers, is further supported by the signifi-
cantly higher circulating IL-10 levels following cardio-
pulmonary bypass in the AGCC haplotype carriers as
compared to carriers of the other haplotypes combined.
At this time-point the endotoxin levels peaked in most
patients. In a study conducted by Suárez et al.
constitutive IL-10 levels were measured in peripheral
blood of healthy volunteers and were correlated to SNPs
in the proximal promoter region. In that study, the GCC
genotype was found significantly more often in the
group with high IL-10 levels (R 2 pg/mL), again
indicating the importance of a G at position 1082
[24]. Constitutive IL-10 gene expression (measured by
IL-10 mRNA detection from whole blood samples) was
higher in subjects carrying the GCC/GCC genotype as
compared to the non-GCC carrying genotypes [24]. In
a study performed by Fijen et al. no differences were
found in IL-10 production between the 1082G/A
genotypes in an experimental human endotoxemia
model in healthy subjects [29]. However, looking more
closely to their findings in a rather small group of
healthy subjects, a trend is visible towards higher IL-10
levels in carriers of a G at position 1082. No other
study investigated the role of IL-10 polymorphisms in
endotoxemia mediated IL-10 production capacity in
vivo.
The common TLR4 polymorphisms (Asp299Gly and
Thr399Ile) are associated with slightly higher IL-10
capacity ex vivo, however, this did not reach the level of
statistical significance. The frequencies of the various
genotypes were similar to those found in other
populations (Table 1) [30e34]. To our knowledge no
other study investigated the correlation between TLR4
polymorphisms and the ex vivo or the in vivo endotoxin
mediated IL-10 production. The common TLR4 poly-
morphisms (Asp299Gly and Thr399Ile) are not associ-
ated with differences in IL-10 production capacity ex
vivo and in vivo.
Although a type II error could be responsible for
overlooking differences in IL-10 production capacity
between the other IL-10 promoter and the TLR4
polymorphisms studied, our data suggest that their role,
if present, is limited, and cannot explain the large inter-
individual differences found in IL-10 capacity, which
was recently estimated at around 50% [23]. The
demographic characteristics of the cardiac surgery
patients were similar to other groups of patients
described in the literature [35,36], making direct
extrapolation of our findings possible.
In summary, based on our results and the findings in
the literature, we propose that it is likely that the IL-10
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promoter polymorphism at position 1082 base pairs
relative to the transcriptional start site plays a functional
role in LPS mediated IL-10 production capacity in vitro
and in vivo. The common TLR4 polymorphisms do not
interact with factors determining IL-10 production
capacity in vivo and ex vivo. Although part of the large
inter-individual variation found in the in vivo and ex
vivo responses to LPS can be explained by known
polymorphisms in the IL-10 promoter region, overall
their effects are limited and can only explain about
5e10% of the variation. Further studies are needed to
determine to what extent the remaining inter-individual
variation found in the IL-10 response to LPS is
determined by genetic or random, environmental
factors.
4. Materials and methods
4.1. Patients
The study was performed at the Leiden University
Medical Center, an 800-bed secondary and tertiary
referral hospital. To be eligible for enrolment, the
patients had to be aged 18 years or older and being
scheduled for elective cardiac surgery with cardiopul-
monary bypass between July 1, 1998, and December 30,
1999. We obtained institutional approval from the local
medical ethics committee (protocol #P168/96). Each
patient gave a written, informed consent. The patients
studied were 159 consecutive patients undergoing
elective cardiac surgery with cardiopulmonary bypass.
Of these, 122 had been included in a previously
published study on the effect of selective gut decontam-
ination (SGD) on endotoxemia and cytokine activation
[37]. Of these 122 patients 24 received preoperative SGD
consisting of polymyxin B and neomycin. In the
previously mentioned study, perioperative endotoxemia
and subsequent cytokine activation were found not to be
influenced by the SGD regimen. Also, the results were
not different when these patients were excluded from the
analysis. Patients were followed-up throughout their
stay in the hospital. Demographic characteristics were
systematically collected for all the patients entering the
study.
4.2. Study design
On the day of surgery blood samples for ex vivo
whole blood LPS stimulation, using pyrogen-free tubes
(Kabi-Vitrum, Amsterdam, The Netherlands), and
DNA extraction were drawn before anesthesia. Blood
samples for the determination of in vivo endotoxin and
cytokine levels were collected from each patient before
anesthetic induction, on aorta declamping, 30 min into
body reperfusion (i.e. 30 min after stopping the extra
corporal perfusion), and at the ICU admission (approx-
imately 2 h after surgery). In a previous pilot study, we
found that endotoxemia occurs most likely at these
time-points [37].
4.3. Whole blood LPS stimulation
Cytokine production was determined in whole blood
samples ex vivo as previously described [38]. Briefly,
whole blood samples were mixed 1:1 with RPMI 1640
(Gibco, Germany) and lipopolysaccharide (E. coli
0111:B4, Difco, Detroit, MI) was added to final
concentrations of 10, 100 and 1000 ng/mL and cells
were stimulated for 24 h at 37 C under 5% CO2
atmosphere. Interleukin-10 concentrations were mea-
sured in the supernatant as described below.
4.4. Endotoxin measurements
Blood for endotoxin determination was collected in
pyrogen-free tubes (Kabi-Vitrum, Amsterdam, The
Netherlands) and the platelet rich plasma was prepared
by centrifugation. Endotoxin was determined by a quan-
titative photometric assay with end-point measurement
as described elsewhere [39]. The assay’s lower detection
limit for endotoxin was about 3.0 pg/mL [39].
4.5. IL-10 measurements
Blood for determination of IL-10 was collected in
pyrogen-free ethylenediaminetetraacetic acid (EDTA)
tubes (Chromogenics, Amsterdam, Netherlands) and
immersed in ice. Plasma was prepared by centrifugation
at 3000g for 5e10 min at 4 C and stored at 70 C.
Interleukin-10 concentrations in the supernatants of the
ex vivo whole blood assay and the samples from the in
vivo IL-10 production were analysed at completion of
the study. Interleukin-10 concentrations were deter-
mined with a standard ELISA technique (Central
Laboratories for Bloodtransfusion, Amsterdam, The
Netherlands; Medgenix diagnostics, Floury, Belgium);
the lower detection limit for IL-10 was 4.0 pg/mL.
4.6. DNA isolation
DNA was isolated from citrate blood from each
patient, red blood cells were lysed with three volumes of
lysis buffer (1.55 M NH4Cl, 0.1 M KHCO3, 0.01 M
EDTA, pH 7.4); the remaining cells were incubated for
17 h at 37 C with SDS and proteinase K. The DNA
was extracted using phenol and chloroform as described
by Maniatis et al. [40].
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4.7. Typing of the proximal IL-10 promoter
polymorphism
The polymorphic regions at positions 1330, 1082,
819 and 592 were evaluated by PCR amplification
using the following primers: 5#-CCCTGACTATA-
GAGTGGCAG-3# (forward) and 5#-GTGCTGAGC-
TGTGCATGCCT-3# (reverse). The single nucleotide
polymorphisms were determined using Allele Specific
Hybridization (ASH-blot) as previously described [10].
Briefly, the PCR products were dot blotted on the
membranes (HybondeNC, Amersham, Buckingham-
shire, UK) and hybridized overnight at 42 C with the
specific biotin labeled oligoprimer. After hybridization
the blot was washed with ASH-buffer at the critical
temperature. Sequences of the sequence-specific oligo-
primers and their respective critical washing temper-
atures are given in Table 5.
4.8. Typing of distal IL-10 promoter polymorphisms
Typing for the IL-10 single nucleotide polymor-
phisms at positions 3575, 2849 and 2763 was
performed by PCR amplification. Forward and reverse
primers used are given in Table 6 [28]. For the positions
2849 and 2763 a second, nested-PCR was performed
using P2BR as reverse primer (Table 6). Primers were
purchased from Biosource International (Foster City,
CA). PCR amplifications were performed using the
Thermolyne Amplitron II Thermal Cycler (Barnstead/
Thermolyne, Dubuque, IA). PCR-amplified products
were electrophoresed on a 10% polyacrylamide gel to
detect the size differences of the fragments between the
polymorphisms, following digestion with a specific re-
striction enzyme (Table 6).
4.9. TLR4 mutation analysis
The presence of the TLR4 Asp299Gly and Thr399Ile
mutations was determined as previously described [17].
4.10. Calculation of ex vivo LPS/IL-10 doseeresponse
For each patient two characteristics (i.e. EC50 and
Emax) of the LPS-induced IL-10 release were calculated
by non-linear regression with the doseeresponse model
according to the Hill equation (Eq. (1)).
ENZEN;max!C=ðEC50CCÞ ð1Þ
where EN is the observed IL-10 production at a given
LPS concentration C, EC50 is the estimated LPS
concentration at which 50% of the maximal IL-10
response is reached, and EN,max is the estimated
maximal IL-10 production. In a previous pilot study
we found that measuring the IL-10 production at the
LPS concentration we used (i.e. 10, 100 and 1000 ng/
mL) was sufficient to calculate the doseeresponse
characteristics EC50 and EN,max (E.S., unpublished
observation, report in preparation).
4.11. Statistical analysis
IL-10 concentrations in vivo and ex vivo in different
haplotype groups and genotypes were not distributed
Table 5
Sequence and specificity of biotin labeled sequence-specific oligonucleotides and critical washing temperature (CWT) in C
Polymorphism Primer sequence (5#/ 3#) CWT Specificity
1330 ACCTAGGTCAATGTTCCTCC 52 G
GGAGGAACACTGACCTAGGT 54 A
1082 TTCTTTGGGAGGGGGAAG 51 G
ACTTCCCCTTCCCAAAGAA 52 A
819 CAGGTGATGTAACATCTCTGTGC 62 C
GCACAGAGATATTACATCACCTGT 63 T
592 CCGCCTGTCCTGTAGGAA 50 C
TTCCTACAGTACAGGCGGG 52 A
Table 6
Primers sequences and restriction enzymes used for detection of the polymorphisms in the IL-10 gene promoter and size of the PCR products and
restriction fragments
Polymorphism Primer sequence (5#/ 3#) PCR product
(bps)
Enzyme Size Allele
3575 GGTTTTCCTTCATTTGCAGC 231 BamHI 121C 110 TT
ACACTGTGAGCTTCTTGAGG 231 AA
2849 CTGTAATCTCAGCACTCTGG 193 AlwI 153C 40 GG
ACCAAGTCTGGCCCTTGGAA/GTTCAAGCCATTCTCCTGCC 193 AA
2763 CTGTAATCTCAGCACTCTGG 193 DdeI 114C 71C 8 CC
ACCAAGTCTGGCCCTTGGAA/GTTCAAGCCATTCTCCTGCC 185C 8 AA
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normally, and so non-parametric testing has been used
throughout. IL-10 concentrations are quoted as the
median with interquartile ranges between parentheses.
For statistical analysis blood samples with IL-10 and
endotoxin levels below the limit of detection were
entered as half of the value of the lower detection limit
(2.0 and 1.5 pg/mL, respectively). To determine wheth-
er polymorphisms in the IL-10 promoter were associ-
ated with levels of in vivo IL-10 production, repeated
measurements models (SPPS 11.0, mixed) were used to
determine whether the patterns of IL-10 production
over time were different between polymorphisms. For
this analysis log-transformed IL-10 and endotoxin
levels were used. The ex vivo and in vivo IL-10
production characteristics between the various haplo-
types and genotypes were compared using Kruskale
Wallis test, individual groups were compared by the
ManneWhitney U test. Correlations were assessed
non-parametrically using Spearman correlation test.
Statistical significance was tested two-tailed, with the
a set to 0.05.
Acknowledgements
We thank Saskia A.C. Luelmo, Tahar van der
Straaten and Michiel Haeseker for excellent technical
support as well as the nursing staff of the cardio-thoracic
intensive care unit, for their kind cooperation.
References
[1] Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S.
High levels of interleukin-10 during the initial phase of fulminant
meningococcal septic shock. J Infect Dis 1995;171:229e32.
[2] Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High
levels of interleukin 10 in serum are associated with fatality in
meningococcal disease. Infect Immun 1995;63:2109e12.
[3] van Furth AM, Seijmonsbergen EM, Langermans JA,
Groeneveld PH, de Bel CE, van Furth R. High levels of
interleukin 10 and tumor necrosis factor alpha in cerebrospinal
fluid during the onset of bacterial meningitis. Clin Infect Dis
1995;21:220e2.
[4] van der Linden MW, Huizinga TW, Stoeken DJ, Sturk A,
Westendorp RG. Determination of tumour necrosis factor-alpha
and interleukin-10 production in a whole blood stimulation
system: assessment of laboratory error and individual variation.
J Immunol Methods 1998;218:63e71.
[5] Westendorp RG, Langermans JA, Huizinga TW, Elouali AH,
Verweij CL, Boomsma DI, et al. Genetic influence on cytokine
production and fatal meningococcal disease. Lancet
1997;349:170e3.
[6] Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG,
Huizinga TW. Interleukin 10 secretion in relation to human IL-10
locus haplotypes. Proc Natl Acad Sci U S A 1998;95:9465e70.
[7] Huizinga TW, Keijsers V, Yanni G, Hall M, Ramage W,
Lanchbury J, et al. Are differences in interleukin 10 production
associated with joint damage? Rheumatology (Oxford) 2000;
39:1180e8.
[8] Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ,
Hutchinson IV. An investigation of polymorphism in the
interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1e8.
[9] Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J,
Ollier WE, et al. Genetic variation in the interleukin 10 gene
promoter and systemic lupus erythematosus. J Rheumatol 1997;
24:2314e7.
[10] Rood MJ, Keijsers V, van der Linden MW, Tong TQ,
Borggreve SE, Verweij CL, et al. Neuropsychiatric systemic lupus
erythematosus is associated with imbalance in interleukin 10
promoter haplotypes. Ann Rheum Dis 1999;58:85e9.
[11] Westendorp RG, van Dunne FM, Kirkwood TB,
Helmerhorst FM, Huizinga TW. Optimizing human fertility and
survival. Nat Med 2001;7:873.
[12] Kurreeman FA, Schonkeren JJ, Heijmans BT, Toes RE,
Huizinga TW. Transcription of the IL10 gene reveals
allele specific regulation at the mRNA level. Hum Mol Genet
2004.
[13] de Jong BA, Westendorp RG, Eskdale J, Uitdehaag BM,
Huizinga TW. Frequency of functional interleukin-10 promoter
polymorphism is different between relapse-onset and primary
progressive multiple sclerosis. Hum Immunol 2002;63:281e5.
[14] Faure E, Equils O, Sieling PA, Thomas L, Zhang FX,
Kirschning CJ, et al. Bacterial lipopolysaccharide activates NF-
kappaB through toll-like receptor 4 (TLR-4) in cultured human
dermal endothelial cells. Differential expression of TLR-4 and
TLR-2 in endothelial cells. J Biol Chem 2000;275:11058e63.
[15] Muzio M, Bosisio D, Polentarutti N, D’amico G, Stoppacciaro A,
Mancinelli R, et al. Differential expression and regulation of toll-
like receptors (TLR) in human leukocytes: selective expression of
TLR3 in dendritic cells. J Immunol 2000;164:5998e6004.
[16] Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of
mutations in the TLR4 receptor in patients with gram-negative
septic shock. Arch Intern Med 2002;162:1028e32.
[17] Schippers EF, van ’t Veer C, van Voorden S, Martina CA, le
Cessie S, van Dissel JT. TNF-alpha promoter, Nod2 and toll-like
receptor-4 polymorphisms and the in vivo and ex vivo response to
endotoxin. Cytokine 2004;26:16e24.
[18] Oudemans-van Straaten HM, Jansen PG, te VH, Beenakkers IC,
Stoutenbeek CP, van Deventer SJ, et al. Increased oxygen
consumption after cardiac surgery is associated with the in-
flammatory response to endotoxemia. Intensive Care Med
1996;22:294e300.
[19] Oudemans-van Straaten HM, Jansen PG, Hoek FJ, van
Deventer SJ, Sturk A, Stoutenbeek CP, et al. Intestinal
permeability, circulating endotoxin, and postoperative systemic
responses in cardiac surgery patients. J Cardiothorac Vasc Anesth
1996;10:187e94.
[20] Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge:
repurification of lipopolysaccharide eliminates signaling through
both human and murine toll-like receptor 2. J Immunol 2000;
165:618e22.
[21] Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-
like receptor 4, but not toll-like receptor 2, is a signaling receptor
for Escherichia and Salmonella lipopolysaccharides. J Immunol
2000;165:5780e7.
[22] Ikushima H, Nishida T, Takeda K, Ito T, Yasuda T, Yano M,
et al. Expression of Toll-like receptors 2 and 4 is downregulated
after operation. Surgery 2004;135:376e85.
[23] Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T.
Differential regulation of interleukin-10 production by genetic
and environmental factors e a twin study. Genes Immun 2002;
3:407e13.
[24] Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. In-
terindividual variations in constitutive interleukin-10 messenger
RNA and protein levels and their association with genetic
polymorphisms. Transplantation 2003;75:711e7.
89 89
IL-10 and toll-like receptor-4 polymorphisms
[25] Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of
interleukin-10 polymorphisms on interleukin-10 expression and
survival in critically ill patients. Crit Care Med 2003;31:34e8.
[26] Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP.
Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in
inflammatory bowel diseases and normal controls: differential
effects on production and allele frequencies. Genes Immun 2000;
1:185e90.
[27] Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G,
Bonafe M, et al. Inflammation, genetics, and longevity: further
studies on the protective effects in men of IL-10 1082 promoter
SNP and its interaction with TNF-alpha 308 promoter SNP.
J Med Genet 2003;40:296e9.
[28] Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW,
Kimberly RP. Novel single nucleotide polymorphisms in the distal
IL-10 promoter affect IL-10 production and enhance the risk of
systemic lupus erythematosus. J Immunol 2001;166:3915e22.
[29] Fijen JW, Tulleken JE, Hepkema BG, van der Werf TS,
Ligtenberg JJ, Zijlstra JG. The influence of tumor necrosis
factor-alpha and interleukin-10 gene promoter polymorphism on
the inflammatory response in experimental human endotoxemia.
Clin Infect Dis 2001;33:1601e3.
[30] Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-
Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF)
gene polymorphism influences TNF-alpha production in lipo-
polysaccharide (LPS)-stimulated whole blood cell culture in
healthy humans. Clin Exp Immunol 1998;113:401e6.
[31] Allen RA, Lee EM, Roberts DH, Park BK, Pirmohamed M.
Polymorphisms in the TNF-alpha and TNF-receptor genes in
patients with coronary artery disease. Eur J Clin Invest
2001;31:843e51.
[32] de Jong BA, Westendorp RG, Bakker AM, Huizinga TW.
Polymorphisms in or near tumour necrosis factor (TNF)-gene do
not determine levels of endotoxin-induced TNF production.
Genes Immun 2002;3:25e9.
[33] Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF,
Ramos R, et al. A frameshift mutation in NOD2 associated with
susceptibility to Crohn’s disease. Nature 2001;411:603e6.
[34] Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F,
et al. Association of TNF2, a TNF-alpha promoter polymor-
phism, with septic shock susceptibility and mortality: a multicenter
study. JAMA 1999;282:561e8.
[35] Kawachi Y, Nakashima A, Toshima Y, Arinaga K, Kawano H.
Risk stratification analysis of operative mortality in heart and
thoracic aorta surgery: comparison between Parsonnet and
EuroSCORE additive model. Eur J Cardiothorac Surg
2001;20:961e6.
[36] Nashef SA, Roques F, Hammill BG, Peterson ED, Michel P,
Grover FL, et al. Validation of European system for cardiac
operative risk evaluation (EuroSCORE) in North American
cardiac surgery. Eur J Cardiothorac Surg 2002;22:101e5.
[37] Bouter H, Schippers EF, Luelmo SA, Versteegh MI, Ros P,
Guiot HF, et al. No effect of preoperative selective gut
decontamination on endotoxemia and cytokine activation during
cardiopulmonary bypass: a randomized, placebo-controlled
study. Crit Care Med 2002;30:38e43.
[38] De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y,
Noizat-Pirenne F, et al. Direct stimulation of cytokines (IL-1
beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in
whole blood. I. Comparison with isolated PBMC stimulation.
Cytokine 1992;4:239e48.
[39] van Dissel JT, van Langevelde P, Westendorp RG,
Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile
and mortality in febrile patients. Lancet 1998;351:950e3.
[40] Maniatis T, Fritsch EF, Sambrook J. Molecular cloning:






Cytokine response to endotoxin in individuals heterozygous for the 






M. Heesen1, E.F. Schippers2, B. Bloemeke3, D. Kunz4 and 






1Department of Anesthesia, Academic Medical Center, University of Amsterdam, 
Amsterdam, the Netherlands 
2Department of Infectious Diseases, Leiden University Medical Center, Leiden, the 
Netherlands 
3Department of Dermatology and 4Clinical Chemistry and Pathobiochemistry, University 


















Reprinted from Cytokine, 21, M. Heesen, E.F. Schippers, B. Bloemeke, D. Kunz and J.T. 
van Dissel, Cytokine response to endotoxin in individuals heterozygous for the Delta32 
mutation of chemokine receptor CCR5, 195-9, Copyright (2006), with permission from 
Elsevier. 

Cytokine response to endotoxin in individuals heterozygous
for the D32 mutation of chemokine receptor CCR5
Michael Heesena,*, Emile F. Schippersb, Brunhilde Bloemekec,
Dagmar Kunzd, Jaap T. van Disselb
aDepartment of Anesthesia, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands
bDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
cDepartment of Dermatology, University Hospital of Aachen, Pauwelsstrasse 30, 52057 Aachen, Germany
dDepartment of Clinical Chemistry and Pathobiochemistry, University Hospital of Aachen, Pauwelsstrasse 30, 52057 Aachen, Germany
Received 10 June 2002; received in revised form 20 November 2002; accepted 2 December 2002
Abstract
Studies of mice with a targeted disruption of the CCR5 gene suggest that the CC chemokine receptor 5 (CCR5) is a determinant
of the cytokine response to endotoxin. In humans, a naturally occurring mutation of the CCR5 gene is a 32-basepair (bp) deletion
which precludes the translation of the gene into a functional transmembrane protein. To evaluate the cytokine phenotype of
heterozygosity for the 32 deletion, we studied the endotoxin-stimulated release of tumor necrosis factor-a, Interleukin (IL)-6, IL-8,
IL-10, and IL-12 in whole blood ex-vivo of healthy volunteers and patients undergoing elective cardiac bypass surgery. This
operation represents a major surgical trauma associated with ischemia-reperfusion-injury and triggers a profound inflammatory
response. In these patients, cytokine plasma concentrations were measured during and after cardiac surgery. No difference was
found between the frequencies of the observed and expected CCR5 genotypes in the groups of individuals studied. Furthermore, no
significant difference in ex-vivo or peri- and postoperative cytokine plasma concentrations was detected between CCR5 wild-type
homozygotes and individuals carrying one defective CCR5 allele. Our results indicate that heterozygosity for the 32 bp deletion of
CCR5 is not associated with an altered cytokine response to endotoxin or to a major surgical trauma when compared with
individuals homozygous for the wild-type allele.
 2003 Elsevier Science Ltd. All rights reserved.
Keywords: CC chemokine receptor 5; Cytokines; Endotoxin; Genetic polymorphism
1. Introduction
The seven-transmembrane spanning G protein-cou-
pled receptor CCR5 binds the CC chemokines macro-
phage inflammatory protein-1a (MIP-1a), MIP-1b, and
RANTES [1]. It is expressed on monocytes as well as
CD45RO+ (memory) T cells [1,2]. Particular interest in
this molecule comes from its role as an HIV co-receptor
required for the infection of CD4 positive cells with
macrophage-tropic HIV isolates [3]. A genetic variant
of this molecule exists consisting of a 32-nucleotide
deletion (D32) in the region encoding the second ex-
ternal loop [4]. This deletion causes a frame shift and
the introduction of a premature stop codon. The pro-
tein encoded by this deleted allele is not translated [4].
Homozygosity for this defect was reported as a mecha-
nism of resistance to HIV infection in multiply exposed
individuals [4,5]. Heterozygosity for the D32 mutation is
associated with a slower progression to AIDS and
a longer disease-free survival compared with wild-type
HIV infected individuals [5,6]. The frequency of the
mutated allele is 10% in Caucasians [7]. Carriers of
the D32 allele are healthy and, so far, under normal
conditions no phenotype could be attributed to the
heterozygous or homozygous genotype. This suggests
that CCR5 function may be dispensable under normal
conditions.
* Corresponding author. Tel.: +31-205-662-533; fax: +31-206-979-
441.
E-mail address: m.heesen@amc.uva.nl (M. Heesen).
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Studies in mice with a targeted disruption of this
molecule presented evidence for a role of CCR5 in host
defense against infection [8]. After intraperitoneal
challenge with different concentrations of endotoxin
CCR5 deficient mice had a higher survival rate than
CCR5 wild types. Also, the LD50 value of endotoxin was
significantly lower in wild-type compared with the
knock-out mice (18.15 vs. 34.05mg endotoxin/kg animal
body weight). Moreover, peritoneal macrophages of
CCR5 knock-out animals differed from their wild-type
littermates with regard to the cytokine production.
Macrophages of mice lacking CCR5 display reduced
endotoxin-stimulated production of Interleukin (IL)-1b
and IL-6. No difference in the release of tumor necrosis
factor (TNF)-a was found between knock-out and wild-
type mice [8]. Since these results of animal studies relate
CCR5 expression to cytokine release, we hypothesized
that heterozygosity for the D32 allele might be associated
with differences in the cytokine response to endotoxin in
humans as well. We studied healthy human volunteers
and patients scheduled for elective cardiac surgery and
evaluated the ex-vivo cytokine release after incubation
of whole blood with endotoxin. In addition, peri- and
postoperative cytokine plasma concentrations were de-
termined in the patients undergoing cardiac surgery.
2. Results
Ninety blood donors and 122 cardiac surgery patients
were genotyped for the CCR5 polymorphism. In both
groups the frequencies of the wild-type (CCR5) allele
and of the mutated D32 allele were found to be 93 and
7%, respectively. Thus, the genotype frequencies were
87% for CCR5/CCR5 and 13% for the heterozygous
genotype (CCR5/D32). Statistical analysis did not reveal
a difference between the frequencies of the observed
genotypes and those of the expected genotypes, in-
dicating that both study groups were in Hardy–
Weinberg equilibrium.
The concentrations of the cytokines TNF-a, IL-1b,
IL-6, and IL-8 obtained after stimulating whole blood of
blood donors with 100 ng/ml endotoxin for 4 h are given
in Table 1. Overall, no significant difference was found
in the cytokine release of individuals homozygous for
the CCR5 allele or CCR5/D32 heterozygotes.
Tables 2 and 3 summarize the data obtained from
patients scheduled for elective cardiac surgery. In the
whole blood samples taken before surgery and stimu-
lated ex-vivo with various concentrations of endotoxin,
a dose-dependent increase in TNF-a, IL-10, and IL-12
release was observed that did not differ between patients
carrying either one of the CCR5 genotypes (Table 2).
Furthermore, the concentrations of TNF-a, IL-10, and
IL-6 in the blood of these patients during and after
cardiac surgery (Table 3) did not reveal a significant
difference between the CCR5/CCR5 and CCR5/D32
genotype, neither on release of the aortic cross-clamp
nor on arrival at the intensive care unit (ICU) 2 h after
completion of surgery.
3. Discussion
The main finding of the present study is that in
humans the endotoxin-stimulated cytokine release did
not differ between individuals homozygous for the wild-
type CCR5 allele and persons heterozygous for CCR5
D32. This conclusion is based on two observations.
Firstly, using an established and validated whole blood
system to assess the release of TNF-a, IL-1b, IL-6, IL-8,
and IL-12 after 4 h incubation with endotoxin, and IL-
10 after 24 h stimulation, the cytokine release was not
affected by CCR5 genotype. This assay avoids con-
founding factors including adherence-induced expres-
sion of cytokines that can be associated with isolation of
certain cell populations such as monocytes. In addition,
whole blood probably represents the most physiological
environment for cytokine-producing cells. In a second
approach, the cytokine release during and after surgery
was determined in patients undergoing cardiac surgery.
Open heart surgery with cardiopulmonary bypass trig-
gers the release of pro- and anti-inflammatory cytokines
into the systemic circulation [9,10]. Also in the peri-
and postoperative blood samples, the cytokine con-
centrations did not differ according to the CCR5
genotype of the patients.
As a response to cardiac surgery plasma concen-
trations of TNF-a and IL-6 increased whereas IL-10
levels decreased. This finding is in agreement with
previous reports [11–13]. The sources of plasma TNF-a
are monocytes/macrophages and the myocardium [14].
IL-6 is produced by a variety of cells including mono-
cytes, fibroblasts, and hepatocytes [15]. Wan et al. [16]
identified the liver as the primary source of IL-10 in the
perioperative phase of cardiac surgery.
In previous approaches to relate a phenotype to the
D32 mutation, the concentrations of the natural ligands
Table 1
Whole blood cytokine response of healthy volunteers to endotoxin
according to CCR5 genotypes
CCR5/CCR5 (n=78) CCR5/D32 (n=12) p Values
TNF-a 2198 (1684–3709) 3278 (2237–3872) 0.345
IL-1b 381 (247–737) 280 (175–725) 0.544
IL-6 2876 (2329–4634) 3586 (2944–4368) 0.717
IL-8 1452 (833–2186) 1025 (582–2670) 0.430
Cytokine concentrations are ng/ml. Values are given as median
with interquartile ranges (25th–75th percentile) in parentheses. Whole
blood was stimulated with 100ng/ml endotoxin (E. coli O5 :B55) for
4 h at 37 C. Cytokine plasma concentrations were determined by
measuring immunoreactivity by means of chemiluminescence.
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of this receptor, the chemokines MIP-1a, MIP-1b, and
RANTES were studied. Higher concentrations of these
chemokines were reported in two individuals homo-
zygous for the D32 mutation compared with wild-type
homozygotes [17]. Yang et al. [18] studied chemokine
concentrations in individuals homozygous for the wild-
type and in D32 heterozygotes. This group was unable
to find a difference in the chemokine synthesis after
endotoxin stimulation.
In contrast, animal studies related the lack of the
CCR5 molecule to the cytokine production. Mice with
a targeted disruption of CCR5 showed a 50% reduc-
tion in the levels of IL-1b and IL-6 after endotoxin
stimulation of peritoneal macrophages whereas no dif-
ference was observed for TNF-a [8]. We therefore hypo-
thesized that the cytokine response may characterize
the CCR5/D32 genotype. The D32 allele is a mutation
introducing a premature stop codon and the deleted
allele is not translated [4]. Carriers of the genotype
CCR5/D32 thus lack one functional allele. One would
expect that individuals carrying one D32 allele which
does not code for an intact protein have about half the
number of CCR5 molecules on the cell surface. How-
ever, the amount of CCR5 surface expression showed
a 20-fold variation among individuals with two intact
CCR5 alleles, using an MIP-1b binding assay or anti-
CCR5 monoclonal antibodies [19,20]. The reasons
for this high interindividual variability in wild-type
homozygotes remain unclear. It cannot be excluded that
genetic factors other than the D32 mutation determine
the cellular density of CCR5. This high variance
may by far outnumber the role of the defective CCR5
allele.
Among the reasons for the lack of association
between cytokine release and CCR5 genotype, genetic
polymorphisms of the cytokine genes have to be
mentioned. Such genetic variations have been identi-
fied for all cytokines determined in our study [21–24].
These polymorphisms were shown to influence the syn-
thesis of the respective cytokine. For instance, the TNF-
a gene has a polymorphism at position 308 of the
promoter region which regulates gene transcription [21].
The promoter region of the IL-1b gene bears two
polymorphic sites, 31 and 511 [22]. The 31
polymorphism affects DNA binding and is in a link-
age disequilibrium with the 511 site. Similarly, the
promoter of the IL-6 gene was also found to carry
a polymorphism consisting of a G/C substitution at
position 174 [23]. In a reporter gene assay, the 174C
oligonucleotide had a lower expression than the 174G
construct suggesting a higher IL-6 synthesis by the G
allele. Polymorphisms were also found in the IL-10 gene
and associations with gene transcription were reported
[24]. The study by Zhou et al. [8] suggested that in mice
the concentrations of IL-1b and IL-6 are under the





























































































































































































































































































































































































































































































































































































































































































Delta32 mutation of chemokine receptor CCR5
whether the above-mentioned IL-1b and IL-6 poly-
morphisms which were described in humans also exist in
mice. In humans, these cytokine genetic variations might
outweigh the effect of a defective CCR5 molecule.
In conclusion, our study suggests that heterozygosity
for the D32 mutation of CCR5 is not associated with
a significant phenotype affecting the cytokine response
to an infectious or inflammatory stimulus when com-
pared with that in individuals homozygous for the wild-
type allele.
4. Materials and methods
4.1. Subjects and cytokine measurements
Written informed consent from each individual and
approval of the local medical ethics committee were
obtained. Two groups of subjects were studied. The first
group consisted of Caucasian healthy blood donors
(aged 18–65 years). Twenty milliliters of heparin-anti-
coagulated blood was drawn and mixed 1 : 1 with RPMI
1640 (Gibco BRL, Karlsruhe, Germany) and stimulated
with 100 ng/ml endotoxin (Escherichia coli O5 : B55,
Sigma, St. Louis, MO) for 4 h at 37 C. The plasma
concentrations of TNF-a, IL-1b, IL-6, and IL-8 were
determined by measuring immunoreactivity by means
of chemiluminescence (Immulite, DPC Biermann, Bad
Nauheim, Germany).
The second group were Caucasian patients under-
going elective cardiac surgery with cardiopulmonary
bypass. On the morning just before surgery blood
samples for the determination of ex vivo cytokine
production were collected using heparin-anticoagulated
tubes. Cytokine production was determined in whole-
blood samples ex vivo as previously described [25].
Lipopolysaccharide (E. coli 0111 : B4, Difco, Detroit,
MI) was added to final concentrations of 10, 100, and
1000 ng/ml and cells were stimulated for 4 or 24 h at
37 C. The operative procedures including premedica-
tion and anesthesia are described elsewhere [9]. During
operation, blood samples were taken immediately upon
release of the aorta clamp and upon arrival at the ICU
2h after completion of surgery. Blood samples were
collected in pyrogen-free ethylenediaminetetraacetic
acid (EDTA) tubes and immersed in ice. Plasma was
prepared by centrifugation at 3000 g for 5–10min at
4 C and stored at 70 C. TNF-a, IL-10, IL-12, and IL-
6 concentrations were determined with an ELISA
technique (Central Laboratories for Bloodtransfusion,
Amsterdam, The Netherlands and Medgenix diagnos-
tics, Floury, Belgium) [26].
4.2. Genotyping for the CCR5 D32 polymorphism
Genomic DNA was isolated from peripheral blood
cells using the QIAmp Blood kit (QIAgen, Hilden,
Germany). Twenty nanograms of DNA was used in
a 50 ll polymerase chain reaction (PCR) containing
1.5mM MgCl2 and 20 pmol of the forward primer 59-
ATCTCAAAAAGAAGGTCTTCATTAC-39 and the re-
verse primer 59-GAGTAGCAGATGACCATGACAA-39,
as described previously [5]. PCR conditions were as
follows: 94 C for 5min followed by 35 cycles with 94 C
for 20 s, 55 C for 30 s, 72 C for 20 s, and a final elonga-
tion step (72 C for 5min). The PCR product was visual-
ized on a 2% agarose gel. Based on the band size an allele
was classified as wild-type (187 bp) or D32 (155 bp).
4.3. Statistical analysis
Data analysis was performed with the SPSS for
Windows Release 10.0.7 program. The 2  2 table chi-
square test was used to test for the Hardy–Weinberg
equilibrium by comparing the expected with the observed
genotype frequencies. Cytokine concentrations are given
as median and interquartile range (25th–75th percentile).
The Wilcox Mann–Whitney-test served for the compar-
ison of cytokine data between the two CCR5 genotypes.
Statistical significance was set at p-levels ,0.05.
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Table 3
Perioperative and postoperative plasma concentrations of various cytokines in patients undergoing elective cardiac bypass surgery
Upon release of aorta cross-clamp Upon arrival at ICU
CCR5/CCR5 CCR5/D32 CCR5/CCR5 CCR5/D32
TNF-a 2.4 (0.6–4.3) 2.7 (0.2–5.9) 4.3 (2.3–7.5) 5.1 (3.1–7.5)
IL-10 32 (11–81) 39 (6–207) 9 (4–26) 5 (0–17)
IL-6 39 (20–64) 35 (13–67) 300 (103–750) 146 (103–198)
Cytokine concentrations are in ng/ml. Values represent median with interquartile range (25th–75th percentile) in parentheses.
All p-values for differences between homozygous and heterozygous genotype > 0.40, except for IL-6 values upon arrival at ICU, p ¼ 0:068.
Data on homozygous and heterozygous genotype available for TNF-a n ¼ 86 and 16; IL-10 n ¼ 110 and 21; IL-6 n ¼ 57 and 9. Plasma cytokine
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Background:  Cardiopulmonary bypass surgery (CPB) may serve as a model for studying 
the host inflammatory response to bacterial products that appear in the systematic 
circulation as a result of ischaemia-reperfusion damage. In a minority of patients the 
inflammatory response eventually progresses into organ dysfunction and death. 
Objective:  To relate perioperative endotoxemia, cytokine release and polymorphisms in 
the IL-10 and TNF-α promoter and the coding regions of TLR4 to clinical outcome 
parameters in patients undergoing elective cardiac surgery involving CPB. 
Design: Prospective, observational, clinical study, with systematic collection of 
postoperative data. 
Setting: Tertiary-care university teaching hospital. 
Patients: One hundred fifty-nine patients (66 % males [n= 105], median age 65 and 67 
years for males and females, respectively). 
Measurement and Main Results: High perioperative endotoxin and IL-10 concentrations 
are independently associated with postoperative hemodynamic instability and pulmonary 
dysfunction. Interleukin-10 promoter polymorphism genotypes associated with high IL-10 
production (the presence of the AGCC allele and/or the absence of the GATA allele), 
helped explain some of the differences in clinical outcome parameters. Of note, 
perioperative TNF-α concentrations, TNF-α and TLR4 polymorphisms did not contribute 
to postoperative outcome. 
Conclusion: High postoperative endotoxin and IL-10 concentrations, independent of 
TNF-α, are associated with hemodynamic instability and pulmonary dysfunction. These 
findings suggest that IL-10 may cause cardio-pulmonary dysfunction, largely independent 






Cardiac surgery with cardiopulmonary bypass (CPB) induces a variable systemic 
inflammatory response that may progress from a relatively mild to a severe and a 
potentially life threatening situation. The response is accompanied by complement 
activation, release of cytokines, leukocyte activation along with expression of adhesion 
molecules, and the production of substances such as oxygen-free radicals, arachidonic acid 
metabolites, platelet-activating factor (PAF), nitric oxide (NO), and endothelins. In severe 
cases the inflammatory response contributes to increased cardiac output in the presence of 
reduced systemic vascular resistance (SVR) and high oxygen consumption, generally 
referred to as ‘hyperdynamic instability’ or postperfusion (or “post-pump”) syndrome, and 
requires fluid replacement and treatment with vasoactive agents (1-4). Ultimately, the 
derangement of hemodynamic variables may be complicated by lactic acidosis, impaired 
organ perfusion, and pulmonary dysfunction, which cause an extended intensive care unit 
stay and even fatal outcome. 
Among other factors (e.g., exposure of blood to artificial surfaces, complement 
activation, surgical trauma) bacterial endotoxin, derived from the gut, is regarded as an 
important precipitating factor of the inflammatory response (5-13). Splanchnic ischemia 
and gut reperfusion injury occurs frequently during and after cardiopulmonary bypass with 
consequent disturbance of gut barrier function marked by translocation of endotoxin to the 
systemic circulation (14-18). In a previous study we showed that lowering the pool of 
aerobic Gram-negative bacteria in the gut was not associated with a reduction of the 
postoperative endotoxemia and inflammatory response (10). However, an association was 
found between the occurrence of perioperative endotoxemia and postoperative 
inflammatory response, indicating endotoxin as etiologic factor in the cytokine release in 
patients undergoing CPB (8-10). Since the inflammatory response following CPB is 
accompanied by changes in many regulatory systems, the culprit factor remains unknown. 
In general, a lot of focus existed on the proinflammatory cytokines (TNF-α, IL-1β, IL-6 
and IL-8). Recently, it has been shown that in an artificial endotoxemia model, rhIL-10 
blunts the human inflammatory response to lipopolysaccharide, without affecting the 
cardiovascular response (19). This could imply that endotoxin exerts its negative effects on 
the cardiovascular system independently of the inflammatory process, or that the 
deleterious effect is exerted directly by IL-10, independently of the proinflammatory 
response. 
Furthermore, the highly variable nature of the syndrome in its occurrence and severity, 
make it crucial to identify factors that help explain this variation, including possible 
genetic determinants that play a role in the inflammatory response in CPB (20). Studies in 
patients with infectious diseases have shown that inter-individual variation in cytokine 
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production capacity, as well as severity and outcome of infectious diseases, can be 
explained partly by differences in the genetic background of the subjects. Since cytokine 
release is most likely transcriptionally regulated, polymorphisms in gene promoters of the 
cytokines involved (i.e., TNF-α and IL-10), are significant targets for this research. Many 
single nucleotide polymorphisms (SNPs) in the promoter region of the TNF-α and IL-10 
gene have been described. Associations between these SNPs and (auto)inflammatory and 
infectious diseases have been described (21-32). More recently a polymorphism in the 
coding region of the toll-like receptor-4 (TLR4) has been found, however it’s clinical 
significance remains unclear (33-39). Since the inflammatory response to CPB has strong 
similarities with sepsis, the condition of natural occurring endotoxemia may serve as an 
elegant model for the host response in sepsis. Currently, it is unknown to what extend the 
known SNPs contribute to the observed large inter-individual variation found in the 
inflammatory response following CPB and the development of the post-pump syndrome. 
The recognition of genetic polymorphisms that are associated with an increased risk of 
development of severe inflammatory response following CPB, should enable clinicians to 
develop preventive strategies targeted at patients that are at increased risk for poor clinical 
outcome associated with this response. 
The aim of the present, prospective study was to investigate in patients undergoing 
elective cardiac surgery with CPB, the role of perioperative endotoxemia, cytokine 
activation and known SNPs in the promoter region of IL-10, the coding region of TLR4 on 
postoperative response leading to hemodynamic stability, morbidity, complications and 
outcome. 
 
Materials and Methods 
 
The study was performed at the Leiden University Medical Center, an 800-bed secondary 
and tertiary referral hospital. To be eligible for enrolment, the patients had to be aged 18 
years or older and being scheduled for elective cardiac surgery with cardiopulmonary 
bypass between July 1, 1998, and December 30, 1999. We obtained institutional approval 
from the local medical ethics committee (protocol #P168/96). Each patient gave a written, 
informed consent. 
The patients studied were 159 consecutive patients undergoing elective cardiac surgery 
with CPB. One hundred and twenty-two patients had been included in a previously 
published study on the effect of selective gut decontamination (SGD) on endotoxemia and 
cytokine activation (10). Of these 122 patients, 24 received preoperative SGD consisting of 
polymyxin B and neomycin. In that study, SGD was not associated with a reduction of 
perioperative endotoxemia and subsequent cytokine activation. The anaesthesia protocol 




maintained by administration of sufentanil and midazolam. Corticosteroids were not 
routinely administered during the anaesthesia induction phase. Patients were heparinised at 
induction, at the end of the procedure the heparin action was antagonized by protamine. 
CPB was established using a membrane oxygenator with nonpulsatile flow rates of about 
2.4 L/min/m2. Cardioplegia was induced with cold crystalloids; the core temperature was 
maintained at 28 0C. 
 
Data collection. 
Demographic characteristics, co-morbid conditions, details on the surgical procedure and 
the logistic 'European System for Cardiac Operative Risk Evaluation' score (EuroSCORE) 
were systematically collected for all patients entering the study (40). During their stay at 
the Intensive Care Unit (ICU) and throughout their stay in the hospital, patients were 
closely monitored. The ICU uses a computerized patient data management system 
(PDMS), wherein all consecutive (clinical) data were entered by the attending nurse. Data 
on body temperature, heart rate, hemodynamic parameters (central venous pressure, mean 
arterial blood pressure and cardiac output), artificial ventilation parameters (inspired 
fraction of oxygen [FiO2], tidal volume, ventilation frequency, level of end-expiratory 
pressure [PEEP]) and the administration of vasoactive agents (dopamine, dobutamine and 
enoximon) were recorded every hour. During the study, vasopressive agents (epinephrine 
and norepinephrine) were not administered. For the analysis we calculated, for each 
patient, the mean value for each of these parameters over 6 hour intervals. Data on 
intravenously administered intravenous fluids (colloids, crystalloids, blood products) and 
urinary output, were routinely recorded as total volumes for consecutive 24-hour 
postoperative interval. Blood gas analysis (i.e. PaCO2 and PaO2, oxygen saturation) was 
entered directly following measurement. Oxygenation index (OI) was calculated by 
dividing the PaO2 by the FiO2. Finally, clinical outcome parameters (i.e. duration of 
artificial ventilation, length of stay [LOS] in the ICU, LOS in the hospital and outcome 
[fatal or non-fatal]) were recorded. All data were collected and entered in a database 
without previous knowledge of the results of the endotoxin, cytokine and genetic 
measurements. Only at the end of the study period, all data were combined in a single 
database, together with data on perioperative endotoxin, TNF-α and IL-10 concentrations, 
as well as the results of the genetic determinants described previously(8-10;41). Briefly, 
for this analysis data on the promoter polymorphisms of IL-10 (positions -592, -819, 
-1082, -1330, -2763, -2849 and -3575) and the common TLR4 SNPs (Asp299Gly and 
Thr399Ile) were available. 
 
Analysis of Data. 
Correlations were assessed non-parametrically using Spearman correlation test, 
comparisons between groups were made using Kruskal-Wallis test, individual groups were 
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compared by the Mann-Whitney U test, unless indicated otherwise. Comparison of 
distribution between categorical variables was performed using χ2 test. Time-trends were 
assessed using log-rank test, censored for fatality. Statistical significance was tested 




We studied 159 consecutive patients undergoing elective cardio-thoracic surgery with 
cardiopulmonary bypass. The patient characteristics have been described previously(10). 
Briefly, there was a predominance of male patients (66 %), the median age for males and 
females was 65 and 67, respectively. Active smoking occurred in 35 patients (22 %) 
whereas 20 patients (12 %) had diabetes mellitus. Surgical procedures were extensive; 20 
patients (12 %) underwent coronary artery bypass surgery (CABG) combined with valve 
replacement, 49 patients (30 %) underwent valve replacement only, whereas 89 patients 
(54 %) underwent CABG only. Eight patients underwent other surgical procedures, mainly 
aortic surgery. Patients aged 65 or older, had significantly longer median duration of 
artificial ventilation (1.25 versus 1.00 days), ICU admission (3.0 versus 2.0) and hospital 
stay (12.0 versus 10.0 days). 
Fourteen patients out of the 159 patients (8.8 %) died in the hospital, mortality rates 
were higher in patients aged 65 and older (13.1 versus 4.0%, p = 0.043), in patients with 
diabetes (20.0 versus 6.6 %, p = 0.042) and females (17.3 versus 4.7, p = 0.008). Multiple 
organ dysfunction (MOF) occurred more often in patients with diabetes as compared to 
patients without diabetes (15.0 versus 2.2%, p = 0.005). EuroSCORE was higher in 
patients with fatal outcome (6.1 versus 3.6, p = 0.014), and correlated significantly with the 
duration of artificial ventilation (r = 0.235, p = 0.005), duration of ICU stay (r = 0.231, p = 
0.004) and hospital stay (r = 0.347, p < 0.00001).  
 
Correlation between perioperative endotoxemia, cytokine release and clinical parameters. 
The relationship between perioperative endotoxemia and cytokine release has been 
described previously (8;9). Perioperative endotoxemia was positively correlated with 
TNF-α and IL-10 release. In the current analysis we assessed correlations between 
perioperative endotoxin concentrations and clinical outcome. We found a consistent 
positive correlation between the endotoxin concentration at aorta declamping (time-point 
2) and the amount of colloids administered to the patient during the first 24, the first 48 
hours, and the 24-48 hour interval at the ICU (r = 0.186; p = 0.040, r = 0.247; p = 0.006, r 
= 0.225; p = 0.012, respectively). Not only but also, the same trend was observed in the 
correlation between the endotoxin concentration 30 mins into reperfusion and upon arrival 




Table 1. Postoperative pulmonary function parameters during the first 24-hours in patients with or without endotoxemia 
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OI = oxygenation index (kPa); PaO2 = arterial oxygen pressure; FiO2 = inspired fraction of oxygen. Endotoxin 
concentrations in pg/mL. Median values and interquartile ranges between parentheses. Mann-Whitney U test. 
during the same postoperative intervals (i.e. the first 24-hours, the first 48-hours and 
between 24-48 hours) however these correlations were less strong and only marginal 
statistically significant (i.e., r = 0.169; p = 0.060, r = 0.198; p = 0.027, r = 0.167; p = 0.064 
and r = 0.124; p = 0.163, r = 0.169; p = 0.055, r = 0.194; p = 0.028, respectively). After 
dichotomization, the endotoxemia positive (defined as endotoxin level > 5 pg/mL) received 
significantly larger amounts of colloids during the first 24, 48 and 72 hours of their 
postoperative stay at the ICU (Figure 1, Mann-Whitney U test) as compared to the 
endotoxemia negative patients (defined as endotoxin level < 5 pg/mL). Also, the 
endotoxemia positive patients received significantly larger amounts of crystalloids during 
the first 72 postoperative hours at the ICU (p = 0.042). Furthermore, a positive correlation 
was found between the endotoxin concentrations at all post-operative time-points 
(time-point 2, 3 and 4) and the amount of dopamine (µg/kg/min) administered in the early 
postoperative phase (i.e. the first three 12-hour intervals of admission to the ICU, r ranging 
from 0.163 to 0.253, p ranging from 0.065 to 0.003). A trend of larger amounts of 
dopamine administered to the endotoxemia positive patients during the first 48-hours of 
their ICU stay was observed, however this did not reach the level of statistical significance 
(p = 0.148, p = 0.076, p = 0.037, p = 0.090 for the first four consecutive 12-hour intervals, 
respectively). Furthermore, patients having significant endotoxemia (defined as endotoxin 
level > 5 pg/mL) upon arrival at the ICU (time-point 4) had significantly lower oxygen 
saturation, arterial oxygen pressure (PaO2) and oxygenation index (OI, i.e. arterial PaO2 
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We found no associations between the intensity of endotoxemia and differences in 
central venous pressure, cardiac output, cardiac index, mean arterial pressure, heart rate 
and mechanical ventilator parameters (i.e., among others tidal volume, PEEP level). Since 
these major indices of the hemodynamic status, in general, are targets of medical 
interventions and therapeutic adjustments and by medical intervention are thus kept 
between desired ranges, these interventions are better markers of the clinical status of the 
patient than these parameters. 
Secondly, the correlations between the perioperative cytokine release and clinical 
parameters were assessed. We observed a negative correlation between IL-10 
concentrations at aorta declamping, 30 mins into reperfusion and upon arrival at the ICU 
and the amounts of colloids administered during the first 24, and the first 48 hours during 
ICU admission (r = -0.218; p = 0.017, r = -0.221; p = 0.017, r = -0.185; p = 0.038 and r = 
-0.200; p = 0.029, r = -0.226; p = 0.013, r = -0.118; p = 0.187, respectively). Interleukin-10 
concentrations at aorta declamping were positively correlated with the amount of 
postoperative administered dobutamine (µg/kg/min) during the first three 24-hour intervals 
(r = 0.210; p = 0.018, r = 0.239; p = 0.007, r = 0.192; p = 0.032, respectively). The same 
trend was observed in the correlation between the IL-10 concentration 30 mins into 
reperfusion and upon arrival at the ICU and the amount of dobutamine (µg/kg/min) 
administered during the same postoperative intervals (i.e. the first three 24-hours intervals) 
however these correlations were less strong and less statistically significant (r = 0.129; p = 
0.153, r = 0.162; p = 0.072, r = 0.141; p = 0.120 and r = 0.148; p = 0.092, r = 0.174; p = 
0.047, r = 0.220; p = 0.012, respectively). For dopamine and enoximon a positive 
correlation was found at all perioperative IL-10 concentrations, however this was not 
statistically significant (data not shown). The ratio's of TNF-α and IL-10 concentrations, at 
aorta declamping, were negatively correlated with the amount of dobutamine during the 
first three 24-hour intervals (r = -0.195; p = 0.047, r = -0.256; p = 0.008, r = -0.264; p = 
0.006, respectively). Positive correlations were observed between IL-10 concentrations at 
aorta declamping and central venous pressure during the first eight 6-hour intervals (r = 
0.243; p = 0.012, r = 0.265; p = 0.006, r = 0.193; p = 0.047 and r = 0.229; p = 0.019, r = 
0.248; p = 0.019, r = 0.293; p = 0.007, r = 0.319; p = 0.003 and r = 0.281; p = 0.016, 
respectively). The same trend, but to a lesser extend, was observed at 30 mins into 
reperfusion (r ranging from 0.168 to 0.306, p ranging from 0.085 to 0.005). A negative 
correlation was found between IL-10 concentrations at aorta declamping and cardiac 
output during the first eight 6-hour intervals (r = -0.204; p = 0.109, r = -0.312; p = 0.014, r 
= -0.418; p = 0.001 and r = -0.308; p = 0.016, r = -0.467; p < 0.001, r = -0.429; p = 0.002, 
r = -0.375; p = 0.007 and r = -0.407; p = 0.005, respectively). Again, the same trend was 
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observed at 30 mins into reperfusion and upon arrival at the ICU however these 
correlations were less statistically significant (r ranging from -0.104 to -0.342, p ranging 
from 0.415 to 0.009 and r ranging from -0.238 to -0.427, p ranging from 0.052 to 0.001, 
respectively). No consistent correlations were found between perioperative IL-10 
concentrations and the other clinical parameters. Finally, no consistent correlations 
between the perioperative TNF-α release and the clinical parameters were observed. 
However, we observed a positive correlation between IL-6 concentrations at both of the 
measured time-points (i.e. at aorta declamping and upon arrival at the ICU) with the 
amount of dopamine administered during the first three 24-hour intervals (r = 0.317; p = 
0.010, r = 0.300; p = 0.014, r = 0.254; p = 0.039 and r = 0.240; p = 0.054, r = 0.276; p = 
0.026, r = 0.268; p = 0.031, respectively). For dobutamine, enoximon and the other clinical 
parameters no significant correlations with IL-6 were observed. 
 
Correlation between genetic factors and clinical outcome parameters. 
Next we investigated whether a correlation could be found between the genetic 
polymorphisms and the aforementioned clinical parameters. In none of the clinical 
parameters a differences was found between carriers of the common polymorphisms in 
TLR4 (Asp299Gly or Thr399Ile carriers as compared to wild-type homozygotes). The 
proportion of patients initiating therapy with dopamine, dobutamine or enoximon directly 
following arrival at the ICU, were significantly different according to the proximal IL-10 
promoter haplotypes. Patients carrying the GATA allele, initiated dopamine therapy 
significantly more frequently as compared to the patients not carrying these alleles (73.2 
versus 52.3 %, p = 0.013, Table 2), whereas patients carrying the AGCC allele initiated 
therapy with dopamine less frequently (53.8 versus 72.5 %, p = 0.023, Table 2). 
 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the patients initiating therapy with either dopamine or enoximon the use of these 
agents was significantly longer in patients carrying the AGCC allele as compared to 
patients not carrying this allele (p = 0.0419 and 0.0269, respectively, Figure 2). Moreover, 
homozygous carriers of the AGCC allele used dobutamine and enoximon longer than the 
heterozygous carriers, whereas patients not carrying the AGCC allele had the lowest use of 
these agents (p = 0.0831 and 0.0389, respectively, Figure 3). For dopamine use this was 




The main finding of the present study is that perioperative endotoxemia and high IL-10 
concentrations are associated with postoperative hemodynamic instability and pulmonary 
dysfunction in elective cardiac surgery patients undergoing CPB. Patients with significant 
endotoxemia upon aorta declamping received higher amounts of colloids during the first 72 
hours of their postoperative ICU stay, moreover perioperative endotoxin concentrations 
were positively correlated with the amount of postoperative administered dopamine. 
Furthermore; during the first 24-hour post CPB the oxygenation index (OI) was lower in 
patients with significant perioperative endotoxemia, indicating impaired oxygenation. 
Also, high IL-10 concentrations at aorta declamping and 30 minutes into reperfusion were 
associated with a postoperative clinical profile characterised by increased central venous 
pressure (CVP) and use of dobutamine, together with a decrease in the volume of 
administered colloids, decreased cardiac output, and decreased urinary output. 
With respect to this study and methodology, several issues need to be considered. We 
repeatedly sampled patients undergoing elective CPB, and performed in these samples 
paired measurements of endotoxin and cytokine concentrations in each patient over time. 
This enabled us to study the inflammatory response to surgery and endotoxemia, and relate 
these to clinical outcome: e.g., hemodynamic status, pulmonary dysfunction, days on 
artificial ventilation and length of intensive care and hospital stay. Since in the ICU 
hemodynamic and ventilatory indices are targets of medical intervention and therapeutic 
adjustments (e.g. an undesired trend in hemodynamic parameters is quickly countered by 
adjustments of intravenous fluids and vasoactive drugs), we also quantitatively analysed 
trends in these medical interventions. The role of the nonpulsatile flow CPB, routinely 
used in our study, on the magnitude of endotoxemia is controversial, but might have led to 
a higher proportion of patients experiencing endotoxemia, as compared to other CPB 
modalities (42;43). In a minority of patients, the postoperative response leads to ultimately 
fatal multiple organ dysfunction (MODS). Little is know about the determinants of the 
broad clinical spectrum of responses observed in patients after CPB. Sofar, no study has 
 
111
Polymorphisms and the outcome of cardiac surgery
convincingly shown association between perioperative endotoxin concentrations and 
patient outcome. Of note, although we studied a reasonably large cohort of patients, this 
study had insufficient power to detect differences for genetic polymorphisms that occur 
only in small minority (less than 5-10%) of patients. 
The occurrence of endotoxemia was associated with an increased need for postoperative 
circulatory support, indicated by the administration of larger volumes of colloids, 
crystalloids and amounts of dopamine. At the same time, higher perioperative endotoxin 
concentrations were associated with higher urinary output during the first 72 hours after 
ICU admission, indicating swift normalisation of the hemodynamic status after volume 
loading, and increased excretion of excessive extracellular fluids later. Of note, these 
observations were not accompanied by changes in indices of the hemodynamic status of 
patients i.e., CVP, cardiac output, cardiac index and ABP. However, keeping these 
parameters constant was the target of the interventions above. In the same way the 
oxygenation index, is a more suitable marker of pulmonary dysfunction as compared to 
inspiratory oxygen fraction or arterial oxygen pressure alone. Patients with endotoxemia 
needed more respiratory support, as indicated by lower OI, as compared to patients without 
endotoxemia. Pulmonary dysfunction following CPB occurred frequently, and led to 
delayed tracheal extubation. The aetiology of pulmonary dysfunction is multifactorial, 
occurring as a result of the combined effects of anaesthesia, CPB, and surgical trauma. It 
has been suggested that the inflammatory response that results in increased pulmonary 
capillary permeability is involved in the pathogenesis of the pulmonary dysfunction as 
well. One study in elective cardiac surgery described an association between circulating 
endotoxin and high postoperative oxygen consumption (13). In that study patients with 
higher perioperative endotoxin levels had high postoperative oxygen consumption. Our 
data support this finding; to our knowledge no other studies in CPB patients have 
addressed this question. 
In patients with high perioperative IL-10 concentrations a hemodynamic profile 
occurred indicative of cardiac depression. Typically these patients are characterised by a 
good venous filling state (high CVP, low volumes of administered colloids) and a tendency 
towards forward failure (low cardiac output and a need for dobutamine). Similarly, one 
other study in CPB patients described an association between high circulating IL-10 levels 
and risk of organ dysfunction in the early postoperative phase (44). Most studies, however 
focused on proinflammatory cytokines (i.e., TNF-α, IL-1, IL-6), and therefore the adverse 
effect of high circulating IL-10 may have been overlooked. In patients with infection high 
IL-10 appears deleterious, likely by inhibiting bacterial clearance (45;46). However a 
reduced bacterial clearance does not apply to the present situation. In a recent study 




bolus of Escherichia coli lipopolysaccharide (19). This infection was preceded by a single 
shot of rhIL-10, at various dosages and time-intervals. The interesting finding of the study 
was that, although the rhIL-10 diminished the proinflammatory response to the LPS 
administration (e.g., reduced the TNF-α, IL-6 and IL-1Ra levels), it did not attenuate the 
hemodynamic changes observed after the administration of LPS. Subjects receiving 
rhIL-10 two hours before administration of LPS had lower mean arterial pressure (MAP) 
five hours after LPS administration, as compared to subjects receiving placebo instead of 
rhIL-10 (19). This suggests that a high level of IL-10, present during LPS administration, 
augments the deleterious hemodynamic effects of LPS, despite down regulation of 
proinflammatory cytokine release (IL-6, IL-1Ra and IL-1β). The observation limits the use 
of rhIL-10 as a immunomodulating agent in sepsis, but also highlights the role of IL-10 in 
the pathophysiology of endotoxin-related hemodynamic deterioration resulting in organ 
dysfunction. 
As to explore the genetic basis of the high IL-10 concentrations we found that patients 
carrying the AGCC haplotype, generally regarded as the high IL-10 producing allele, 
initiated treatment with dopamine less frequently as compared to the patients not carrying 
the AGCC haplotype. This is consistent with the findings described above. However, once 
initiated on dopamine or enoximon, these patients used these agents for a longer period of 
time as compared to patients not carrying this allele. This observation seems conflicting 
since it suggests that the IL-10 promoter haplotype associated with high IL-10 production 
to endotoxin is not associated with the clinical profile associated with high perioperative 
circulating IL-10 levels that we described in the previous paragraph. We are not sure as to 
how to explain this observation. In one earlier study, high levels of circulating IL-10 were, 
like in our study, associated with the development of organ dysfunction in the early 
postoperative period (44). 
Of note, perioperative TNF-α concentrations did not predict clinical outcome 
parameters. This suggests that the adverse effects of IL-10 occur largely independent of an 
ongoing proinflammatory reaction. 
In summary, endotoxemia in CPB triggers an inflammatory response as reflected by the 
release of TNF-α and IL-10. Perioperative TNF-α concentrations did not predict 
postoperative outcome. However, postoperative hemodynamic and respiratory function is 
negatively affected by high IL-10, largely independent of the concentration of TNF-α. 
Furthermore, these IL-10 associated hemodynamic changes occurred according to the 
proximal IL-10 promoter genotype associated with high and low IL-10 production capacity 
in vitro and in vivo. 
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Summary and general discussion 
 
The results of the studies described in Chapters 2 through 8 will be briefly summarized and 
discussed in the following sections. 
 
Effect of preoperative selective gut decontamination and the role of perioperative 
endotoxemia on postoperative cytokine activation and clinical outcome in elective 
cardiac bypass surgery. 
 
In the study described in Chapter 2 and 3, we found no effect of preoperative selective 
gut decontamination (SGD) on perioperative endotoxemia and cytokine activation in 
cardiac surgery patients undergoing elective cardio-pulmonary bypass (CPB). This is 
notwithstanding the positive relationship between occurrence of endotoxemia and intensity 
of the perioperative cytokine response. This observation that bowel decontamination did 
not reduce the incidence of endotoxemia is in contrast with two previous studies, one 
performed in rats and one in human subjects. In our study, over half of the patients 
experienced translocation of endotoxin from the gut into the systemic circulation following 
the surgical procedure. Although SGD was highly effective in eliminating the aerobic 
Gram-negative bacteria from the feces, it did not reduce the percentage of patients with 
endotoxemia or the level of endotoxemia. This indicates that during SGD the pool of 
endotoxin in the bowel lumen is not a key limiting factor in the pathophysiological 
mechanism that controls translocation of endotoxin from the gut into the bloodstream. In 
addition, it should be realised that aerobic Gram-negative microorganisms constitute only 
about 0.5-1% of the Gram-negative bowel flora, and the remaining anaerobic Gram-
negative bacteria might well be responsible for a large part of the intraluminal endotoxin 
potentially available for translocation. 
Although we were unable to register an alternative - causative - mechanism associated 
with the occurrence of endotoxemia, several possible factors might come into play. First, 
there is the compromised circulatory state during and directly following the procedure and 
this is generally believed to be the most critical mechanism leading to translocation of 
endotoxin from the gut. The intestine is amongst the metabolically most active organs and 
therefore sensitive to hypoperfusion, any compromise rapidly leading to tissue hypoxia. In 
animal studies, experimental shock inflicted by various means (i.e., hemorrhagic shock, 
trauma, thermal injury), led to similar occurrences of endotoxemia. In humans, the 
systemic blood pressure might be a poor indicator of gut tissue perfusion during non-
pulsatile flow. As a physiologic mechanism, splanchnic blood flow is down-regulated 
during hypotension by regional vasoconstriction. In patients with vascular occlusive 
disease of the intestine, not uncommon in patients undergoing coronary artery bypass 
grafting for atherosclerosis narrowing of the arteries, these factors might have amplified 
the effect of hypoperfusion of the gut, in about half the patients leading to critical 
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ischemia-reperfusion injury and subsequent translocation of endotoxin, despite a seemingly 
adequate systemic blood pressure during the surgery. 
Several studies found that in Gram-negative infection the mortality of patients is 
substantially higher in those experiencing endotoxemia as well. Likely, endotoxemia is 
associated with the level of bacteremia, i.e., the actual number of microorganisms per mL 
blood, and not all patients with Gram-negative bacteremia develop endotoxemia. 
Moreover, endotoxemia does not occur exclusively in Gram-negative bacteraemia. In 
patients with shock and culture proven Gram-positive infection, endotoxemia exists in a 
significant proportion of patients. This observation suggests that the role of endotoxin in 
septic shock goes beyond Gram-negative infection. Furthermore, in various diseases not 
related to infection, any state of shock (hemorrhagic, cardiac, burns) was associated with 
endotoxemia in a substantial proportion of the patients. Taken together, these observations 
imply that it is not Gram-negative infection per se that causes endotoxemia and a poor 
outcome, but rather suggest that endotoxemia should be considered both as indicator of 
poor tissue perfusion allowing translocation of endotoxin from the gut, as well as 
inflammatory mediator triggering an inflammatory response that leads to a deterioration of 
a compromised hemodynamic situation. Such a hypothesis would explain why 
endotoxemia is an indicator of poor outcome in infections caused by microorganisms that 
do not carry endotoxin, e.g., the gram-positive bacteria, and in inflammatory states due to 
causes other than infection. In future studies it would be of great interest the look in severe 
infections in more detail to other markers of insufficient gut perfusion, and relate these to 
the incidence of endotoxemia and outcome. 
In the studies described in Chapters 5 and 6, we described the correlation between the 
level of endotoxemia during the reperfusion phase of CPB and the perioperative release of 
TNF-α and IL-10. The positive, proportional relationship between these mediators 
indicates that endotoxin is responsible for at least part of the cytokine activation in these 
patients. Although the correlation was statistically significant, the extent of its scope 
seemed limited (i.e., the correlation was relatively weak) and this implicates other factors 
triggering the cytokine response, such as the surgical insult, cardiac stunning, activation of 
cells by tubing, etc. plat a role. In accordance we found, as was shown by others as well, 
that during CPB cytokine activation can occur in the absence of endotoxemia. Despite the 
presence of additional factors causing cytokine release, the finding indicated that the 
surgical procedure accompanied by CPB may serve as a model to study the in vivo 
response to endotoxemia. 
In Chapter 8 we investigated clinical parameters and outcome in relation to the 
occurrence and intensity of perioperative endotoxemia and subsequent cytokine release 
into the systemic circulation. In this respect, the occurrence of pathophysiological changes 
(e.g. hemodynamic status, pulmonary dysfunction) and clinical outcome (i.e. days on 
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artificial ventilation, length of intensive care and hospital stay) of the patient in the period 
following CPB were studied. Since in the ICU hemodynamic and ventilatory indices are 
targets of routine medical intervention and therapeutic adjustments (e.g., undesired trends 
in hemodynamic parameters let the attending physician adjust the amount of intravenous 
fluids and vasoactive drugs), we also quantitatively analyzed trends in these medical and 
drug interventions. It was reasoned that the amount of circulatory support needed to keep 
hemodynamic parameters (i.e., central venous pressure [CVP], blood pressure, cardiac 
output and urinary output) within certain preset levels, these would serve as an adequate 
surrogate marker for the underlying hemodynamic status of a patient. In the same way the 
generally used indicator of respiratory support, i.e., the oxygenation index (OI calculated 
by dividing the PaO2 by the FiO2), is a better marker of pulmonary dysfunction as 
compared to inspiratory oxygen fraction or arterial oxygen pressure alone.  
We found that the occurrence of endotoxemia was associated with hemodynamic 
instability, and this was generally reversed within 48 hours. Of note, patients with 
endotoxemia needed a longer period of respiratory support, as compared to patient without 
endotoxemia.  
Another finding of our study described in Chapter 8 was that in patients with high 
perioperative IL-10 concentrations cardiac depression occurred. Typically these patients 
are characterised by an adequate venous filling state (i.e., high CVP in combination with 
low volume of colloids being administered) and a tendency towards forward failure as 
evidenced by a low cardiac output and high amounts of dobutamine administered. Little is 
known about adverse effects of high circulating concentrations of IL-10, partly because 
most studies have focused on pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6. 
Nevertheless, some studies found deleterious effects of high circulating concentrations of 
IL-10 in patients with acute infectious disease, most likely, but not exclusively, as a result 
of reduced bacterial clearance by the anti-inflammatory effect of IL-10. However, in our 
study patients did not suffer from infection as bacterial products translocated to the 
circulation as a result of ischemia-reperfusion damage and so stimulated cytokine 
producing cells. Therefore, the argument of a reduced bacterial clearance does not apply. 
In healthy subjects, administration of IL-10 shortly before an intravenous bolus of LPS, 
diminished the pro-inflammatory response (e.g., resulted in a lower TNF-α, IL-6 and 
IL-1Ra levels as compared to untreated controls), but - of interest here - did not attenuate 
the deleterious hemodynamic effects of LPS. Thus, subjects receiving IL-10 two hours 
before administration of LPS had lower mean arterial pressure (MAP) five hours after LPS 
administration, as compared to subjects receiving placebo (in stead of rhIL-10). This 
suggests that high circulating levels of IL-10, shortly before LPS administration, potentates 
the deleterious hemodynamic effects of LPS, despite down regulation of pro-inflammatory 
cytokine release (IL-6, IL-1Ra and IL-1β). Obviously, the observation limits the potential 
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use of rhIL-10 as an immunomodulating agent in sepsis. Also, it suggests a potential role 
for IL-10 in the pathophysiology of endotoxin induced hemodynamic changes leading to 
organ dysfunction. 
We did not find a correlation between perioperative TNF-α concentrations and clinical 
outcome parameters. This was somewhat unexpected because generally TNF-α is regarded 
as the most potent cytokine leading to pro-inflammatory response and is held responsible 
for the development of harmful effects of a progressing systemic inflammatory response, 
such as capillary leak, hypotension, acute respiratory distress syndrome (ARDS), and 
multiple organ system failure. We did not observe such a trend in this model of natural 
occurring endotoxemia. 
 
An individual’s ex vivo cytokine response to LPS and the in vivo response to 
endotoxin: which ex vivo parameter foresees best the in vivo response? 
 
The main finding of the study described in Chapter 4 was that the dose-response 
characteristics of TNF-α and IL-10 release by human peripheral whole blood, upon 
stimulation with a wide range of LPS concentrations, can be described adequately by a 
receptor-ligand interaction model. This model is fully characterized by two parameters, 
i.e., EC50, the estimated LPS concentration at which half of the cytokine concentration is 
reached and the Emax, the estimated maximal concentration of cytokine released. We found 
that these two parameters were highly constant for individuals, yet differed between 
individuals. For instance, we detected significant differences between two subjects with 
respect to the cytokine release at the lowest LPS concentration and, more importantly, the 
dose-response parameters based on the whole range of LPS concentrations remained 
significantly different between the subjects. Such differences in dose-response 
characteristics would have been discarded, however, if only one or two LPS concentrations 
had been used to test the cytokine response of these individuals. Thus, relevant information 
on cytokine release is lost when the commonly applied approach is taken, i.e. testing the 
TNF-α and or IL-10 release after stimulation with a single, and often high, LPS 
concentration. Such an approach yields a single value that doesn't represent a physiological 
model of release and often shows significant variation over time. By contrast, we estimated 
two parameters that fully characterize an underlying model and are intrinsic parameters 
that are much less sensitive to day-to-day variation. 
In Chapter 5 we describe that the in vivo release of TNF-α was correlated with the 
maximal TNF-α release (the TNF-αmax) ex vivo upon stimulation with LPS. This indicates 
that the maximal TNF-α production capacity measured ex vivo is at present the best 
predictor of in vivo TNF-α levels in the perioperative stage of cardiac surgery. Similarly, in 
Chapter 6 we found that the in vivo release of IL-10 during reperfusion (i.e., at aorta 
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declamping and 30 min into reperfusion) in patients experiencing endotoxemia was 
predicted by the IL-10 production ex vivo upon stimulation with 1000 ng LPS/mL and the 
estimated maximal IL-10 production capacity (the IL-10max). Thus, the ex vivo LPS 
stimulation assay is a predictor of the in vivo release of IL-10 during endotoxemia after 
cardiac surgery. Of note, the correlation was best in the patients experiencing endotoxemia, 
indicating the relevance of endotoxin as stimulus in the in vivo TNF-α and IL-10 
production. 
 
TNF-α and IL-10 promoter polymorphisms and the in vivo and ex vivo response to 
LPS. 
 
Since several studies indicated a role of genetic determinants in the cytokine responses in 
innate immunity, we investigated if and to what extend known polymorphism in the TNF-α 
and IL-10 promoter are to be held responsible for differences in the release of the 
cytokines in vivo and ex vivo upon stimulation with LPS. 
In Chapter 5 we described that in vivo endotoxin-stimulated release of TNF-α did not 
differ between patients according to their TNF-α promoter polymorphisms, including the -
308 G/A substitution. Although earlier studies described an increased susceptibility and/or 
severe outcome of sepsis or septic shock in carriers of a common TNF-α promoter 
polymorphism (i.e. -308 G/A), in none of the studies was the in vivo release of TNF-α 
positively correlated with this increased risk. The findings suggest that this TNF-α 
promoter polymorphism does not exert its effect on sepsis susceptibility and/or outcome by 
causing a differential gene expression and/or release of TNF-α. Overall, the effects on 
TNF-α release by promoter polymorphism appeared rather limited, both in vivo in patients 
experiencing endotoxemia, and ex vivo upon stimulation of peripheral blood cells by LPS. 
Given its proximity to many other innate immune genes located on chromosome 6 and to 
the HLA system, it cannot be excluded that the TNF-α promoter polymorphism acts as 
marker of another gene variation.  
In Chapter 6 we described that patients carrying the AGCC allele of the IL-10 
promoter, had slightly higher post-operative IL-10 levels as compared to carriers of all 
other haplotypes combined. Homozygous carriers of the GATA allele had lower 
postoperative IL-10 levels as compared to all other patients. Furthermore, AGCC allele 
carriers had higher LPS sensitivity ex vivo, whereas carriers of the GATA allele showed 
lower LPS sensitivity. Furthermore, homozygous GATA carriers also had lower IL-10 
production in vivo. This emphasizes the importance of the SNP at position -1082 in the 
transcriptional activity of the proximal promoter. The phenotype of increased LPS 
sensitivity was confirmed ex vivo in AGCC haplotype carriers, and is further supported by 
the significantly higher circulating IL-10 levels following cardiopulmonary bypass in the 
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AGCC haplotype carriers as compared to carriers of the other haplotypes combined. 
Although part of the large inter-individual variation found in the in vivo and ex vivo 
responses to LPS can be explained by known polymorphisms in the IL-10 promoter region, 
overall their influence is limited and can only explain about 5-10% of the variation in IL-
10 concentrations. Similar reasoning applies to the release of TNF-α. This raises the 
question whether or not the observed differences, although small in the light of large inter-
individual differences, are relevant to the individual. This question appears the more 
fascinating since the human population shows a preserved heterogeneity in some specific 
alleles. When assuming that these polymorphisms each arise from one single spontaneous 
mutation in one of our ancestors, their conservation in evolution must have bared some 
advantage, even though that may not exist at present time. In this respect it should be 
realized, nevertheless, that in a complex, highly organized biological system, a sustained 
and repeated 5% difference in the direction of a particular response might add up to a 
highly relevant overall difference. In such systems, a beneficial outcome or catastrophe 
may follow directed, repeated small events. To fully appreciate this issue, an analogy can 
be made to the analysis of the dynamic behavior of a macrophage lining the lung surface 
reaching for a bacterium delivered into the alveolus. In the presence of such a target for 
phagocytosis, chemotaxis is an important component of the immune response, the success 
of which depends on the time to ingestion of the bacterium relative to rate of replication of 
the microorganism (i.e., producing two, four, eight and so on separate targets). To reach an 
effective encounter time to control bacterial multiplication, some directed motion of the 
phagocyte is necessary. Analyses of dynamic models of this process have demonstrated 
that the biggest reduction in average encounter time results in very small changes in 
probability of moving in the direction of the target rather than exhibiting random 
movement, i.e., when only 5 to 15 percent is directed movement. The complex immune 
system, somewhat artificially divided up into a pro- and anti-inflammatory pillar, similarly 
depends on the interplay of multiple, repetitive signals and is susceptible to disturbances of 
this delicate balance. An exaggerated pro-inflammatory response may lead to an undesired 
outcome due to ‘collateral’ damage, whereas an inhibited, slow reaction may lead to an 
unacceptable lag in response. Clearly, further studies should elucidate what balance is 
optimal in what situation, and to extent to which the inter-individual variation in cytokine 
responses are determined by preprogrammed, genetic or random, environmental factors. 
 
Polymorphisms in LPS signaling molecules (i.e., Nod2, TLR4, CCR5) and the in vivo 
and ex vivo response to LPS. 
 
In the study described in Chapter 5, we did not detect an influence of the 3020insC 
mutation in the Nod2 gene on the in vivo and ex vivo TNF-α production capacity upon 
124
Chapter 9
endotoxin. In view of the conflicting data in the literature, the finding indicates that in 
studies exploring presumed ligand-receptor relations, great care must be taken to use 
highly purified ligands rather than crude materials that often contain contaminants that act 
as ligands for the same or other receptors. 
In the study described in Chapter 5 and 6, we found no correlation between the level 
of perioperative and ex vivo TNF-α and IL-10 production, and the common TLR4 
polymorphisms (Asp299Gly and Thr399Ile). Therefore their role, if present, appears rather 
limited, and cannot explain the large inter-individual differences found in TNF-α and IL-10 
production capacity. In the study described in Chapter 6, we found that the common 
TLR4 polymorphisms were associated with slightly higher IL-10 production capacity ex 
vivo; however, this did not reach the level of statistical significance. At present it remains 
unclear which and to what extent additional polymorphisms in molecules involved in LPS 
triggering (e.g. sCD14, MD-2, LBP) add to the large inter-individual variation found in in 
vivo and ex vivo responses to LPS. 
In Chapter 7, we found that the endotoxin-stimulated cytokine release ex vivo and in 
vivo did not differ between the individuals homozygous for the wild-type CCR5 allele and 
persons heterozygous for CCR5 ∆32. In mice, a disruption of CCR5 showed a large 
reduction in the production of some cytokines upon stimulation with LPS. In humans, 
however, polymorphisms in competing genes involved in the cytokine production pathway 
outweigh the effect of a defective CCR5 molecule 
 
In conclusion, our studies in patients undergoing elective cardiac surgery and CPB indicate 
that naturally occurring endotoxemia can be a stimulus for the release of cytokines, even in 
the absence of overt infection. Because endotoxemia cannot be predicted before the 
surgery and occurs in only about half of the patients, i.e., the others may serve as control, 
studying the elective surgery presents an elegant model of the effect of a relatively frequent 
yet naturally occurring endotoxemia and cytokine release. The pattern of cytokine 
responses to endotoxemia in vivo appeared much more complex than the relatively simple 
to describe endotoxin dose-dependent increase in cytokine release ex vivo. The cytokine 
responses to endotoxin appear to be influenced by many factors, most of which are at 
present ill-defined. Of these factors the genetic background of the individual plays only a 
minor yet - through its consistent direction - not to be discarded role.  
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Al sinds mensenheugenis is het mensen opgevallen dat infectieziekten bij de ene persoon 
veel ernstiger verlopen dan bij de andere. Terwijl de één nauwelijks ziekteverschijnselen 
vertoont wordt de ander levensbedreigend ziek. Vaak is er wel een duidelijk aanwijsbare 
oorzaak voor deze verschillen. Zo zijn mensen met al aanwezige ziekten, zoals ziekten van 
de bloedvaten of kanker meer kwetsbaar. Soms ligt de oorzaak in het feit dat iemand een 
bijzonder agressieve bacterie heeft opgelopen, die in korte tijd ogenschijnlijk kerngezonde 
mensen doodziek kan maken (vleesetende bacterie, nekkramp bacterie). Het komt ook voor 
dat iemand door een infectie zodanig wordt verrast dat hij of zijn arts de ziekte onderschat 
en er te laat een behandeling wordt ingesteld. Vaak is er echter geen voor de hand liggende 
verklaring voor de grote verschillen tussen de ziekteverschijnselen van dezelfde ziekte bij 
verschillende personen. 
Om beter te begrijpen hoe de verschillen verklaard kunnen worden, is het belangrijk te 
kijken naar de werking van het afweersysteem van de mens. Ons afweersysteem is vrij 
ingewikkeld en bestaat uit allerlei verschillende onderdelen die voor een deel met elkaar 
zijn verweven. Tijdens ons leven ontwikkelen wij een afweersysteem dat specifiek gericht 
is tegen bepaalde ziekteverwekkers (verworven immuniteit, acquired immunity). Dit 
systeem wordt levenslang getraind en zal bij ieder contact met een nieuwe ziekteverwekker 
een afweerreactie tot stand brengen. Omdat het afweersysteem daar enige tijd voor nodig 
heeft zijn we dan wel een tijdje (meestal een kleine week) ziek. Als er vervolgens geen 
complicaties optreden herstellen we volledig en zijn we voor de rest van ons leven immuun 
tegen deze ziekteverwekker. Van deze laatste eigenschap van het verworven 
afweersysteem wordt dankbaar gebruik gemaakt door mensen te vaccineren. Door het 
inbrengen van een entstof wordt de infectie nagebootst en zijn we, vaak levenslang, 
beschermt tegen deze ziekte. Hoewel dit afweersysteem prachtig werkt, heeft het ook een 
groot nadeel. Het heeft vrij veel tijd nodig om met een reactie te komen. Waarschijnlijk is 
de mens daarom nog met een ander soort afweersysteem uitgerust, dat dit nadeel niet heeft. 
Dit onderdeel van het afweersysteem is al direct bij de geboorte aanwezig en wordt om die 
reden het aangeboren afweersysteem (innate immunity) genoemd. Dit afweersysteem is in 
staat om heel snel na het binnendringen van een ziekteverwekker te reageren, en vormt in 
feite de eerste verdedigingslinie. Ziekteverwekkers verraden hun aanwezigheid door het al 
dan niet opzettelijk afgeven van stoffen aan hun omgeving. Deze stoffen worden herkend 
door een groot arsenaal aan antennes (receptoren) die vóórkomen op cellen van het 
afweersysteem. Bij het gelijktijdig prikkelen van verschillende antennes ontstaat een 
patroon dat het afweersysteem in staat stelt een gerichte reactie te maken tegen de 
binnengedrongen ziekteverwekker. Lipopolysaccharide (LPS) is zo’n stof en is afkomstig 
uit de celwand (het omhulsel) van sommige bacteriën. LPS wordt herkend door cellen van 
het aangeboren afweersysteem (vooral door de zogenaamde monocyten) en deze cellen 
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worden er vervolgens door geactiveerd. Ze gaan activerende stoffen produceren waarvan 
de belangrijkste Tumor Necrosis Factor(TNF)-α wordt genoemd. Deze stof zweept het 
gehele afweersysteem op tot een verhoogde activiteit. Tegelijkertijd worden er ook 
remmende stoffen geproduceerd, de belangrijkste daarvan is Interleukine(IL)-10. De 
balans tussen deze twee stoffen is van groot belang. Als de balans in één van beide 
richtingen doorslaat ontstaat er een probleem. Zowel een te hoge als een te lage activiteit 
van het afweersysteem kan ertoe leiden dat er schadelijke effecten voor het lichaam 
ontstaan, hetzij door de afweerreactie zelf of door de binnendringende ziekteverwekker. 
Bloedvergiftiging (sepsis) is een ernstige ziekte die kan optreden zodra een infectie uit de 
hand loopt. In Nederland sterven per jaar naar schatting 5000 mensen aan 
bloedvergiftiging. De meest voorkomende ziekten die bloedvergiftiging kunnen 
veroorzaken zijn longontsteking, buikvliesontsteking en blaasontsteking. 
Als we ervan uitgaan dat de balans tussen stimulatie en remming van het 
afweersysteem van belang is voor het verdere verloop van een infectie, dan ligt het voor de 
hand om aan te nemen dat erfelijke factoren hierbij een rol spelen. In genen van 
verschillenden personen blijken soms heel kleine verschillen te zitten, die polymorphismen 
worden genoemd. Vaak gaat het om een verschil in slechts 1 schakeltje (base-paar, Single 
Nucleotide Polymorphism of SNP) in een lange DNA keten dat we een gen noemen. Uit 
eerder onderzoek is gebleken dat deze kleine verschillen verantwoordelijk kunnen zijn 
voor verschillen in het verloop van, onder andere, infectieziekten. Het onderzoek 
beschreven in dit proefschrift was erop gericht meer inzicht te krijgen in de rol van 
bekende, genetische verschillen in genen die betrokken zijn bij het tot stand komen van een 
afweerreactie op LPS. 
Zoals hiervoor beschreven herkent het afweersysteem ziekteverwekkers door de 
aanwezigheid van stoffen die door ziekteverwekkers worden afgegeven aan hun omgeving. 
LPS bindt aan een oppervlaktestructuur (antenne) die toll-like receptor-4 (TLR4) wordt 
genoemd (zie Figuur 1 in hoofdstuk 1). Na binding aan TLR4 wordt een cascade in 
beweging gezet (domino effect) die uiteindelijk leidt tot activatie van genen in de kern van 
de desbetreffende cel. De genen die worden geactiveerd bevatten de genetische code voor 
eiwitten, cytokines genaamd (zoals TNF-α en IL-10) die vervolgens door de cel worden 
uitgestort in hun omgeving. In de genen van TLR4, TNF-α en IL-10 zijn in de afgelopen 
jaren diverse ‘single nucleotide polymorphisms’ (SNPs) ontdekt. In het onderzoek 
beschreven in dit proefschrift hebben wij onderzocht in hoeverre deze SNPs 
verantwoordelijk zijn voor verschillen in de reactie op LPS. Om dit bij mensen te 
onderzoeken zijn we op zoek gegaan naar een omstandigheid waaronder patiënten met LPS 
worden geconfronteerd. We zijn terecht gekomen bij patiënten die een operatie aan hun 
hart moeten ondergaan. Tijdens deze operatie worden patiënten aangesloten op een hart-
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longmachine. Het hart kan dan tijdelijk worden stilgezet, zodat de chirurg de operatie 
rustig kan uitvoeren. De hart-longmachine houdt de bloedsomloop kunstmatig in stand. 
Hoewel dit op zich goed lukt, is de bloedsomloop toch minder goed dan onder normale 
omstandigheden. Vooral de darmen worden onder deze omstandigheid minder goed van 
zuurstof voorzien. Daardoor raken de darmen een beetje doorlaatbaar (lek), en komen 
stoffen die zich in de darminhoud bevinden in het bloed terecht. Omdat het gaat om heel 
kleine hoeveelheden, is dat voor de meeste stoffen geen probleem. Een belangrijke 
uitzondering is het LPS. Zelfs heel kleine hoeveelheden van deze stof kunnen een 
afweerreactie tot stand brengen. In de praktijk blijkt dat ongeveer de helft van de patiënten 
die een dergelijke operatie ondergaat een zekere mate van afweerreactie op LPS vertoond. 
Om deze reden hebben wij deze situatie gebruikt om ons onderzoek uit te voeren. 
Uiteindelijk hebben we bijna 200 patiënten onderzocht. Kort voor de operatie hebben we 
van deze mensen bloed afgenomen waaraan we in het laboratorium LPS hebben 
toegevoegd en vervolgens ook de cytokines hebben gemeten. Tijdens en kort na de 
operatie hebben we bloed afgenomen dat werd onderzocht op de aanwezigheid van LPS en 
meerdere cytokines (zoals TNF-α en IL-10). Daarnaast hebben we van deze patiënten de 
genen onderzocht en gekeken of er bepaalde SNPs aan- of afwezig waren. Vervolgens 
hebben we de verschillende metingen met elkaar vergeleken om te onderzoeken welke 
factoren de verschillen in productie van cytokines verklaarden. 
In het onderzoek beschreven in hoofdstuk 2 en 3 hebben we onderzocht of het 
toedienen van antibiotica in de week voor de operatie kan voorkómen dat er tijdens en na 
de operatie LPS in de bloedsomloop terecht komt. Hoewel het aantal bacteriën in de darm 
duidelijk lager werd, bleek er geen vermindering op te treden in de hoeveelheid LPS die in 
de bloedsomloop terecht kwam. Verder was ook de mate van afweerreactie niet 
verschillend tussen de patiënten die antibiotica hadden gebruikt en zij die dat niet hadden 
toegediend gekregen. Uit verder onderzoek zal moeten blijken wat de verklaring is voor 
deze waarneming.  
In het onderzoek beschreven in hoofdstuk 5 en 6 hebben we onderzocht wat de 
samenhang was tussen de mate van LPS dat tijdens de operatie - en kort daarna - in de 
bloedsomloop kwam en de hoeveelheid vrijgekomen cytokines (TNF-α en IL-10). We 
hebben gevonden dat er een duidelijke samenhang is. Hoe meer LPS er tijdens de operatie 
in het bloed komt hoe groter de hoeveelheid aan cytokines die wordt geproduceerd. We 
hebben echter ook waargenomen dat er cytokines vrijkomen bij patiënten die helemaal 
geen LPS in hun bloed hadden. Dit betekent dat er nog andere factoren betrokken zijn bij 
het vrijkomen van cytokines. Uit vervolgonderzoek zal moeten blijken welke factoren dat 
zijn.  
In hoofdstuk 8 hebben we onderzocht in hoeverre het verschijnen van LPS in de 
bloedsomloop en de productie van cytokines invloed had op de toestand van de patiënt na 
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de operatie. Wat we gevonden hebben is dat patiënten die meer LPS in hun bloed hadden 
grotere problemen kregen met het functioneren van hun bloedsomloop. Verder hadden 
patiënten met een hoge concentratie van IL-10 in het bloed na de operatie een slechter 
functionerend hart. 
In hoofdstuk 4, 5 en 6 hebben we onderzocht of het mogelijk is om met een 
bloedonderzoek te voorspellen hoe mensen op LPS in hun bloed zullen reageren. We 
hebben dat onderzocht door bloed, afgenomen voor de operatie, in het laboratorium bloot 
te stellen aan LPS. Vervolgens hebben we de hoeveel cytokines die vrijkwamen gemeten. 
Tijdens de operatie hebben we in het bloed van deze mensen soortgelijke metingen gedaan. 
Door de metingen van iedere patiënt naast elkaar te leggen, konden we kijken of er 
bepaalde patronen optraden die een zekere mate van voorspelling gaven. Het bleek dat de 
hoeveelheid TNF-α die in het laboratorium vrijkwam na stimulatie met een hoge 
concentratie LPS in grote mate voorspellend was voor de hoeveelheid TNF-α die tijdens de 
operatie vrij kwam. Voor IL-10 hebben we hetzelfde gevonden.  
In hoofdstuk 5 hebben we onderzocht in hoeverre SNPs in het TNF-α gen effect 
hebben op het vermogen om TNF-α te produceren, zowel tijdens de operatie als in het 
laboratorium. We hebben hiervoor geen bewijs kunnen vinden.  
In hoofdstuk 6 hebben we hetzelfde onderzocht als in hoofdstuk 5, maar dan voor het 
IL-10 gen. We hebben van een aantal SNPs in het IL-10 gen kunnen aantonen dat dit effect 
heeft op de hoogte van de IL-10 productie. Inmiddels zijn er ook onderzoeken door 
anderen verricht die soortgelijke resultaten hebben opgeleverd. We hebben hier dus een 
belangrijke aanwijzing gevonden dat deze SNPs voor een deel verantwoordelijk zijn voor 
de verschillen die worden gevonden in de wijze van het ontwikkelen van een 
afweerreactie.  
In de hoofdstukken 5, 6 en 7 hebben we onderzocht in hoeverre genetische verschillen 
in de receptoren van LPS (TLR4, nod2) en het CCR5 gen effect hadden op het vermogen 
om te reageren op LPS. We hebben van de verschillende genetische polymorphismen geen 
effect kunnen aantonen. 
De belangrijkste conclusie van ons onderzoek is dat het bestuderen van patiënten die 
een hartoperatie ondergaan een goede manier is om onderzoek te doen naar de 
afweerreactie op LPS. Het vrijkomen van LPS is bij deze patiënten een belangrijke factor 
bij het ontstaan van een afweerreactie. We moeten ons echter wel realiseren dat er nog vele 
andere factoren een rol spelen bij het ontstaan van deze afweerreactie. Deze factoren zijn 
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